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Abstract 
  
Type II diabetes is a chronic metabolic disorder that carries a significant and increasing economic 
burden. Unfortunately, there is no cure for type II diabetes and treatments are limited. Adipose 
tissue cross talk with skeletal muscle and adipose-secreted cytokines (adipokines) have been 
implicated in driving skeletal muscle insulin resistance typical of type II diabetes; although this is 
largely based on evidence from animal models and rodent cell lines. 
The aim of this thesis was to investigate the role of novel adipose/skeletal muscle cross talk 
mechanisms in mediating human skeletal muscle insulin signalling. This thesis demonstrates that the 
novel adipokine vaspin is secreted from human subcutaneous adipose tissue, and is more highly 
expressed in obese older individuals compared to lean older individuals. Furthermore, using primary 
human myotubes derived from lean and obese donors, vaspin was demonstrated to induce 
activation of the PI3K/AKT axis, promote both GLUT4 expression and translocation, and sensitise 
older obese human skeletal muscle to insulin-mediated glucose uptake.  
This thesis also presents the first evidence of differential secretion of extracellular vesicles from lean 
and obese subcutaneous adipose tissue. Such vesicles were capable of increasing skeletal muscle 
inflammation, in addition to upregulating both atrophic and metabolic skeletal muscle gene 
expression, supporting the notion that extracellular vesicles are novel mediators of adipose tissue 
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2 
1.1 General Introduction 
Improved healthcare systems, living conditions and vaccinations, coupled with a decline in birth rates 
have resulted in an ageing population within many developed countries. In the UK, 18% of the 
population were aged 65 or older in 2016. Over the next 50 years this demographic is predicted to 
increase to 26% of the population, equating to an additional 8.6 million people. Greater increases still 
are expected in older age groups, with the number of residents over 85 expected to increase 3-fold 
over the same time period (1). Importantly such increases in lifespan do not directly correlate with 
increases in health span, as highlighted by the UK average healthy life expectancy being just 65, 
despite an average life expectancy of approximately 80 (2). Consequently, many elderly individuals 
are living with chronic, age-associated morbidities such as coronary artery disease, arthritis, chronic 
kidney disease, sarcopenia and diabetes during the last decades of life. Not only does this have an 
impact on the person’s quality of life, it is likely to have a considerable future economic impact, with 
a proportionally reduced workforce having to fund an increased cost of healthcare (3). Additionally, 
decreased physical activity and alterations in metabolism typically lead to an accumulation of 
adipose tissue mass with age, particularly in countries with a Western diet (4-6). As a result, there is a 
significant positive association between age and the proportion of the population that are over-
weight (having a body mass index (BMI) greater than 25 kg/m2) and importantly, clinically obese (BMI 
>30 kg/m2) (7).  
Critically, the prevalence of obesity is becoming worryingly high. The World Health Organisation 
(WHO) estimated that, globally; 300 million people were clinically obese in 2005 (8). By 2016, revised 
estimates indicated that this figure had risen to 650 million adults worldwide, which equates to 
approximately 10% of the global population (8). In the UK, the most recent Government statistics 
indicated that 63% of adults and 28% of children aged 2-15 were overweight or obese in 2015 (9).  
    
   
3 
Obesity is associated with increased mortality and the development of a number of diseases 
including cancer (10), osteoarthritis (11), chronic obstructive pulmonary disease (12), obstructive 
sleep apnoea (13) and type 2 diabetes (T2D). 
Over 3 million people in the UK were living with T2D in 2014 (4.5% of the total population) (14) and it 
is estimated that between 2010 and 2011 T2D cost the NHS £21.8 billion (15). If diagnosis and 
treatment options remain unchanged, it is projected that this cost will increase to £35.6 billion by 
2035-2036 (15). To put this into perspective, the annual spend on the treatment of T2D in the UK is 
currently greater than the budgets for the police, judicial system and fire service combined (9). 
Therefore, T2D is a significant problem that carries a growing economic burden, particularly in 
developed countries (9, 16).   
It is now known that skeletal muscle is responsible for the majority of insulin stimulated glucose 
uptake in humans (17). Therefore, skeletal muscle is not only central to the regulation of blood 
glucose in healthy individuals, but is also the primary site of insulin resistance in individuals 
presenting with T2D. As a result, significant efforts have been made to determine how increasing 
adiposity impacts skeletal muscle function, in order to better understand the causal link between 
obesity and the development of T2D. Ultimately, such mechanistic knowledge is critical for the 
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1.2 Skeletal muscle structure and function 
1.2.1 Skeletal muscle function 
Skeletal muscle is the most abundant tissue type in the human body, accounting for approximately 
40-50% of total body mass and up to 75% of total body proteins in adults (18). Primarily, skeletal 
muscle facilitates voluntary movement and locomotion via the contraction and relaxation of 
antagonistic muscle pairs, innervated by the somatic nervous system. Additionally, skeletal muscle 
has important autonomic functions such as facilitating spontaneous breathing, via innervation of the 
diaphragm by cervical nerves 3-5 (19) and providing postural support, through contraction of muscles 
such as the lumbar multifidus, which runs along the spine (20). Skeletal muscle also provides 
important physical protection of vital internal organs and is central to thermoregulation, contracting 
involuntarily to enable shivering when cold (21). Importantly, recent evidence has also demonstrated 
that skeletal muscle secretes a plethora of cytokines (myokines), thereby establishing skeletal muscle 
as a vital endocrine organ, regulating numerous whole body functions through tissue crosstalk, 
particularly following exercise (22). 
Adult skeletal muscle is a very plastic tissue and responds rapidly to exercise and dietary nutrients to 
increase in size (hypertrophy), force production and aerobic capacity, ultimately leading to increased 
performance. On the other hand, disuse of skeletal muscle leads to rapid muscle wasting (atrophy). 
Indeed, it appears that as little as 5 days of bed rest can result in a significant loss on skeletal muscle 
mass of around 4%, which translates to a decline in skeletal muscle strength of 9% (23). Following 
longer time periods, this trend continues, with 2 weeks of muscle disuse causing a loss of isometric 
strength of approximately 30% (24). Such disuse atrophy has been shown to be a predictor of 
morbidity, particularly following hospitalisation and therefore has significant implications for patient 
outcome, especially for the elderly and those with debilitating conditions such as cancer and 
traumatic injury (25, 26). 
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1.2.1 Skeletal muscle structure 
Embryonically, skeletal muscle begins do develop from the mesoderm by 10-13 weeks of gestation, 
with mature structures typically observed by 25 weeks (27). In adult humans, the organisation of 
skeletal muscle is complex and the exact number of individual skeletal muscles is not definitive, with 
estimations ranging from 520 -700 muscles. 
Skeletal muscles are composed of many individual skeletal muscle fibres (Figure 1.1). A skeletal 
muscle fibre (myofiber) is formed when muscle cells (myocytes) fuse, forming multinucleated 
structures that are typically between 10-100 µm in diameter and around 3 cm in length, but 
remarkably may reach up to 40 cm in the case of the satorious muscle (28). Each individual myofibre 
is surrounded by a basement membrane (endomysium) consisting of an inner basal lamina which has 
direct contact with the skeletal muscle fibre’s sarcolemma and an outer reticular lamina (29). This 
structure is predominantly formed of laminins and type IV collagen and plays an important role in 
myogenesis, the protection and maintenance of myofibre structure and facilitating regeneration 
following injury by acting as a scaffold (29).   
Furthermore, bundles of individual skeletal muscle fibres are surrounded by the perimysium, a 
collagenous (predominantly thought to be type I collagen) structure, forming a fascicle (30). In turn, 
multiple fascicles are themselves surrounded by an epimysium, formed from a mix of large bundles 
of collagens type I and III and this collectively forms a muscle (Figure 1.1) (30). Finally, the 
endomysium, perimysium and epimysium extend beyond muscle fibres forming tendons, facilitating 
the muscle-bone connection.  
 
 
    





Figure 1. 1. Skeletal muscle structure. 
Multiple skeletal muscle cells (myocytes) fuse to form a multinucleated muscle fibre, each enclosed by the 
endomysium. Muscle fibres are collectively bundled together by the perimysium, forming a fascicle. 
Fascicles are encapsulated by the outermost epimysium forming the complete muscle fibre structure. 
Skeletal muscle fibres are innervated by motor neurones and have an extensive capillary network. Image 
adapted from Betts et al (31). 
 
Importantly, skeletal muscle also has a population of satellite cells, located between the muscle 
plasma membrane and the basal lamina (32), identifiable by a number of cell surface markers, with 
paired box proteins 7 (Pax7) (present in both quiescent and proliferative states) typically the most 
specific (33). These are skeletal muscle specific stem cells, capable of differentiation into mitotic 
muscle cells termed myoblasts. In turn, myoblasts fuse generating new myofibres, allowing 
regeneration of skeletal muscle following injury.  
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Activation of quiescent satellite cells from the G0 stage of the cell cycle is multifaceted. Firstly, 
physical damage (e.g. injury) results in disruption of the basal lamina which consequently frees 
satellite cells via disruption of α7/β1 integrin mediated adhesion and thus increases their mobility 
(34, 35). Additionally, damage to the extracellular matrix also causes release of hepatocyte growth 
factor (HGF) from extracellular matrix proteins including versican, fibrillin-2, and glypicans (36). 
Furthermore, damage to muscle fibres and blood vessels, coupled with infiltration of macrophages, 
B-cells and T-cells leads to the additional release of nitric oxide and cytokines, including Interleukin-6 
(IL-6) and Interferon-γ (IFN). Collectively these signalling molecules promote quiescent satellite cells 
to enter into the cell cycle, leading to commitment to the skeletal muscle cell lineage (35, 37-39). 
Initially in this process, the expression of Pax3/7 on satellite cells decreases, which in turn permits 
the increase of the transcription factor MYF5 (40). Upregulation of MYF5 is followed by upregulation 
of the additional transcription factors; myogenic regulatory factor 4 (MRF4), MyoD and myogenin. 
Evidence suggests that following MYF5 upregulation, the order in which the expression of subsequent 
myogenic factors increase is not critical. Indeed these factors appear to possess the ability to activate 
each other, indicating the presence of redundancy (41). Ultimately the activation of these 
transcription factors in turn induces the upregulation of a plethora of muscle specific genes and thus 
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1.2.3 Skeletal muscle fibre types 
Human skeletal muscle fibres can be sub-classified as either type I (slow twitch) or type II (fast 
twitch) based on their myosin heavy chain (MHC) expression (Table 1.1). Type I fibres contract slowly, 
with little force, but have a high resistance to fatigue as they primarily depend on oxidative 
phosphorylation. In contrast, type II fibres contract quickly and with greater force, but rapidly fatigue 
due to being heavily reliant on anaerobic glycolysis (43).  
Type I fibres appear red in colour due to having a dense capillary network and high myoglobin 
content necessary to support oxidative phosphorylation. Conversely, type II fibres have a lower 
oxygen demand and so have less myoglobin and a smaller capillary network, pertaining to a white 
appearance. Human type II fibres can be further divided into type II A and type II X, depending on 
MHC gene expression (Table 1.1), while it has also become apparent that some fibres co-express 
different isoforms of MHC, giving rise to intermediate or hybrid fibres (44). Therefore it is now 
apparent that a spectrum of fibre types exists, with the proportion of each in a muscle group 
determining its functional ability. For example, muscles with a high proportion of type I fibres better 
facilitate endurance exercise, while greater heterogeneity of type II fibres enables explosive 
movements such as sprinting (45). 
Due to the plastic nature of skeletal muscle, muscle fibre types can shift, to an extent, in response to 
regular training, leading to either increased muscular endurance or power (46). Additionally, 
different disease states often associate with the loss of specific fibre types. For example, elderly 
individuals with sarcopenia primarily present with a loss of type II fibres, while chronic obesity or 
muscle unloading following injury is primarily associated with type I fibre atrophy (47-49). Recent 
evidence also suggests that such specific fibre type loss may differentially impact whole body 
metabolism, with type I fibre atrophy having a greater association with reduced insulin sensitivity 
(50). 
    

















Table 1. 1 Characteristics of the main human skeletal muscle fibre types 
Fibre type Speed of contraction Metabolism MHC Isoform Myosin gene 
I Slow Oxidative MHC-I MYH7 
IIA Fast Oxidative/glycolytic MHC-II MYH2 
IIX Fast Glycolytic MHC-II MYH1 
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1.3 The role of insulin and skeletal muscle in glucose homeostasis  
1.3.1 The mechanism of insulin production 
In a healthy individual, plasma glucose is maintained within the range of 4.0-6.1 mmol/L. If blood 
glucose is elevated, for example following a meal, glucose uptake in various cell types increases. 
Glucose uptake is a process driven by the hormone insulin, a 5.8 KDa anabolic peptide hormone. In 
response to elevated plasma glucose, beta cells of the pancreas secrete insulin into the blood, which 
is then able to bind to its complementary insulin receptor in target tissues, initiating the insulin 
signalling pathway (51). Importantly, approximately 20% of intracellular insulin is transported along a 
microtubule network in order to associate with the cell membrane. Thus, beta cells are primed for 
rapid insulin release when stimulated (52). 
The Initial step in the production of insulin involves the translation of the insulin gene INS, resulting 
in the production of preproinsulin. Next, a signal sequence present on preproinsulin is cleaved in the 
rough endoplasmic reticulum (RER) to produce proinsulin. Then, semi-helical A and helical B domains 
of proinsulin are linked via disulphide bonds, stabilising its structure. Finally, in the Golgi apparatus, 
the enzymes prohormone convertase 1/3 and prohormone convertase 2 cleave a c-peptide chain 
which links the A and B domains of proinsulin, generating the final insulin structure.  
Intracellular insulin couples to Zn2+ resulting in the formation of hexameric crystal structures which 
are predominantly stored in cytoplasmic granules, of which there are approximately 10,000 per β-cell 
(53, 54). This is a very efficient and swift production process, with up to 99% of translated RNA 
yielding mature insulin protein molecules, within approximately 2 hours (53). 
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1.3.2 The mechanism of insulin secretion 
Upon increased extracellular glucose concentrations, glucose diffuses down its concentration 
gradient into pancreatic β-cells by facilitated diffusion, mediated by membrane spanning GLUT1 
channels (55). In turn, uptaken glucose enters the glycolysis pathway, rapidly generating ATP. 
Subsequently the intracellular ATP:ADP ratio increases, which inhibits membrane ATP-sensitive K+ 
channels (56). Inhibition of such channels in turn elicits depolarisation of the β-cell membrane. If 
depolarisation surpasses a membrane potential of -50 mV, then voltage gated Ca2+ channels are 
activated enabling an influx of Ca2+ ions (56). Critically, increased intracellular calcium initiates fusion 
of the insulin containing granule (described above) with the plasma membrane, resulting in insulin 
secretion via exocytosis. 
In the pancreas, ß-cells are organised into structures called islets. Importantly, it appears that 
complex communication occurs between ß-cells within an islet and also between islets themselves 
(57). This allows insulin to be released in controlled, rhythmic waves, at approximately 5 minute 
intervals (58, 59). It is thought that the purpose of such a phenomenon is to maintain insulin 
sensitivity in target tissues, by preventing insulin receptor internalisation and down regulation due to 
a sustained presence of insulin (58). Such intercellular communication appears to be multifaceted; 
firstly, the protein connexin-36 forms gap junctions between ß-cells, allowing Ca2+ transfer and thus 
depolarisation to rapidly spread throughout adjacent cells (60). Further, paracrine signalling is also 
likely to be an important regulator of insulin secretion, with ß-cells releasing signalling molecules 
such as ATP to drive insulin release in surrounding cells (61). Emerging data suggests that insulin 
secretion may also be regulated by even more sophisticated mechanisms. For example, Johnston et 
al. recently described a subset of pancreatic ß-cells with pacemaker properties. These cells were 
demonstrated to function as ‘hubs’, communicating with numerous ‘follower’ cells in order to 
regulate their insulin release (62). Additionally, Tang et al. recently reported the novel neuronal 
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innervation of β-cells via 3D histology, suggesting that regulation of insulin release is not just local 
between adjacent cells and islets, but universal throughout the pancreas (63). 
 
1.3.3 The insulin signalling pathway 
The extracellular binding of insulin to the insulin receptor (IR) causes a conformational change in the 
receptor that enables auto-phosphorylation of intracellular tyrosine domains within its activation 
loop region. Following phosphorylation of the activation loop, the insulin receptor is further 
phosphorylated in additional regions, including Tyrosine-960 (64). This provides a site for a family of 
membrane localised proteins known as insulin receptor substrate (IRS) proteins (IRS1-6) to associate 
with, forming an IR-IRS complex (64, 65). Numerous other proteins have since been demonstrated to 
associate with the insulin receptor, including DOCK1 and-2, APS, CBL, GAB1 and SH2B, although such 
interactions are less well studied. Association of IRS, (predominantly IRS1 and IRS2) with the insulin 
receptor facilitates phosphorylation of up to 20 residues within their central C-terminal domain. In 
turn, this allows signalling proteins containing a src-homology 2 (SH2) domain to bind and initiate 
downstream signalling (66). One such protein is Phosphoinositide 3-kinase (PI3K), which contains 2 
regulatory subunits (P55 and P85). Binding of PI3K to IRS results in phosphorylation of these 
regulatory subunits, which in turn promotes activation of P110, the catalytic subunit of PI3K. 
Activated PI3K functions to phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2), generating 
phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 is localised to the membrane and provides a 
docking site for the recruitment and activation of Phosphoinositide-dependent kinase-1 (PDK-1), in 
turn allowing PDK-1 to phosphorylate the threonine-308 (Thr308) residue of protein kinase B 
(PKB)/AKT, leading to its partial activation. Additional phosphorylation of serine residue-473 (Ser473) 
within the hydrophobic motif of AKT is needed for its full activation (67). Such phosphorylation is 
necessary to stabilize Thr308 phosphorylation and is mediated by a downstream target of AKT, the 
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mechanistic target of rapamycin complex 2 (mTORC2), in a positive feedback process (Figure 1.2) (68, 
69).  
There are 3 known subtypes of AKT, of which AKT2 is reported to have the highest expression in 
human insulin sensitive tissues such as skeletal muscle. Thus AKT2 is thought to be the most 
important subtype for transduction of insulin signalling in such tissue types (70). In support of this, 
Cho et al. demonstrated that AKT2 knock out mice display insulin resistance and a diabetic 
phenotype, while AKT1 or AKT3 selective knock out mice are unaffected in this regard (71). Critically, 
AKT acts to phosphorylate various effector proteins causing either upregulation or downregulation of 
a number of cellular processes (discussed in detail below and depicted in Figure 1.2) and is therefore 
central to the cellular effects driven by activation of the insulin signalling pathway. Therefore, it is 
critical that AKT activation is tightly regulated. In order to achieve this, negative feedback 
mechanisms are initiated following activation of AKT. For example, AKT facilitates activation of 
mechanistic target of rapamycin complex 1 (mTORC1), in turn, mTORC1 facilitates the 
dephosphorylation of AKT, via degradation of IRS1/2 (Figure 1.2) (72, 73). Dysregulated AKT 
activation has been identified as a key driver of many diseases such as cancer (74, 75) immune cell 
dysfunction, atherosclerosis (76) as well as insulin resistance and T2D (77). 
 
 
    




















Adapted from May, 2005 (78). 
mTORC2  
Figure 1. 2. The insulin signalling pathway. 
IRS proteins recognise and bind to the activated insulin receptor, resulting in phosphorylation of IRS. 
Phosphorylated IRS proteins are then able to phosphorylate and activate PI3K. In turn PI3K activation 
leads to the downstream phosphorylation of AKT (protein kinase B) at 2 sites, namely Thr308 and 
Ser473. In its active form, p-AKT is able to phosphorylate various effector proteins that upregulate a 
number of cellular processes. Firstly phosphorylation of AS160 mediates insertion of GLUT4 into the 
plasma membrane and thus glucose uptake, while activation of mTORC1 drives skeletal muscle 
hypertrophy and regulation of proteins such as GSK3B and FOXO, which modulate cellular metabolism 
and gene transcription respectively.  
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1.3.4 The effect of insulin on skeletal muscle glucose uptake 
Skeletal muscle is responsible for up to 80% of insulin stimulated plasma glucose uptake in healthy 
individuals and is therefore critical for the maintenance of glucose homeostasis (17). Insulin 
stimulated activation of AKT causes increased translocation and insertion of glucose transporter 4 
(GLUT4) from intracellular vesicles to the cell membrane. GLUT4 is a protein consisting of 12 
transmembrane domains that facilitates the movement of plasma glucose down its concentration 
gradient into the cell (79). Importantly, only approximately 5% of cellular GLUT4 is localised at the 
plasma membrane during rest, but increases to around 50% in response to insulin (80). 
The trafficking of GLUT4 and insertion into the plasma membrane is a complex process that is yet to 
be fully elucidated. Current evidence indicates that a target of AKT, the AKT Substrate 160 (AS160), 
also known by its gene name TBC1D4, plays an important role. AS160 is thought to be a GTPase 
activating protein (GAP), a family of proteins that act to hydrolyse guanine triphosphate (GTP) bound 
to Rab proteins (81). Rab proteins have an important role in vesicle trafficking and are active in their 
GTP bound state (82, 83). Following knockdown of AS160 in 3T3-L1 adipocytes, an up to 6-fold 
increase in membrane bound GLUT4 is observed, thus in unstimulated conditions AS160 acts to 
maintain its target Rab protein in an inactive guanine diphosphate (GDP) bound state, holding GLUT4 
vesicles within the cytoplasm (84, 85).  
Phosphorylation of AS160 inhibits its GTPase function and in turn prevents GTP hydrolysis of Rab 
proteins (86). The simultaneous exchange of RabGDP for RabGTP mediated by guanine exchange 
factors (GEFs) promotes a net increase in RabGTP. GLUT4 vesicle associated Rab proteins are now 
active and free to facilitate translocation of GLUT4 vesicles to the plasma membrane (Figure 1.2) (86, 
87). Such a mechanism is demonstrated by overexpression of AS160, which prevents substantial 
GLUT4 translocation and so limits insulin stimulated GLUT4 translocation and glucose uptake. 
    
   
16 
Importantly, Consitt et al. demonstrated that insulin stimulated phosphorylation of AS160 in skeletal 
muscle is negatively associated with insulin sensitivity (88). Similarly, blunted AS160 phosphorylation 
is reported in the skeletal muscle of subjects with T2D and insulin resistant women with Polycystic 
Ovary Syndrome (89, 90). In vitro studies investigating insulin stimulated activation of AS160 are 
limited. However, treatment of primary human myotubes with palmitate, replicating an obese 
microenvironment, elicited a similar reduction in insulin stimulated AS160 phosphorylation (91). 
Whether such blunting of AS160 occurs directly or is simply due to dysregulation upstream in the 
insulin signalling pathway requires further study. 
The precise mechanism of how intracellular vesicles associate with the membrane to increase GLUT4 
insertion is currently not well understood, although SNARE proteins are thought to be involved in this 
process (92). Additionally recent evidence suggests that, in skeletal muscle, PI3K also activates the 
signalling protein rac1 and this protein facilitates GLUT4 translocation through inducing 
reorganisation of the intracellular cytoskeleton (93). 
 
1.3.5 Effect of insulin on skeletal muscle metabolism.  
In addition to driving glucose uptake in skeletal muscle, insulin also directly increases glycogen 
synthesis. Following increased transport into skeletal muscle, glucose is first phosphorylated to 
glucose-6-phosphate by hexokinase and then further converted to UDP-glucose. Increased glucose-6-
phosphate drives an increase in glycogen synthase activity by inducing allosteric changes in glycogen 
synthase (94). Additionally, insulin further augments glycogen synthase activation through AKT-
mediated phosphorylation and thus inhibition of glycogen synthase kinase-3 beta (GSK3ß), an 
inhibitor of glycogen synthase (95). Further, insulin inhibits the opposing enzyme, glycogen 
phosphorylase, to limit glycogen breakdown. Collectively, these effects facilitate the conversion of 
UDP-glucose to glycogen, promoting net glycogen synthesis.  
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In addition to glucose, insulin also has a profound effect on skeletal muscle protein metabolism. 
Firstly, numerous studies have shown insulin augments amino acid uptake by skeletal muscle (96). 
McDowell et al. demonstrated that such insulin stimulated amino acid uptake may be due to both 
the direct activation and membrane insertion of the Sodium-coupled neutral amino acid transporter-
2 (SNAT2) (97). More recently, Walker et al. showed insulin is also able to increase the mRNA 
expression of SNAT2, in addition to large neutral amino acid transporter-1 (LAT1) and Proton-
Assisted Amino Acid Transporter (PAT1) in C2C12 myotubes (98). Surprisingly, further mechanistic 
studies of insulin stimulated amino acid uptake, particularly in human cells, are limited. 
Insulin also has a major anabolic effect on skeletal muscle and it appears such an effect is achieved 
through multiple mechanisms. Firstly, following its activation (described above), pAKT 
phosphorylates and inhibits Forkhead box protein O1 (FOXO1). FOXO1 is a positive regulator of the 
muscle specific ubiquitin E3 ligases MAFbx and MuRF-1 and therefore its inhibition reduces 
proteasomal mediated protein degradation, promoting net protein synthesis (99, 100).  
Additionally, pAKT mediates phosphorylation of the tuberous sclerosis complex (TSC1/2) (101). In 
unstimulated conditions, TSC1/2 acts as a GAP, which functions to hold the effector protein Ras 
homolog enriched in brain (RHEB) in its inactive GDP bound state. Phosphorylation of TSC1/2 inhibits 
its GAP function, therefore allowing activation of RHEB. In turn, RHEB facilitates activation of 
mTORC1. Importantly mTORC1 is the central regulator of a number of cellular processes which 
collectively promote skeletal muscle hypertrophy (102). 
Firstly, mTORC1 activates ribosomal P70 S6 kinase 1 (p70S6K1), a key step in driving protein synthesis 
(103, 104). Simultaneously, mTORC1 also phosphorylates and consequently inhibits 4E-binding 
protein 1 (4EBP1) (105). This releases 4EBP1 from its inhibitory binding to eukaryotic initiation factor 
4E (eIF4E). Once free from 4EBP1, eIF4E can facilitate protein translation, thus further increasing 
protein synthesis. Conversely, mTORC1 also phosphorylates and inhibits unc-51-like kinase 1 (ULK1) 
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(106). This is the key protein involved in activation of the autophagy pathway, therefore its inhibition 
prevents muscle protein breakdown and contributes to net protein synthesis (106). 
In vivo, it appears that insulin only directly increases muscle protein synthesis in humans when amino 
acid delivery to the skeletal muscle is also increased, often above physiological levels (107, 108). 
Indeed, a recent meta-analysis of studies investigating the anabolic effect of insulin indicated that 
such an effect is more likely attributable to reducing muscle protein breakdown (107). Importantly, in 
the absence of sufficient stimuli such as regular resistance exercise, skeletal muscle mass declines 
from approximately 35 years of age, with rates of muscle mass and strength loss accelerating to 1% 
and 5% per year respectively from the age of 60 (109). One of the primary causes for such muscle 
wasting with age is the development of anabolic resistance (110). As insulin is a key anabolic 
hormone, a reduction in the anabolic response to insulin is likely an important contributory factor to 
the decline in skeletal muscle mass with age. Critically this may lead to the development of 
sarcopenia, frailty, decreased quality of life and ultimately increased mortality (111, 112).  
Similarly, insulin resistance is also associated with a reduction in both muscle mass and quality. 
Muscle mass is reported to decline up to 2-fold faster in individuals with T2D in comparison to non-
diabetic controls, while the incidence of sarcopenia in T2D patients is up to 3-fold higher in 
comparison to non-diabetic controls, even when adjusting for additional risk factors such as BMI 
(113-115). It is likely that a reduction in insulin-stimulated muscle protein synthesis and increased 
muscle protein breakdown is an important contributing factor to such declines in muscle loss, 
particularly with progression of the T2D. 
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1.3.6 The effect of insulin on adipose tissue and liver metabolism 
In adipose tissue, insulin has the same effects on glucose metabolism as observed in skeletal muscle. 
Insulin directly increases glucose uptake via the translocation of GLUT4, while driving increased 
glycogen synthesis and decreased glycolysis (116). Importantly, insulin also regulates adipose tissue 
lipid metabolism and this is essential for maintaining whole body energy balance (116). In times of 
nutrient depletion, lipids that are predominantly stored in adipose tissue as triglycerides, are 
hydrolysed to free fatty acids by the enzyme hormone-sensitive lipase (117). In turn, such free fatty 
acids are able to enter the circulation and are taken up by tissues such as skeletal muscle, where they 
are then oxidised to provide energy. 
In contrast, during times of nutrient excess, insulin directly prevents such lipolysis and subsequent 
mobilization of fatty acids by inhibiting hormone-sensitive lipase (118). Simultaneously, insulin 
promotes expression and activation of the enzyme lipoprotein lipase (119-121). This enzyme, located 
on the extracellular membrane of vascular endothelial cells, acts to hydrolyse lipoproteins in the 
circulation generating fatty acids (122). This therefore allows for the increased uptake of such newly 
liberated fatty acids by adipocytes. Furthermore, insulin also increases the synthesis of a number of 
enzymes involved in lipid synthesis, through activation of transcription factors such as ubiquitous 
cellular transcription factor (USF) and sterol regulatory element binding protein 1c (SREBP1c) (123). 
This in turn facilitates increased synthesis of triglycerides from the influx of free fatty acids. 
Insulin receptors are also present in the liver and therefore insulin exerts a number of direct effects 
on liver metabolism. Firstly, like in adipose tissue, insulin drives an increase in lipid synthesis. Indeed, 
specific knockdown of the hepatic insulin receptor prevents hepatic lipid accumulation, even in 
response to challenges with high fat diet (124). This effect is again partly due to increased expression 
of enzymes that promote lipid synthesis, mediated by insulin induced increases in SREBP-1c, via 
mTORC1, (125, 126). Additionally, FOXO-1 is also implicated in driving hepatic lipid synthesis. FOXO-1 
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is a transcription factor that when active reduces lipogenesis, potentially via suppression of SREBP-1c 
(127). However phosphorylation of FOXO1 by AKT inhibits this function, thus driving hepatic lipid 
synthesis (128). 
Furthermore, liver glucose metabolism is also regulated by insulin. Since the human liver is 
responsible for up to 80% of glucose production and stores up to 35% of ingested glucose following a 
meal such regulation is vital (129). Firstly, insulin can directly reduce liver gluconeogenesis, via the 
inhibition of gluconeogenic gene transcription (130). Additionally, similarly to in muscle, direct 
activation of insulin signalling in the liver inhibits hepatic glycogenolysis and instead drives increased 
glycogenesis via the activation of glycogen synthase (131). Additionally, tissue cross talk provides 
important indirect regulation of liver glucose metabolism. Following increased insulin stimulated 
glucose uptake by skeletal muscle, glucose can be rapidly converted to lactate and secreted, 
particularly in times when muscle glycogen stores are already considerable (132, 133). This primarily 
acts to maintain a glucose diffusion gradient in muscle, facilitating continued glucose uptake. 
However this also has an important indirect effect on the liver, as the secreted lactate is taken up by 
hepatocytes and in turn converted to glycogen (132). 
Similarly, indirect regulation of hepatic lipid metabolism has also been reported. As described above, 
insulin reduces lipolysis in adipose tissue and consequently levels of circulating free fatty acids 
decline. Importantly, FFA have been shown to increase glucose production in the liver of healthy 
individuals, therefore this process is blunted following insulin stimulation due to the decline in 
circulating FFAs, further promoting net glycogen synthesis (134, 135). 
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1.4 Skeletal muscle insulin resistance and the development of type II 
diabetes 
T2D is a metabolic disorder in which blood glucose concentrations are unable to be managed 
effectively. This is due to a combination of factors, including the increased insulin resistance of target 
tissues and also a decline in insulin secretion caused by pancreatic β-cell dysfunction (136). In insulin 
resistant individuals, the quantity and functionality of insulin receptors are similar to that of non-
insulin resistant individuals (137). This therefore indicates insulin resistance is mediated by a 
disruption in insulin signalling in target tissues, such as skeletal muscle and adipose tissue, thus 
preventing glucose uptake from the blood (137-139). Unfortunately, there is no cure for T2D and 
treatments are limited. Furthermore, the inability of patients to maintain plasma glucose 
concentrations in a healthy range is associated with a number of chronic pathologies, including 
microvascular diseases and macrovascular diseases such as stroke and coronary artery disease (140, 
141). 
One of the major treatment strategies for T2D patients is to increase insulin sensitivity, either 
through lifestyle modifications such as weight loss, or via the administration of insulin-sensitising 
drug therapies including Biguanides such as Metformin (142, 143) and Thiazolidinediones (144). 
Alternatively, some patients are prescribed Sulphoylureas, which stimulate insulin secretion (145, 
146). However, these medications are associated with significant side-effects when taken chronically 
and can become ineffective as disease progresses (147-152). Therefore, there is great unmet clinical 
need to develop more effective and more targeting therapeutics for T2D patients. 
In attempting to identify new therapies, skeletal muscle has emerged as an important area of drug 
discovery research. Skeletal muscle metabolic function is considered central to maintaining insulin 
sensitivity (153, 154), being responsible for up to 80% of insulin-mediated glucose uptake in healthy 
individuals (155). 
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It is well known that T2D patients display significantly impaired skeletal muscle glucose uptake in 
response to insulin, however the direct cause of such impaired glucose uptake is currently not well 
defined and is likely multifactorial. Leading hypotheses include the ectopic accumulation of 
intramuscular lipids and exposure to chronic low grade inflammation associated with ageing and 
increased adiposity.  
In obese individuals, adipose tissue is known to become more “inflammatory”, with an increase in 
the infiltration of immune cells including T-cell subsets (156) and inflammatory M1 macrophages 
(157), which drive the production of proinflammatory cytokines, referred to in this context as 
adipokines. Importantly, secretome analysis of human adipocyte culture medium has identified over 
200 adipokines (158) and recent studies have implicated that adipokines play a central role in the 
development of a number of obesity associated diseases. Therefore, understanding the functional 
and mechanistic role of adipokines on skeletal muscle insulin signalling may identify novel targets for 
therapeutic intervention of insulin resistance and T2D.  
Although obesity is the primary risk factor for T2D, a number of other factors are also associated with 
its development. Firstly, a greater proportion of men present with T2D in comparison to women with 
the same BMI (159). This is likely attributable to gender specific fat distribution. Although women 
typically have greater adipose tissue mass, they display increased gluteal-femoral adipose 
accumulation, which has been demonstrated to protect against the development of T2D and 
metabolic disease (160, 161). In contrast, men typically present with greater central, and visceral 
adiposity associated with increased inflammation (162). 
Genetically, it appears that the risk of developing type II diabetes is significantly (2-fold) increased in 
individuals of an Asian or Pima Indian ethnicity, particularly when exposed to a Westernised diet 
(163). T2D also appears to run in families, with an individual being 6 times more likely to develop T2D 
if their parents have the disease, in comparison to someone born to non-diabetic parents (163). 
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Finally, environmental factors such as alcohol consumption and smoking, as well as sleep deprivation 
have also been reported to significantly increase the risk of developing T2D (164-166). 
 
1.5 Intramuscular lipids and the development of skeletal muscle insulin 
resistance 
1.5.1 Intramyocellular lipids  
In addition to intracellular glycogen stores and metabolic substrates obtained via the circulation, 
intramyocellular lipid (IMCL) droplets provide an important substrate for the generation of energy via 
oxidative phosphorylation, particularly during moderate to intense exercise, where IMCL can provide 
up to 25% of energy (167, 168). Lipid droplets are intracellular structures comprising of a core of 
organic neutral lipids, encapsulated by phospholipids, thus organic lipids are separated from the 
aqueous cytoplasm (169). Additionally, phospholipids are often decorated with additional proteins 
specific to cell type and function. Such proteins include perilipins, a family of structural proteins 
involved in both lipid synthesis such as acyl-CoA synthetase, and lipid breakdown such as lipases 
(169). 
Lipid droplet size, lipid content and intracellular location also differ between cell types. In the skeletal 
muscle of lean individuals, intramyocellular lipid droplets primarily consist of esterified lipids 
including triacylglycerol (TAG), cholesterol and diacylglycerol (DAG) and contribute approximately 1% 
to total myocyte volume (170). Additionally, intramyocellular lipid droplets associate with 
mitochondria and primarily localise between myofibrils and to a lesser extent near the sarcolemma 
(171). In comparison to lipid droplets found in white adipocytes, intramyocellular lipid droplets are 
considerably smaller in diameter (100 μm and 0.3 -1.5 μm respectively), but are found in much 
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greater quantities (172, 173). This increases the ability for enzymatic interaction with lipid droplets, 
therefore facilitating more rapid fat oxidation when required.  
 
1.5.2 The generation of intramyocellular lipid droplets 
The starting material for the generation of lipid structures present within lipid droplets are FFAs. 
Within skeletal muscle, FFAs derived from either the circulation or intracellular lipolysis are initially 
linked to acyl-CoA by CoA synthetases, in turn forming FA-CoAs. From this point, FA-CoAs have two 
fates, they can be either oxidised or stored predominately via the formation of the neutral lipid TAG. 
The synthesis of TAG initially involves monoacylglycerol molecules first being re-acylated via addition 
of FA-CoAs to monoacylglycerol via acyltransferase to form diacylglycerol. In turn, diacylglycerol can 
be further acylated via DAG-O-acyltransferase to form TAG (174).  
Other notable lipids present within skeletal muscle lipid droplets are sphingolipids. Synthesised from 
serine and palmitate, these lipids, such as ceramide, have a number of important bioactive roles. 
These include the regulation of both cellular processes and intercellular signalling pathways and are 
implemented as central drivers of skeletal muscle insulin resistance as discussed below (175). How 
such intracellular lipids get packaged and form the lipid droplet structure is a topic of debate, with 
complete mechanisms not yet fully elucidated. A leading theory is that phospholipids bud from the 
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1.5.3 Intramyocellular lipids and the development of insulin resistance. 
There is substantial evidence that demonstrates the concentration of IMCL increases with obesity in 
humans. Specifically, infusion of non-essential fatty acids produces increases in IMCL stores in as 
little as 2 hours in humans, while consumption of a high fat diet (55–60% of energy intake), for just 3 
consecutive days, has a similar effect (176). Conversely IMCL content decreases following diet 
induced weight loss (177). 
There is also evidence demonstrating increased IMLC correlates with the development of insulin 
resistance (178, 179), while weight loss and in turn a reduction of IMLC is associated with 
improvements in insulin sensitivity (180). However it should be noted that this is only relevant to 
untrained individuals, since exercise trained subjects often exhibit an elevated IMLC, while also 
having increased insulin sensitivity. This suggests that total TAG content is not necessarily the 
principal driver of insulin resistance. Indeed, in some cases obese insulin sensitive and insulin 
resistant cohorts have been shown to display similar IMLC (181, 182). As a result, it is hypothesised 
that the accumulation of lipotoxic intermediates, primarily DAG and ceramide play a more important 
role in this process (183). 
 
1.5.4 DAG and the development of skeletal muscle insulin resistance 
Concentrations of intracellular DAG are increased with obesity and demonstrate a negative 
association with the development of insulin sensitivity in humans (184). Additionally, a reduction in 
the enzyme diacylglycerol kinase δ (DGK δ), which functions to convert DAG to phosphatidic acid is 
reported in individuals with T2D (185). This suggests such individuals not only have increased DAG 
accumulation through diet but also have a disruption in DAG metabolism; in turn further increasing 
DAG induced insulin resistance (185). 
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DAG increases the activity of a number of protein kinase C (PKC) isoforms, of which PKCθ and PKCε 
subtypes appear to have significant roles in the development of insulin resistance by inhibiting IRS-1 
and thus downstream insulin signalling (186). 
PKCθ achieves such IRS-1 inhibition by two different mechanisms. Firstly, Li et al. demonstrated that 
PKCθ directly phosphorylates IRS‐1 at its serine residue 1101 in C2C12 myotubes (187, 188). 
Additionally, Werner et al. demonstrated that PKCθ also evokes insulin resistance via promoting 
indirect phosphorylation of IRS-1ser302 and IRS-1ser307 via JNK in vitro. The authors also demonstrated 
that such residues are phosphorylated in murine models of insulin resistance, namely following HFD, 
ob/ob mice and hyper-insulineamic mice (189). Similarly, PKCε phosphorylates IRS1Ser 636 and 
IRS1Ser639 in the skeletal muscle of Psammomys obesus gerbils, whilst preventing such 
phosphorylation protects against diet induced insulin resistance in these animals (190). 
Improvements in insulin sensitivity are also observed following PKCε knockout in diabetic mice (191). 
Furthermore, Ikeda et al. reported that PKCε directly inhibits the activation of the insulin receptor 
through a direct structural association, in addition to inducing IR downregulation, further limiting IRS-
1 activation (192). 
 
1.5.5 Ceramide and the development of skeletal muscle insulin resistance 
A clear positive correlation exists between intramyocellular ceramide content and obesity (193) 
(194). There is also significant evidence indicating the accumulation of ceramide is associated with 
the development of insulin resistance in humans (195). 
Treatment of both L6 and C2C12 myotubes with either palmitate or low-density lipoprotein (LDL) 
containing ceramide increases intramyocellular ceramide content and myotube insulin resistance 
(194) (196). In support of this, Chavez et al. demonstrated that overexpression of ceramidases in 
C2C12 myotubes results in an increased ability to reduce ceramide content, which prevented the 
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development of myotube insulin resistance following treatment with fatty acids (197). Preventing 
ceramide accumulation in C2C12 myotubes by increasing the expression of glucosylceramidase has 
recently been demonstrated to have a similar effect (198). Conversely, both inhibition and 
knockdown of this enzyme has the opposite effect, facilitating the development of insulin resistance 
in this myotube model (198). 
Similarly to DAG, ceramides also activate PKC, specifically PKCζ. In turn, PKCζ has been demonstrated 
to phosphorylate Thr34 and Ser34 residues of AKT in L6 myotubes (199, 200). This prevents the 
recruitment of AKT to the plasma membrane, a crucial step for its activation. In support of this, 
Mahfouz et al. recently demonstrated that palmitate treated primary human myotubes and primary 
human myotubes cultured from diabetic subjects display increased ceramide content and insulin 
resistance mediated by PKC (201). Ceramide also directly activates the protein phosphatase-2A, 
which in turn targets and dephosphorylates active AKT, further blunting the downstream effects of 
this crucial protein in the insulin signalling pathway (202, 203). Although these mechanisms are well 
defined in animal models and rodent cell lines, it is important to note that evidence in primary 
human myotubes is currently lacking. Validation of these mechanisms in human muscle tissues is 
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1.6 The impact of obesity on adipose tissue structure and function 
1.6.1 Adipose tissue structure 
As described in section 1.3.6, adipose tissue is critical for energy balance in humans. Post-prandially 
and during caloric surplus, white adipocytes (the predominant cell population within adipose tissue) 
primarily act to uptake and store FFAs and glucose. Conversely, fasting and limited nutrient 
availability upregulates lipolysis, generating energy as required. As discussed above, adipose tissue 
exhibits distinct sex differences in humans, with women exhibiting around 10% more adipose tissue 
at the same BMI as men (204). Typically, such increased fat mass in females is accumulated around 
the abdominal and gluteal regions (162).  
Adipose tissue can be further classified as subcutaneous white adipose tissue (SWAT), visceral 
adipose tissue (VAT) and brown adipose tissue (BAT). SWAT is located directly beneath the skin and is 
the largest adipose depot by total mass, typically contributing up to 80% of total adipose tissue (205). 
VAT is located centrally, around the viscera, where it provides physical protection of the internal 
organs in addition to its metabolic role. In comparison to SWAT, VAT has a reduced capacity to 
expand in response to chronic caloric surplus due to fewer, small insulin responsive adipocytes which 
more readily uptake FFAs (206). However, visceral adipose tissue is more inflammatory and increased 
VAT mass with obesity has been extensively linked with a host of diseases including T2D, 
cardiovascular disease, cancer, atherosclerosis, as well as non-alcoholic fatty liver disease (207-209). 
In contrast, BAT is formed of ‘brown adipocytes’. These cells express mitochondrial uncoupling 
protein 1 (UCP1) and have a far greater mitochondrial content in comparison to white adipocytes 
(210). Consequently, brown adipocytes are able to uncouple mitochondrial respiration, generating 
considerable amounts of heat energy. This process is thought to be driven primarily by exposure of 
brown adipocytes to cold conditions (211, 212). In humans, BAT is typically found in greater amounts 
during childhood before declining with age and as a result was thought to have a negligible function 
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in adults. However, recent evidence indicates that BAT is present in paravertebral, supraclavicular 
and periadrenal regions in much larger amounts than previously believed, contributing up to 2% of 
total body mass or 5% of total adipose tissue (213).  
Interestingly, in contrast to SWAT and VAT, BAT displays an inverse correlation with both increasing 
BMI and total fat mass and recent evidence suggests it may play a considerable role in whole body 
energy homeostasis (214-216). Pioneering work by Stanford et al. demonstrated that transplantation 
of murine brown adipose tissue depots into the central region of recipient mice increased energy 
expenditure, induced weight loss and importantly prevented high fat diet induced insulin resistance 
(217). Additionally, BAT is also capable of considerable triglyceride clearance in mice, mediated by 
increased BAT endothelial permeability and activation of lipoprotein lipase in response to cold (218). 
It now appears that there is also a subset of white adipocytes, typically expressing CD137 and 
transmembrane protein 26 (Tmem26), that are able to undergo a functional shift or “browning” 
resulting in the gain of functional properties associated with brown adipocytes. As a result, such 
adipocytes are often referred to as being ‘brite’ or ‘beige’ adipocytes (219). Current evidence 
suggests that adipose tissue browning can be initiated by either sustained exposure to cold 
conditions, the sympathetic nervous system and also exercise (220). Such stimuli activate PGC-1α, 
which in turn upregulates UCP1 and drives mitochondrial biogenesis, thus promoting the brown 
adipocyte phenotype (220). In light of such data, the potential to induce white adipose tissue 
browning has gathered interest in recent years as a potential therapeutic mechanism to substantially 
increase energy expenditure and improve symptoms of metabolic disease. Murine studies have 
demonstrated that caloric restriction may promote adipocyte browning (221). However, this does 
not seem to translate to humans since 8 weeks of caloric restriction in a relatively large cohort of 289 
individuals induced significant weight loss, but had no effect on the expression of brown adipocyte 
markers (222). Although, the β3-adrenoceptor agonist mirabegron did elevate metabolic rate and 
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elicit direct glucose uptake via activation of BAT in a trial of 12 healthy humans (223). Further 
research, particularly in obese and diseased cohorts, is needed to confirm potential benefits of BAT 
and adipose tissue browning on metabolic diseases. 
Finally, in addition to adipocytes and their precursors (pre-adipocytes), adipose tissue also has a 
substantial immune cell population. Critically, secretion of monocyte chemoattractant 1 (MCP-1) and 
to a lesser extent cytokines such as TNFα, IL-6 and IFN-γ by adipocytes recruits monocytes from the 
circulation (224). The local adipose tissue microenvironment then drives infiltrating monocyte 
differentiation into the more proinflammatory M1 macrophage subset. Obesity induced 
dysregulation of immune cell infiltration and consequent adipose tissue inflammation has profound 
effects on total body metabolic health as discussed below. 
 
1.6.2 The impact of obesity on adipose tissue function 
Excess circulating lipids are buffered by white adipocytes, leading to an increase in white adipocyte 
size (hypertrophy). In lean individuals this is necessary to maintain energy balance and importantly 
prevents damage to other organs through lipid toxicity. However, exposure to a chronic caloric 
surplus over months and years leads to progressive and sustained adipocyte hypertrophy and 
ultimately adipocyte dysfunction.  
One of the major implications of adipocyte hypertrophy is the generation of a hypoxic 
microenvironment. In comparison to other tissues, adipose tissue has a limited vasculature network 
(225). Therefore, when adipocytes surpass approximately 100 M in diameter the diffusion of O2 to 
adipocytes becomes inefficient, at a time when demand is high due to increased adipose tissue mass 
(226). Subsequently, this leads to a significant disruption of multiple adipocyte functions. 
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Hypoxia is thought to drive increased adipocyte lipolysis and reduced lipid clearance from the 
circulation, resulting in a net release of FFA from hypertrophic adipocytes into the circulation (227) 
(228). Additionally, hypoxia is associated with increased adipocyte cell death and therefore the direct 
release of FFAs from dying cells may also contribute to increased accumulation of lipids in the 
circulation (229). Increased concentrations of circulating FFAs results in aberrant accumulation of 
lipids in internal organs such as the liver and skeletal muscle, with this process associated with the 
development of a number of obesity related pathologies, such as insulin resistance as described 
above.  
Additionally, hypoxia increases adipocyte expression of hypoxia-inducible factor 1a (HIF-1a) a 
transcription factor which induces NF-κB signalling and in turn leads to increased proinflammatory 
cytokine secretion (230, 231). Due to this increased inflammatory burden with obesity, adipose tissue 
becomes inflamed, leading to increased accumulation of proinflammatory immune cells including M1 
macrophages and T-cell subsets (231). This further increases adipose tissue inflammation and is 
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1.7 The role of established adipokines in obesity associated inflammation 
and skeletal muscle insulin sensitivity. 
As introduced in sections 1.4 and 1.6.2, it is now widely accepted that adipose tissue also functions 
as an important endocrine organ, secreting a number of adipokines which play important roles in 
mediating tissue crosstalk and physiological processes. Importantly, secretome analysis of human 
adipocyte culture medium has identified over 200 adipokines (158) and there is substantial evidence 
that such adipokines contribute to the development of chronic low grade inflammation, associated 
with ageing and obesity (236). For example, serum TNFα concentrations display a significant positive 
correlation with both BMI and a waist to hip ratio (237). Leptin, adiponectin, resistin and visfatin are 
amongst the most well studied adipokines and have all been implicated in the development of 
metabolic diseases, including T2D. Studies conducted on these adipokines which relate to their 
functional role in skeletal muscle insulin signalling are discussed below and summarised in Table 1.2 
in relation to animal and human data. 
 
1.7.1 Leptin 
The role of leptin as an inflammatory adipokine in metabolic disorders is well studied. Systemic levels 
of leptin positively correlate with both BMI and waist circumference, and are associated with the 
development of insulin resistance (238, 239). Several studies have reported that leptin impacts on 
skeletal muscle insulin signalling. Stimulation of the rat L6 skeletal muscle cell line with recombinant 
leptin reduced phosphorylation of IRS-1 and impaired glucose uptake, suggesting that leptin 
promotes insulin resistance (240). However, in contrast, leptin stimulation of murine C2C12 
myotubes was found to increase glucose uptake, whilst overexpression of leptin in a ‘skinny’ mouse 
model increased insulin sensitivity (241, 242). These contrasting data highlight the need to conduct 
functional studies on leptin in human myotubes. To this end, Yau et al. reported that leptin increased 
    
   
33 
AKT phosphorylation in commercially available human myotubes (243). However, to date the 
functional role of leptin on human skeletal muscle insulin signalling is still understudied. 
 
1.7.2 Adiponectin 
Adiponectin, a 30 KDa protein with structural similarities to collagen types XIII and X, has been 
identified to be predominantly secreted by adipocytes into the blood, where plasma levels in healthy 
individuals reach approximately 10 g/ml (238). This concentration is approximately 3-fold greater 
than the majority of other hormones, indicating an important role for adiponectin in human 
physiology. Adiponectin is considered to be a beneficial adipokine in relation to metabolism; plasma 
concentrations inversely correlate with weight, central obesity, risk of T2D and insulin resistance in 
humans (244, 245). Furthermore, maintenance of a low calorie intake increases both adipocyte 
expression of adiponectin and circulatory concentrations (246). 
Three different molecular weight isoforms of adiponectin are found in the circulation, of which the 
high molecular-weight isoform is believed to be the most functional in terms of glucose homeostasis. 
Functional studies suggest that adiponectin promotes insulin sensitivity in skeletal muscle. In C2C12 
myocytes, adiponectin increases fatty acid oxidation via sequential activation of AMPK, p38 MAPK 
and PPARα (247, 248) and promotes glucose uptake (248). Similarly, in L6 myotubes adiponectin 
induces GLUT4 translocation and glucose uptake (249). In vivo, adiponectin knockout mice 
demonstrate an obese, insulin resistant phenotype, whereas systemic administration of adiponectin, 
or its delivery as a transgene direct to skeletal muscle, improves insulin sensitivity (250-253). 
Adiponectin has also been shown to induce fat oxidation via AMPK activation in human myotubes, 
and further, this mechanism was found to be impaired in myotubes from obese T2D patients (254). 
Critically, this suggests that the function of adiponectin as a promoter of insulin sensitivity translates 
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to humans. Furthermore, it suggests that impairment of adiponectin function in skeletal muscle of 
obese T2D patients may contribute to the development of insulin resistance.   
 
1.7.3 Resistin 
First identified in murine adipocytes as a secreted protein capable of inducing insulin resistance 
(255), resistin is a proinflammatory adipokine that induces the secretion of TNFα and IL-6 from 
various cell types including PBMCs and pancreatic acinar cells (256, 257). The correlation between 
plasma resistin with both obesity and insulin resistance in humans supports a role for resistin in the 
development of insulin resistance (258, 259). In vitro, studies have demonstrated a reduction in AKT 
phosphorylation and glucose uptake in C2C12 and L6 myotubes stimulated with recombinant resistin 
(260-262). However, at present, few studies have investigated the functional role of resistin in the 
development of insulin resistance in human skeletal muscle cells.  
 
1.7.4 Visfatin 
Visfatin exists in both an intracellular (iVisfatin) and extracellular (eVisfatin) form (263, 264). eVisfatin 
is primarily produced and secreted from visceral adipose tissue, where it is more highly expressed in 
obese individuals(265). Similarly, higher systemic levels of eVisfatin are associated with obesity, 
ageing and the development of T2D (266-268).  
 
Regarding the role of visfatin in mediating insulin sensitivity, overexpression of visfatin in male wistar 
rats increased whole body insulin sensitivity (269), and in adipose tissue and liver, promoted insulin-
mediated IRS-1 phosphorylation (269). Data on the function of visfatin in skeletal muscle insulin 
sensitivity is limited to studies in rodents. Visfatin increases glucose transport in rat skeletal muscle 
fibres (270). Furthermore, in C2C12 myotubes, visfatin activates AMPK/p38 MAPK, induces GLUT4 
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expression and translocation, and promotes glucose uptake (270). Based on these data, similar 
insulin sensitizing effects may occur in human skeletal muscle. 
 
1.8 The role of novel adipokines in skeletal muscle inflammation and 
insulin sensitivity. 
In addition to the well-known adipokines, proteomic studies of adipose tissue have identified several 
less characterised adipokines that may also play important roles in mediating skeletal muscle insulin 
sensitivity. At present the functional effects of the majority of these novel adipokines on human 
skeletal muscle insulin sensitivity is poorly understood. Some of the more prominent novel 
adipokines are discussed below and also summarised in Table 1.3. 
 
1.8.1 Vaspin 
First reported as a 47 KDa protein in the visceral adipose tissue of genetically obese OLETF rats (271), 
administration of vaspin to obese mice increased insulin sensitivity and glucose tolerance (272). 
Additionally, subcutaneous adipose tissue expression of leptin, resistin and TNFα was suppressed, 
whilst GLUT4 and adiponectin expression was increased following vaspin administration (272). 
Similar increases in insulin sensitivity have since been reported in db/db and C57BL6 mice following 
recombinant vaspin delivery (273). Central administration of vaspin to obese mice resulted in a 
sustained suppression of appetite that resulted in reduced bodyweight and plasma glucose 
concentrations (274). Furthermore, transgenic mice overexpressing vaspin displayed improved 
glucose tolerance, reduced systemic IL-6 concentrations and were protected from obesity when fed a 
high fat diet (275).  
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In humans, vaspin expression has been reported in several tissues including subcutaneous adipose 
tissue, skin, stomach and skeletal muscle (274, 276, 277). Serum concentrations of vaspin in non-
diabetic and diabetic patients positively correlate with BMI, bodyweight and impaired glucose 
tolerance (278-281). Given the functional effects of vaspin demonstrated in rodent models, its 
increased expression with BMI in humans may reflect a compensatory mechanism. 
The effect of vaspin on insulin signalling and metabolism in human skeletal muscle is currently 
undetermined. Similarly, the mechanism of action and receptor for vaspin has also not been 
elucidated. Recently, it was reported that in HepG2 cells vaspin binds glucose-regulated protein 
(GRP78), a 7KDa voltage-dependent anion channel. Further, stimulation of H-4-II-E-C3 cells with 
recombinant vaspin activated AKT and AMPK signalling pathways, which was prevented by GRP78 
inhibition (275). Vaspin may therefore mediate its effects on insulin signalling via binding to GRP78. 
However, at present the expression of GRP78 has not been profiled in human adipose or skeletal 
muscle tissue, nor the functional studies conducted in human skeletal cells to validate GRP78 as the 
vaspin receptor.   
 
1.8.2 Fibroblast growth factor 21 
Fibroblast growth factor 21 (FGF-21) is established as a key mediator of fat oxidation and energy 
homeostasis (282-284). Numerous studies report that serum concentrations of FGF-21 are elevated 
in obese individuals and positively correlate with insulin resistance, BMI, % fat mass and circulatory 
concentrations of leptin and LDL (285-288). Although predominantly produced by the liver, FGF-21 is 
also expressed in adipose tissue, where it is more highly expressed in both obese and diabetic mouse 
models.     
In vivo, administration of FGF-21 to mice fed a high fat diet decreased intramuscular triglyceride 
content, increased insulin sensitivity and glucose uptake, and elevated secretion of adiponectin from 
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adipocytes (289). Continuous cerebral administration of FGF-21 for 2 weeks increased whole body 
insulin sensitivity in rats with dietary-induced obesity (290), whilst daily intravenous or subcutaneous 
delivery of FGF-21 for 6 weeks improved glucose handling in diabetic rhesus monkeys (291). 
Following such positive effects on insulin sensitivity and glucose tolerance, two FGF-21 mimetics 
(LY2405319 and PF-05231023) have progressed to phase 1 clinical trials (NCT01869959, 
NCT01923389) (292-296), and antibodies targeting FGFR1c/b-Klotho have been developed (297, 
298). With regards to a direct functional role of FGF-21 in skeletal muscle, incubation of isolated 
mouse EDL muscle with FGF-21 increased insulin-stimulated glucose uptake, and in human myotubes 
FGF-21 increased both basal and insulin-stimulated glucose uptake (299). Furthermore, FGF-21 has 
also been shown to prevent palmitate-induced insulin resistance in primary human myotubes by 
inhibiting stress kinases and NF-κB (300). Finally, FGF-21 is has also been demonstrated to be a 
myokine. In turn, such skeletal muscle derived FGF-21 can reportedly drive adipocyte browning, by 
upregulating adipocyte UCP-1 expression. Thus increased FGF-21 may also indirectly reduce adipose 
tissue mass via this mechanism (301).  
 
1.8.3 Chemerin 
Chemerin, was initially described as a novel chemoattractant for macrophages and dendritic cells via 
activation of several GPCRs including CMKLR1/ChemR23, GPR1, and CCRL2 (302, 303). More recent 
data suggests chemerin plays an important role in the differentiation of human adipocytes, and in 
the development of insulin resistance (304, 305). Circulatory concentrations of chemerin are 
associated with obesity, diabetes and metabolic syndrome (306-308). Furthermore, adipose tissue 
from obese subjects exhibits greater secretion of chemerin (309). 
 
At present, in vivo studies have drawn differing conclusions regarding the role of chemerin in the 
development of insulin resistance and glucose tolerance. Becker et al. reported that overexpression 
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of chemerin increased insulin resistance in LDL-receptor deficient mice fed a high fat diet, as 
evidenced by reduced insulin-mediated AKT phosphorylation (310). Importantly this effect was only 
observed in skeletal muscle, and not liver or pancreas (310). Additionally, glucose handling and 
serum insulin concentrations were reduced by chemerin administration to both obese and diabetic 
mice (311). However, no such effect was observed following chemerin administration to control 
mice. Takahashi et al. also report a negative effect of chemerin on skeletal muscle insulin sensitivity, 
with chemerin knockout mice displaying increased skeletal muscle insulin stimulated AKT 
phosphorylation and glucose uptake. However, despite this effect chemerin -/- mice demonstrated 
whole body glucose intolerance, due to a disruption of hepatic glucose production and reduced 
insulin secretion from pancreatic ß-cells (312).  
 
In vitro studies provide support for chemerin as a driver of insulin resistance. Pre-treatment of C2C12 
myotubes with chemerin reduced insulin-stimulated glucose uptake, while increasing the secretion 
of proinflammatory cytokines including IL-6 and TNF-α (313). Additionally, treatment of primary 
human myotubes with recombinant chemerin reduced insulin-stimulated glucose uptake (314). 
Further cross-talk studies with primary human myocytes and myotubes, particularly from obese and 
diabetic cohorts may help to clarify the function of chemerin in human metabolic disease states. 
 
1.8.4 Preadipocyte factor 1 
Preadipocyte factor 1 (Pref-1) is a transmembrane protein processed to generate a circulating form, 
which is also known as Foetal Antigen 1 (FA1) (315). Studies have described an association of 
increased Pref-1/FA1 serum concentrations with obesity and T2D (316, 317). Pref-1 is also reported 
to negatively regulate adipogenesis, with Pref-1 deficient mice displaying significant obesity and 
stunted growth (318, 319). Overexpression of Pref-1 in mice promotes a lipodystrophic phenotype 
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and insulin resistance via decreased skeletal muscle glucose uptake and impaired skeletal muscle 
insulin signalling (320). 
 
In humans, Pref-1 stimulation of myotubes from lean, obese, and T2D patients did not affect insulin 
sensitivity. However Pref-1 did induce the production of the proinflammatory cytokines IL-6 and CCL2 
(321), and thus chronic exposure of muscle to pathological levels of Pref-1 may impair insulin 
sensitivity indirectly. Clearly, further studies utilising human myotubes are warranted to fully 
determine the functional role of Pref-1 in skeletal muscle insulin sensitivity. 
 
1.8.5 Follistatin-like 1 
Follistatin-like 1 (FSTL1) is a glycoprotein with homology to osteonectin and its expression is 
associated with systemic inflammatory diseases including rheumatoid arthritis, lupus and ulcerative 
colitis. Several in vitro studies have established FSTL1 as a proinflammatory cytokine. For example, 
over-expression of FSTL1 in the fibroblast-like COS7 cell line or in human U937 monocytes induced 
the secretion of proinflammatory cytokines IL-6, TNF-α and IL-1β (322). 
 
With regards to adipose biology, FSTL1 is highly expressed in 3T3-L1 pre-adipocytes and its 
downregulation is implicated in their differentiation to adipocytes (323, 324). Furthermore, 
stimulation of 3T3-L1 adipocytes with recombinant FSTL1 inhibited insulin signalling (323). In vivo, 
increased adipose tissue expression of FSTL1 is reported in the leptin-deficient ob/ob mouse, and in 
humans serum levels of FSTL1 positively correlate with BMI (323). Despite being expressed and 
secreted by human myotubes (325) no studies to date have reported the functional effects of FSTL1 
on skeletal muscle insulin signalling, using either rodent or human cells. 
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1.8.6 SPARC 
SPARC (osteonectin) was first discovered as a glycoprotein secreted from bone. However, it is now 
known that SPARC is also expressed and secreted from adipose tissue. SPARC adipose tissue 
expression is increased in dietary-induced obesity in rats (326). In humans, SPARC is secreted from 
adipose tissue and appears to be an important driver of adipocyte differentiation and hyperplasia 
(327), while its expression in adipose tissue correlates with fat mass (328). Furthermore, serum levels 
of SPARC are associated with insulin resistance, dyslipidaemia and inflammation in patients with 
gestational diabetes mellitus (329). Mechanistically, overexpression of SPARC in 3T3-L1 adipocytes 
downregulated GLUT4 expression and inhibited insulin-stimulated glucose uptake (326). Given these 
data, it seems likely that SPARC could impair skeletal muscle insulin signalling. At present, these 
studies have not yet been conducted and so its functional role in skeletal muscle is not established.   
 
1.8.7 CTRP3 
CTRP3 is a member of a family of proteins which includes adiponectin. Similar to adiponectin, CTRP3 
has been identified as an anti-inflammatory adipokine. In humans, CTRP3 levels in the serum are 
lower in obese subjects compared to normal-weight individuals (330, 331), and negatively correlate 
with markers of insulin resistance (331). In vitro, CTRP3 inhibits LPS-induced expression of 
proinflammatory cytokines in human macrophages (332), whilst RNAi-mediated knockdown in 
preadipocytes increased the expression of chemokines and reduced adiponectin expression (333). Its 
functional role in skeletal muscle insulin signalling has not been characterised. 
 
1.8.8 Omentin-1 
Originally identified as a lectin-binding protein (334), Omentin-1 (intelectin-1) is highly expressed in 
visceral adipose tissue (335). In humans, systemic concentrations and adipose tissue expression of 
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Omentin-1 are lower in obese individuals (335) and negatively correlate with BMI and insulin 
resistance (335). Furthermore, lower serum levels of omentin-1 are observed in newly diagnosed T2D 
patients and its secretion from human adipose tissue is decreased by both insulin and glucose (336, 
337).    
 
In vitro, studies support a role for Omentin-1 as an anti-inflammatory adipokine, which suppresses 
the activity of TNF- in vascular inflammation via inhibiting p38 and JNK pathways. A role for 
Omentin-1 in promoting insulin sensitivity is supported by studies in human adipocytes where 
recombinant Omentin-1 induced AKT phosphorylation and enhanced insulin-stimulated glucose 
uptake (338). Thus far, studies to determine its functional role in skeletal muscle using either rodent 
models or human tissue have not been reported.   
 
1.8.9 Lipocalins 
Lipocalins are a functionally diverse group of proteins with a highly conserved tertiary structure that 
have been implicated in inflammation and immune responses. Importantly, a number of lipocalins, 
most notably lipocalin-2 (LCN2) and RBP4 have been associated with adipose tissue expression and 
obesity. Recently, a new member of the lipocalin family was identified, termed lipocalin-14 (LCN14), 
which in mice was found to be predominantly expressed in WAT and was downregulated in dietary-
induced obese mice (339). Furthermore, adenovirus over-expression of LCN14 in obese mice 
improved insulin sensitivity (339). Again, the functional role of lipocalins in mediating human skeletal 
muscle insulin sensitivity has not been reported.     
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Adipokine Association with obesity 
and/or T2D in humans  
Adipokine effect on insulin signalling in animal models Adipokine effect on insulin signalling in 
human skeletal muscle 
 In Vivo In Vitro 
  
  
Leptin Increased (238, 239, 340). Overexpression of leptin in a skinny 
mouse model increased insulin 
sensitivity (242). 
 
Administration of leptin (12-15 days) 
reversed insulin resistance in obese 
Wistar rats (341). 
 
Leptin reversed high fat diet induced 
skeletal muscle insulin resistance in 
rats, indirectly via reducing 
intramuscular triglycerides not though 





Recombinant leptin reduces IRS-1 
phosphorylation and glucose uptake in 
L6 myotubes (240). 
 
Increased phosphorylation of AKT in 
commercially available primary human 
myotubes (243). 
Recombinant leptin increased glucose 
uptake in C2C12 myotubes (241). 
 
Acute (10 mins-1 h) stimulation of L6 
Myotubes directly increased glucose 
uptake via a PI3K-dependent pathway. 
Leptin pre-treatment (10min) of L6 
myotubes inhibits insulin stimulated 
glucose uptake (343). 
 
24 h Pre-treatment of L6 myotubes had 
no effect on glucose uptake but did 
inhibit adiponectin stimulated glucose 
uptake (344). 
Adiponectin Decreased (244, 245). Adiponectin knockout mice 
demonstrate an obese and insulin 
resistant phenotype (250, 252). 
Promotes glucose uptake in both C2C12 
and L6 Myotubes (248, 249). 
 
 
Induces fat oxidation through activation of 
AMPK in myotubes from lean subjects. 
Mechanism impaired in myotubes from T2D 
patients (254). 
  Systemic administration and Recombinant adiponectin increased  
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Table 1. 2 Evidence for the role of known adipokines in mediating skeletal muscle insulin sensitivity.
Overexpression of adiponectin drives 
increased insulin sensitivity in insulin 
resistant mice [38, 40]. 
glucose uptake via AMPK mediated 
reorganisation of the actin cytoskeleton 
and GLUT4 translocation via an 
independent mechanism [132]. 
 
Resistin Increased (258, 259). Administration of resistin (6 days) to 
wild type mice induces a state of 
insulin resistance (345). 
 
Recombinant resistin impaired insulin 
signalling and glucose uptake in both 
C2C12 and L6 myotubes (261, 262). 
Unknown 
Targeted reduction of resistin in insulin 
resistant mice via antisense 
oligodeoxynucleotide restored hepatic 
but not skeletal muscle insulin 
sensitivity (346). 
 
Visfatin Increased (347-349). Visfatin overexpression in rats 
increased whole body insulin 
sensitivity and adipose tissue and liver 
IRS-1 phosphorylation in response to 
insulin (269). 
Stimulated glucose uptake and 
increased GLUT4 membrane 
translocation and mRNA and protein 
expression in C2C12 myotubes via AMPK 
p38 MAPK signalling (270). 
 
Unknown 
  Increased glucose uptake in rat EDL 
muscle (350). 
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Adipokine Association with obesity 
and/or T2D in humans  
Adipokine effect on insulin signalling in animal models Adipokine effect on insulin signalling in 
human skeletal muscle 
  In Vivo In Vitro  
  
  
FGF-21  Increased (299). Increased insulin sensitivity and glucose 
uptake in mice, via FGF-21 mediated 
increases in adiponectin production and 
secretion from adipocytes (289). 
 
6h incubation of mouse EDL muscle 
with FGF-21 resulted in a 54% increase 
in insulin stimulated glucose uptake 
(299). 
 
Directly increased glucose uptake in primary 
human myotubes(299). 
 
Prevents palmitate-induced insulin 
resistance in primary human myotubes by 
inhibiting stress kinases and NF-κB (300). 
  Continuous cerebral administration for 2 
weeks increased whole body insulin 




  Daily administration for 6 weeks 
improved glucose handling in diabetic 
rhesus monkeys (291). 
 
  
Chemerin Increased (308, 351). Overexpression increased insulin 
resistance in LDL receptor deficient mice 
by reducing AKT phosphorylation in 
response to insulin in skeletal muscle, 
but not liver or pancreas (310). 
 
24h pre-treatment reduces insulin 
stimulated glucose uptake in C2C12 
myotubes in a dose dependent manor 
(313). 
 
24h chemerin Increased insulin resistance 
and reduced insulin stimulated glucose 
uptake in primary human myotubes, 
mediated by increased ERK signalling (309). 
 Knockout mice display increased skeletal 
muscle insulin resistance while 
transgenic mice exhibit increased 
skeletal muscle insulin resistance (312).  
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  Acute chemerin treatment exacerbated 
glucose intolerance and lowered serum 
insulin levels in obese and diabetic mice. 
No effect observed in normoglycemic 
mice (311). 
 
CTRP3  Decreased (330, 352, 
353).  
Administration of recombinant CTRP3 
directly lowers glucose levels in normal 
and insulin-resistant ob/ob mice (354). 
 
Administration of recombinant CTRP3 
to L6 myotubes had no effect on 
glucose uptake (354). 
Unknown 
Overexpression of CTRP3 improved 
insulin sensitivity in HFD fed mice (355). 
 
Increased glucose uptake and GLUT 4 
mRNA expression in insulin resistant 
adipocytes (356). 
RBP4  Increased (357, 358). Overexpression or direct administration 
of RBP4 increased insulin resistance in 
mice. RBP4 knockout improves insulin 
sensitivity in mice (358). 
 
unknown Unknown 
Reducing circulating RBP4 in obese mice 
models improved glucose tolerance and 
increased insulin stimulated glucose 
uptake in skeletal muscle up to 60% 
(359). 
 
Vaspin Increased (278, 280, 
281). 
Vaspin treatment increased insulin 
sensitivity and glucose tolerance in 
obese and diabetic mice (272, 273). 
 
Unknown Unknown 
Transgenic mice overexpressing vaspin 
displayed improved glucose tolerance 
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and were protected from obesity when 
challenged with a high fat diet (275). 
 
Pref-1 Increased (316). Overexpression in mice drives insulin 
resistance via decreased adipose tissue 
and skeletal muscle glucose uptake and 
impaired skeletal muscle insulin 
signalling (320). 
 
Unknown 4 Day exposure to primary human myotubes 
from lean, obese and T2D subjects had no 
effect on glucose uptake (321). 




Increased (360). Unknown 
 






Decreased (361, 362). Unknown Omentin-1 induced AKT 
phosphorylation and enhanced insulin-





Lipocallin-14 Unknown Over expression in diet induced obese 
mice reduced glucose and insulin levels 
while improving glucose tolerance (339). 
 
Unknown  
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1.9 The impact of exercise on insulin sensitivity 
Both aerobic fitness and the physical activity levels demonstrate positive correlations with insulin 
sensitivity, while numerous studies have reported a significant improvement of insulin sensitivity 
following exercise intervention (363-366). Furthermore, it appears such beneficial effects occur both 
acutely in the hours after exercise and persist for several days post exercise (367). However, exercise 
is quite a generalised term and therefore deciphering the effects of different types of exercise, 
including; aerobic, resistance and high intensity interval training (HIIT) on insulin sensitivity in 
different cohorts has gained significant attention. A detailed discussion of such research is not 
possible here, so only key impacts of different exercise modalities on insulin sensitivity are discussed 
below. A more comprehensive summary of recent studies can be found in the recent review article 
by Bird et al. (366). 
There is significant evidence demonstrating that performing a minimum of 30 minutes of moderate 
intensity aerobic exercise, 3 times per week for at least 8 weeks, elicits a significant improvement in 
insulin sensitivity in a broad range of cohorts. This includes both young and old males and females, 
T2D patients, obese adolescents and even young sedentary individuals (368, 369). Increasing the 
volume of moderate intensity exercise elicits increased improvements in insulin sensitivity, but with 
diminishing returns. For example, moderate exercise equating to 600 calories per day produced only 
slight improvements in insulin sensitivity in comparison to 300 calories per day protocols (370).  
Furthermore, improvements in insulin sensitivity have also been reported in response to performing 
high intensity exercise, particularly HIIT exercise (367, 371, 372). Such HIIT may also evoke greater 
improvements in insulin sensitivity when compared to moderate aerobic exercise, despite lower total 
energy expenditure and significantly reduced exercise time (372, 373). Indeed, recent data indicates 
that even a single bout of maximal exercise of 2-3 minutes is enough to improve insulin sensitivity of 
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overweight/obese males for many hours post exercise, with a 38% increase in fat oxidation still 
present 1 day post-exercise (374). 
Additionally, resistance exercise such as weightlifting also demonstrates improvements in insulin 
sensitivity in diabetic and obese cohorts (375, 376). Interestingly, it appears that resistance exercise 
mediated improvements may occur independently to aerobic exercise, with a combination of aerobic 
exercise and resistance exercise being more effective than aerobic exercise alone (377, 378). One 
possible explanation for this is that the increased muscular demands of resistance exercise 
necessitates increased recruitment and activation of type II muscle fibres, in comparison to aerobic 
exercise that is more predominantly associated with type I fibre activation. Therefore, it may be of 
benefit for patients with insulin resistance/T2D to follow a diverse exercise programme consisting of 
both resistance and aerobic exercise. 
A final consideration when investigating the effect of exercise on insulin sensitivity is that of the 
nutritional state of the individual temporal to exercise. It appears performing exercise in the fasted 
state may evoke greater improvements in insulin sensitivity post exercise, with this effect potentially 
attributable to an increase in exercise induced myocellular GLUT4 protein content (379). Additionally, 
Taylor et al. presented evidence that, in healthy individuals, consuming carbohydrates to replenish 
glycogen stores after performing 90 min of exercise (70% VO2 max) resulted in blunted insulin 
sensitivity the following morning when compared to individuals who did not consume carbohydrates 
post exercise. Therefore, performing fasted exercise and limiting carbohydrate intake immediately 
following exercise is potentially the most effective strategy to maximise beneficial effects of exercise 
on insulin sensitivity in obese/diabetic cohorts (380). 
Mechanistically, both aerobic exercise and resistance exercise training directly increase the content 
of GLUT4 protein in skeletal muscle and thus facilitate increased insulin stimulated glucose uptake 
(381-383). With time, increased vascularisation of the skeletal muscle in adaptation to regular 
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exercise also likely contributes to improvements in insulin sensitivity, by increasing insulin and 
glucose delivery (384-386). Finally, exercise may also improve pancreatic ß-cell function and thus 
improve insulin secretion, as recently observed in T2D and obese populations (387, 388).  
In summary, exercise is a potentially effective treatment option for many individuals with poor 
insulin sensitivity. Therefore, lifestyle changes to increase physical activity that incorporate both 
aerobic and resistance exercise would likely be beneficial in such individuals. The fact that lower 
intensity exercise can be beneficial is of particular interest, as initially, performing high intensity 
exercise is often challenging for many individuals who are obese or display T2D, especially as these 
conditions are also often associated with numerous co-morbidities, such as cardiovascular disease, 
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1.10 Thesis Hypothesis and Aims 
1.10.1 Hypothesis 
It is evident that adipose tissue has a considerable effect on skeletal muscle function in the obese 
state, driving skeletal muscle dysfunction associated with the development of insulin resistance and 
T2D, as summarised in Figure 1.3. However, the functional role of many adipokines in mediating such 
insulin sensitivity is unknown. We propose that novel adipokines, currently unstudied in human 
skeletal muscle, mediate changes in skeletal muscle insulin sensitivity and inflammation associated 
with the obese state. We also hypothesise that, like adipokines, adipose tissue derived extracellular 
vesicles are novel mediators of adipose tissue and skeletal muscle crosstalk and are implicated in the 
development of obesity associated skeletal muscle dysfunction. 
 
Figure 1. 3. Proposed mechanism for skeletal muscle dysfunction associated increased adipokine 
secretion in the obese state 
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1.10.2 Aims 
1. Determine the impact of obesity on the functional properties of primary human myotubes in 
order to validate primary human myotubes as an in vitro model for studies investigating the 
impact of candidate adipokine in mediating the obese phenotype (Chapter 3). 
 
2. Characterise the effect of obesity on the expression and secretion of the novel adipokine vaspin 
in human skeletal muscle and adipose tissues and determine the functional effect of vaspin on 
primary human myotube insulin sensitivity (Chapter 4). 
 
3. Validate extracellular vesicles as novel mediators of adipose tissue and skeletal muscle crosstalk. 
Perform the first characterisation of extracellular vesicles derived from lean and obese human 
adipose tissue and investigate the effect of human adipose tissue derived extracellular vesicles 
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2.1 Ethical approval and subject recruitment 
Informed consent was obtained from all patients prior to sample collection and full ethical approval 
for the study was obtained from the UK Research Ethics Committee (NRES 13/NE/0222). Sample 
collection, processing, storage and subsequent experimental procedures were carried out in 
compliance with Human Tissue Authority guidelines under the Human Tissue Act (2004). 
 
2.2 Subject data and sample collection 
Gluteus maximus skeletal muscle, subcutaneous adipose tissue (SAT) and blood samples were 
obtained intraoperatively from individuals undergoing elective hip-replacement surgery at either the 
Royal Orthopaedic Hospital (Birmingham, UK) or at Russell’s Hall Hospital (Dudley, UK). Diabetic 
patients and those taking anti-inflammatory medication within two weeks prior to surgery were 
excluded from the study. 
 
2.3 Blood sample processing 
5 ml of blood was collected at the time of surgery in a red-top vacutainer and allowed to clot at room 
temperature (RT) for 20–30 min. Next, samples were centrifuged at 1620 X g for 10 min. The upper 
serum layer was collected and aliquoted into 1 ml cryovials. Samples were snap frozen immediately 
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2.4 Primary human myoblast isolation and culture 
Skeletal muscle samples (~200 mg) obtained as described in section 2.2 were sliced with a scalpel, 
placed in 5 ml of 0.05% trypsin-EDTA (Gibco®, Invitrogen, Paisley, UK) solution and rotated in an 
incubator (37 °C, 5% CO2) for 15 min. Trypsin was inactivated by the addition 5 ml of myoblast 
growth media [Ham’s F10 nutrient mix (Sigma-Aldrich, Dorset), supplemented with 20% HyClone™ 
research grade foetal bovine serum (GE healthcare, Buckinghamshire, UK) and 1% penicillin and 
streptomycin (Sigma-Aldrich, Dorset, UK)]. This solution was centrifuged for 5 min at 360 X g and the 
resulting pellet re-suspended in 12 ml of myoblast growth medium and incubated in an uncoated T75 
cell culture flask for 20 min. Finally, the solution was transferred to a T75 cell culture flask pre-coated 
with 0.2% gelatin (Sigma-Aldrich, Dorset, UK) in PBS. Myoblast growth medium was replaced every 
48 h.  
 
When cultures approached approximately 80% confluency, myoblasts were passaged 1:2-1:5, 
depending on the growth rate of each individual cell culture, or seeded into multi-well plates as 
required for experimentation. Specifically, cells were washed with PBS, followed by incubation with 5 
ml of 0.05% trypsin EDTA for 5 min (37 °C, 5% CO2) to detach the cells. Cells were then immediately 
transferred to a universal tube containing an equal volume of myoblast growth media to quench the 
trypsin. Next, myoblasts were pelleted by centrifugation (360 X g, 5 min), re-suspended in myoblast 
growth media and then transferred into either a T-75 flask, 96, 48, 24, 12 or 6 well plate (pre-coated 
coated with 0.2% gelatin). The volume of myoblast growth media used in each vessel is reported in 
Table 2.1. For experiments that required a specific number of myoblasts, the cell pellet was first re-
suspended in 1 ml of growth media. Next, a 10 µl aliquot was removed and mixed with 10 µl of 
trypan blue and cell count performed using a Countess II (life technologies, Paisley, UK). 
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Culture flask Volume per flask/well 
T-75 flask 12 ml 
6-well plate 2 ml 
12-well plate 1 ml 
24-well plate 500 µl 
48-well plate 250 µl 
96-well plate 150 µl 
Table 2. 1 Volume of culture medium used during the culture of primary human myoblasts/ 
myotubes. 
 
2.5 Cryopreservation of primary human myoblasts 
If myoblasts were not required for subculture or experimentation, myoblast pellets were re-
suspended in 1 ml of freezing media (90% myoblast growth media + 10% dimethylsulfoxide (Sigma-
Aldrich, Dorset, UK) before being aliquoted into 1 ml cryovials and transferred to a freezing container 
(Mr Frosty, Thermo Fisher Scientific, MA, USA). Cells were then immediately placed into a -80 °C 
freezer before being transferred to liquid nitrogen the following day for long term storage at 
approximately -150 °C. 
 
2.6 Differentiation of primary human myoblasts 
Differentiation of myoblasts into multinucleated myotubes was induced by replacing myoblast 
growth media from >90% confluent myoblasts with differentiation media [Ham’s F10 nutrient mix, 
supplemented with 6% horse serum (Sigma-Aldrich, Dorset, UK) and 1% penicillin and streptomycin]. 
The volume of differentiation media used was equal to growth media (Table 2.1) and was also 
replaced every second day. All experiments were conducted on the 8th day of differentiation. 
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Myoblast cultures generated desmin positive, multinucleated myotubes, which have previously been 
confirmed to be negative for the fibroblast marker TE7 (389). 
2.7 Generation of adipose/skeletal muscle tissue conditioned medium 
SAT or skeletal muscle derived from lean and obese subjects was incubated (37 °C, 5% CO2) in serum 
free Ham’s F10 nutrient mix (Sigma-Aldrich, Dorset, UK), containing 1% penicillin and streptomycin, 
for up to 24 h at a ratio of 1 g: 10 ml. Larger samples were divided into segments of ~ 1 g to ensure 
that the surface area of tissue exposed to medium remained approximately constant. For time 
course analysis, 50 µl aliquots were taken hourly for 6 h. Following incubation, supernatants were 
removed and stored at -80 °C.  
 
Additionally, SAT samples were also incubated (37 °C, 5% CO2) in myotube differentiation media at a 
ratio of 1 g: 10 ml, to facilitate chronic incubation of primary human myotubes with adipose 
conditioned media (ACM). Following incubation, supernatants were removed and stored at -80°C. 
 
2.8 Preparation of adipose conditioned media samples for extracellular 
vesicle isolation 
Following collection of serum free ACM as described in section 2.7, samples were immediately 
centrifuged at 2000 X g, 4 °C, for 20 min using a benchtop micro-centrifuge (S418R, Eppendorf, 
Stevenage, UK). Supernatants, containing EVs were then transferred to a sterile Eppendorf tube and 
spun again at 12,000 X g, 4 °C, for 2 min. Finally, supernatants containing EVs were collected, 
transferred to bijoux tubes and stored at -80 °C. 
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2.9 Isolation of extracellular vesicles from ACM 
ACM samples prepared as described in section 2.8 were thawed on ice on the day of 
experimentation. Samples were transferred to ultracentrifuge tubes. Samples were centrifuged at 
100,000 X g, 4 °C, for 1 h using an ultracentrifuge (WX Ultra80, Thermo Fisher Scientific, MA, USA) in 
order to pellet EVs.   
 
2.10 Stimulation of primary human myoblast and myotubes with 
recombinant proteins 
Primary human myoblasts and myotubes were stimulated with a variety of recombinant proteins as 
detailed in Table 2.2. Lyophilised recombinant proteins were diluted in double distilled H2O (ddH2O) 
or PBS as specified by the manufacturer, to produce a concentrated stock solution in accordance 
with the manufacturer’s protocol. Stock solutions were then aliquoted and frozen at -20 °C, allowing 
the same batch of recombinant protein to be used across experiments. For experimentation, stock 
solutions were diluted in myoblast growth medium or myotube differentiation medium as required 




Manufacturer Source Sequence Catalogue #  
Insulin Sigma Yeast (Proprietary 
host) 
N/A I2643 
Vaspin  Bio Vision 
 
E. Coli Full length (aa 1-415) 4915 
IL-1ß Sigma  E. Coli Unknown (153 aa 
residues 
I9401 
Table 2. 2 Recombinant proteins used to stimulate primary human myoblasts and myotubes 
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2.11 Isolation of total protein from primary human myoblasts and 
myotubes 
Myotubes grown in 6-well plates were lysed with 250 µl of ice-cold RIPA buffer (Thermo Fisher 
Scientific, MA, USA), containing phosphatase inhibitor cocktail 3 (1:100) (Sigma-Aldrich, Dorset, UK) 
and protease inhibitor cocktail (1:100) (Sigma, Dorset, UK). After addition of RIPA buffer, plates were 
placed on ice for 20 min before each well was scraped using a cell scraper and contents transferred 
to a 1.5 ml Eppendorf tube. Total protein was quantified by performing a BCA assay (Thermo Fisher 
Scientific, MA, USA) in a clear 96-well plate as described by the manufacture’s protocol. Samples and 
standards were assayed in duplicate and optical density was measured at 550 nm using a Biotek 
EL808 spectrophotometer (Biotek, Swindon, UK). Subsequently a standard curve was generated in 
Microsoft Excel and used to determine the protein concentration of samples (µg/µl). 
 
2.12 Isolation of total protein from skeletal muscle tissue 
Snap-frozen skeletal muscle tissue samples (~100 mg) were ground into a fine powder using a pestle 
and mortar under liquid nitrogen. Powdered tissue was immediately transferred to a 1.5ml 
Eppendorf tube containing 500 µl of ice-cold RIPA buffer as described in 2.11. After addition of RIPA 
buffer, samples were placed on ice for 20 min and total protein content quantified by performing a 
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2.13 SDS polyacrylamide gel electrophoresis and immunoblotting 
Protein samples from cell and tissue lysates were diluted to a desired concentration in loading buffer 
consisting of 2-mercaptoethanol (Sigma-Aldrich, Dorset, UK), 4x Laemmli Sample (Bio-Rad, 
Hertfordshire, UK) and ddH2O as required.  
 
Samples were loaded into a 5% SDS-polyacrylamide stacking gel and separated by performing 10-
12% SDS-page depending on the protein of interest. Gels were cast in Novex 1.0 mm Cassettes (Life 
technologies, Paisley, UK) as described in Table 2.3. Cassettes were placed into an Invitrogen Novex 
mini-cell (Thermo Fisher Scientific, MA, USA), filled with 1 X running buffer prepared from ultrapure 
10 X tris/glycine/SDS (Geneflow, Staffordshire, UK ) and ddH20. Gels were then run at 150 Volts and 
50 milliamps using a Novex x-cell surelock (Thermo Fisher Scientific MA, USA), powered by a 
Omnipac CS-300 V power supply (Cleaver Scientific, Rugby, UK). 
 
Separated proteins were transferred to a methanol activated PVDF membrane (Bio-Rad, 
Hertfordshire, UK) using a Trans Turboblot™ transfer system (Bio-Rad, Hertfordshire, UK). Following 
transfer, membranes were rinsed in ddH20 and washed in 1 X tris buffered saline with 0.1% 
Tween®20 (Sigma-Aldrich, Dorset, UK) (TBS-T) for 15 min, on a shaker at RT. Next, membranes were 
blocked with TBS-T containing 5% bovine serum albumin (BSA) for 1 h, on a shaker at RT. Membranes 
containing protein samples from serum and conditioned media were blocked with TBS-T containing 
5% milk, 2% BSA and 0.5% H2O2 for 1 h, on a shaker at RT. Membranes were then immuno-probed 
overnight at 4 °C on a shaker, with primary antibodies as described in Table 2.4. The following day 
membranes were subject to 3 x 15 min washes with 1X TBS-T and incubated with the appropriate 
secondary antibody (Table 2.5) in TBS-T, for 2 h, on a shaker at RT. Antibody was then removed and 
membranes washed 3 x 15 min with 1 X TBS-T on a shaker at RT. 
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Finally, Amersham ECL Western Blotting Detection Reagent (GE Healthcare, Buckinghamshire, UK) 
was added to cover membranes. Proteins were then visualised using a ChemiDoc™ MP System (Bio-
Rad, Hertfordshire, UK). In order to normalise protein load, membranes were stripped by performing 
2 X 10 min washes on a shaker at RT with Restore™ Western Blot Stripping Buffer (Life technologies, 
Paisley, UK). Membranes were then blocked as described above before being re-probed with the 
appropriate primary antibody (Table 2.4) overnight at 4 °C on a shaker. Proteins were probed with 
secondary antibody (Table 2.5) and visualised as described above. Protein expression was quantified 
using image J software. 
 
 









 Protogel ddH2O 1.5M Tris HCL 
pH 8.8 
0.5M Tris 






10% Separating gel 10.0 ml 12.5 ml 7.5 ml  N/A 150 µl 150 µl 30 µl 
12% Separating gel 12.0 ml 10.5 ml 7.5 ml N/A 150 µl 150 µl 30 µl 
5% Stacking gel 2.6 ml 12.2 ml N/A  5.0 ml 100 µl 100 µl 20 µl 
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  Table 2. 5 Secondary antibodies used for immunoblotting 
 
Protein target Manufacturer Catalogue # Clone  Dilution  Species 
Phospho AKT 308 Cell signalling technology CST 9275 05/2015 1:1000 Rabbit 
Phospho AKT 473 Cell signalling technology CST 9271 193H12 1:1000 Rabbit 
Total AKT Cell signalling technology CST 9272 C67E7 1:1000 Rabbit 
Phospho AMPK Cell signalling technology CST 2535S 40H9 1:1000 Rabbit 
Total AMPK Cell signalling technology CST 2532 N/A polyclonal 1:1000 Rabbit 
ß actin Sigma AC40 N/A polyclonal 1:5000 Mouse 
GLUT4  Abcam ab65267 mAbcam65267 1:1000 Mouse 
PI3K p85 Cell signalling technology CST 42285 19H8 1:1000 Rabbit 
Total PI3K Cell signalling technology CST 4257 N/A polyclonal 1:1000 Rabbit 
Phospho P38 MAPK Cell signalling technology CST 9211 N/A polyclonal 1:1000 Rabbit 
P38 MAPK  Cell signalling technology CST 9212 D13E1 1:1000 Rabbit 
Puromycin Millipore  MABE343 12D10 1:1000 Rabbit 
Vaspin  Abcam Ab 101391 N/A polyclonal 1:1000 Rabbit 
Protein target Manufacturer Catalogue # Dilution  
Rabbit IgG GE Healthcare Life Sciences NA931 1: 10,000 
Mouse IgG GE Healthcare Life Sciences NA934 1: 10,000 
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2.14 ELISA Enzyme-Linked Immunosorbent Assays (ELISA) 
2.14.1 IL6/IL-8 ELISA 
Concentrations of IL-6 and IL-8 in myotube supernatants were quantified using the relevant ELISA 
DuoSet (DY206/ DY208 R&D Systems, Minneapolis, MN, USA) following the manufacturer’s protocol. 
Firstly, capture antibody was diluted in PBS (pH 7.2) as specified by the manufacturer and added to 
the required wells of an uncoated nunc-ImmunoT ELISA plate (Thermo Fisher Scientific, MA, USA) 
overnight at RT. The following day, wells were washed 3 times with 300 µl wash buffer (PBS pH 7.2, 
containing 0.05% Tween® 20) and then blocked with reagent diluent (PBS containing 1% BSA) for 1 h. 
Plates were then aspirated and washed as described above. Next, protein standards were serially 
diluted 2-fold in reagent diluent. Standards and samples were then added to the plate in duplicate 
and incubated for 2 h at RT. Following incubation, plates were again washed as above, before the 
addition of capture antibody (diluted in reagent diluent to manufactures specification) for 2 h at RT. 
Streptavidin-HRP (diluted in reagent diluent) was then added to wells for 20 min at RT, in the dark. 
Following a final wash step as above, substrate solution was added to wells for up to 20 min. Finally, 
reactions were stopped by the addition of stop solution (2N H2SO4) and optical density immediately 
measured at 450 nm using a BioTek EL808 microtiter plate reader (BioTek, Swindon, UK). Optical 
imperfections in the plate were limited by correcting with absorbance measured at 570 nm. The 
average absorbance for each standard was used to generate a standard curve using GraphPad Prism 
v5 statistical package. Concentrations of unknown samples were then calculated using this standard 
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2.14.2 Vaspin ELISA 
Serum vaspin concentrations were measured using a commercially available human vaspin ELISA kit 
(AdipoGen Life Sciences, San Diego, CA, USA), following the manufacturer’s instructions. Firstly, 
vaspin standards were serially diluted 2-fold with ELISA buffer provided. Standards were then added 
to the ELISA plate along with serum samples (diluted 1:4 in ELISA buffer) in duplicate. The plate was 
then covered and incubated for 1 h at 37 C. Afterwards, wells were aspirated and washed 3 times 
with 1 X wash buffer supplied. Then, detection antibody was diluted 1:2000 with ELISA buffer and 
added to wells for 1 h at 37 C. Next, wells were aspirated and washed 3 times as described above 
before the addition of TMB substrate for 20 min, in the dark, at RT. Thorough mixing was ensured by 
tapping the plate gently. Finally, stop solution was added to wells and optical density was measured 
at 450 nm immediately using a BioTek EL808 microtiter plate reader (BioTek, Swindon, UK). Vaspin 
concentrations were determined from a standard curve as described in 2.14.1 
 
2.14.3 Human glycated haemoglobin A1c (HbA1c) 
Human serum HbA1c was quantified using a commercially available ELISA kit (Cusabio Biotek 
Hertfordshire, UK) following the manufacturer’s protocol. Firstly, standards were diluted in sample 
diluent to produce a 4-fold dilution series. Additionally, serum samples were diluted 1:5 in sample 
diluent. 50 µl of standards and samples were added to ELISA wells in duplicate. Next, 50 µl of Biotin-
conjugate was added to all wells except a blank and the plate incubated for 40 min at RT. Wells were 
then aspirated and washed 3 times by the addition of 200 µl of wash buffer provided. Then, 100 µl of 
HRP-avidin was added to all wells except the blank and incubated for 40 min at 37 °C. Following 
incubation, wells were washed 5 times as above before the addition of 90 µl TMB for 20 min at 37 °C 
in the dark. Finally, 50 µl of stop solution was added and optical density measured as described in 
2.14.1. 
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2.15 Isolation of total RNA 
Snap-frozen skeletal muscle and subcutaneous adipose tissue samples (~100 mg) were first ground 
into a fine powder using a pestle and mortar under liquid nitrogen. Powdered tissue was immediately 
transferred to a 1.5 ml RNAse free Lo-bind Eppendorf tube (Eppendorf, Stevenage, UK) containing 1 
ml of Trizol® reagent (Life technologies, Paisley, UK) and homogenised using a Qiagen Tissue Ruptor 
(Qiagen, Manchester, UK). Primary human myotubes were lysed by the addition of 1 ml of TRIzol® 
reagent directly to the tissue culture plate. Wells were scraped using a filter tip and TRIzol® solution 
transferred to a 1.5ml RNAse free Lo-bind Eppendorf tube. RNA was then extracted as described in 
the manufacturer’s protocol. Specifically, 200 µl of chloroform (CO549, Sigma-Aldrich, Dorset, UK) 
was added to TRIzol® samples and the chloroform/Trizol mixture shaken by hand for 15 s. Samples 
were then incubated at RT for 3 min before centrifugation (12,000 x g , 15 min, 4 °C). Next, the upper 
clear layer was transferred to a fresh Eppendorf tube and 500 µl of isopropanol (19516, Sigma-
Aldrich, Dorset, UK) and 2 µg of glycoblue (AM9156, Thermo Fisher Scientific MA, USA) was added to 
samples, before incubation overnight at -20 °C. The following day, samples were centrifuged (12,000 
X g, 4 °C, 15 min), supernatants were removed and RNA pellets re-suspended in 1 ml of 70% ethanol 
diluted in ddH2O. RNA was again pelleted by centrifugation (7500 X g, 5 min, 4°C) and the 
supernatant removed. Finally, RNA was vacuum dried and re-suspended in 30 μl of RNAse free water 
(Thermo Fisher Scientific, MA, USA) before heating at 55°C for 10 min. RNA was quantified using a 
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2.16 Quantitative Real-Time PCR 
One-step quantitative real-rime polymerase chain (qRT-PCR) was performed using either SYBR green 
or TaqMan chemistry in a 384 well PCR plate. The constituents per reaction are detailed in Table 2.6 
for SYBR chemistry and 2.7 for Taqman chemistry. The sequence of primers and probes used are 
reported in appendix 1. All reactions were performed using a Bio-rad sfx cycler (Bio-Rad 
Hertfordshire, UK) as described in Table 2.8. Samples were assayed in triplicate and a non-template 
control was included for each gene of interest to identify the formation of primer-dimers. CT values 
were determined as the point where the curve crossed the defined threshold in the exponential 
phase of RNA amplification. The efficiency of all primers was validated to be >95% and melt curves 
were included for all reactions to confirm the amplification of a single product. The quantity of target 
gene RNA, relative to the quantity of housekeeping gene RNA was calculated by 2 -ΔCt of target gene (treated -
control)/ 2-ΔCt housekeeping gene(treated -control). 
 
Additionally, the expression of 48 genes (appendix 2) related to the insulin signalling pathway were 
measured in human skeletal muscle tissue from lean, overweight and obese individuals using custom 
designed micro fluidics Taqman array cards (Thermo Fisher Scientific, MA, USA) as specified by the 
manufacture’s protocol. Briefly, RNA was extracted as described in section 2.15 and reverse 
transcribed to generate cDNA using TaqMan® MicroRNA Reverse Transcription Kit (Thermo Fisher 
Scientific, MA, USA). For each set of 48 genes, a 100 µl mastermix was then prepared from 50 µl of 
TaqMan® Fast Advanced Master Mix (2X) and 50 µl cDNA (10 ng/µl) in nuclease-free Water. Next, 
mastermix was transferred to wells by loading 100 µl of mastermix into the plate reservoirs. qRT-PCR 
was performed as described in table 2.8 (without reverse transcription) using a Quant Studio 12K 
Flex Real-Time PCR System (Thermo Fisher Scientific, MA, USA). Each sample was run in duplicate for 
all 48 genes. Data were analysed as above. 
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Reagent Volume/ reaction (µl) 
2X Precision one-step plus qRT-PCR (with SYBRgreen) mastermix 
(primer design, Eastleigh, UK) 
2.5  
Primers  0.2  
RNAse free H2O (primer design, Eastleigh, UK) 1.3  
RNA (5ng/l) 1.0  




Reagent Volume/ reaction (µl) 
2X iTaq Universal Probes reaction mix (Bio-Rad, Hertfordshire, UK) 2.5  
iScript advanced reverse transcriptase (Bio-Rad, Hertfordshire, UK) 0.125 
Probe/primer mix 0.2  
RNAse free H2O 1.175 
RNA (5ng/l) 1.0  










    

















Table 2. 8 qRT-PCR Protocol 
 
Protocol step Temperature (°C) Time Number of cycles 
1. Reverse transcription 55 10 min 1 
2. Activation of polymerase 95 8 min 1 
3. Denaturation  95 10 s 40 
4. Annealing and extension 60 60 s 40 
5. Melt curve 95 continuous 1 
6. Cooling 37 30s 1 
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2.17 Transfection of primary human myoblasts and Myotubes 
siRNA complexes (Table 2.9) were thawed on ice and TransIT-X2 reagent (Mirus Bio, WA, USA) was 
warmed to room temperature and vortexed gently. Transfection mixtures were then prepared in an 
RNAse free Eppendorf tube with volumes stated in table 2.10 and incubated at RT for 30 min. Fully 
differentiated primary human myotubes, or 2.5 X 104 primary human myoblasts seeded in a 96-well 
plate 24 h prior to transfection were incubated with the transfection mixture for 24 h. Following 
transfection, RNA was extracted as described in section 2.15 or functional studies performed. 
 
 
Target Manufacturer siRNA 
Non-targeting control (NTC 1) Dharmacon Non-targeting ON-TARGETplusTM Control siRNA #1   
Non-targeting control (NTC 2) Dharmacon  Non-targeting ON-TARGETplusTM Control siRNA #2 
HSPA5 (GRP78) (siRNA #1) Dharmacon ON-TARGETplus J-00819-09-0002 #1   
HSPA5 (GRP78) (siRNA #2) Dharmacon  ON-TARGETplus J-00819-06-0002 #2   
Table 2. 9 siRNAs used during myoblast and myotube transfection 
 













92 l 263 l 500 l 1.0 ml 2.5 ml 
Optimem medium 9l 26l 50l 100l 250 l 
siRNA (20 nM stock) 0.125 l 0.35l 0.7 l 1.4 l 2.8l 
TransIT-X2 reagent 0.3 l 0.78 l 1.5 l 3 l 7.5l 
Table 2. 10 Constituents per reaction for transfection using TransIT-X2 Dynamic Delivery System 
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2.18 Oil Red O staining of primary human myotubes 
Primary human myotubes grown in a 24-well plate were washed in PBS and fixed by the addition of 
250 µl 2% paraformaldehyde (PFA) (10160052, Thermo Fisher Scientific, MA, USA) diluted in PBS, for 
30 min at RT. PFA was removed and cells washed a further 3 times in PBS. Next, Oil red O (0625, 
Sigma-Aldrich, Dorset, UK) was diluted (0.5% (w/v) in 60% triethyl-phosphate (538726, Sigma-Aldrich, 
Dorset, UK) (diluted in ddH20). This stock was diluted 3:2 in ddH20 and filtered using a 0.22 µm filter. 
Working Oil red O stain was applied to myotubes for 1 h at RT. Oil red O stain was then removed and 
the cells washed 3 times with PBS. Cells were then imaged by bright field microscopy using a Leica 
DMI6000 microscope, with images taken from multiple locations per well. Lipid particle size was then 
quantified using image J software. To do this, images were first converted to 8-bit grayscale (2.1 A-B), 
next, the threshold of each image was adjusted to highlight pixels containing lipid stained areas (2.1 
C), and exclude background and large artefacts. Image J software was then used to calculate the 
average particle size of those selected particles (2.1 D). 
 
Following imaging, 250 µl of 100% isopropanol was added to liberate total oil red stain. 100 µl of Oil 
red containing isopropanol was then added in duplicate to a clear flat bottom 96-well plate. 
Absorbance was measured at 480 nm using a Synergy 2 Multi-Detection Microplate Reader (BioTek, 








    
   
70 
Figure 2. 1. Conversion of a bright field microscopy image to allow quantification of oil red O 























A                                                         B 
C                                                         D 
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2.19 Immunofluorescent staining of primary human myotubes 
Primary human myotubes were cultured in a 24-well plate and fixed in PFA as described in section 
2.19. Next cells were washed 3 X with PBS (500 µl) before being permeabilised by the addition of 
100% methanol for 10 min. Cells were then blocked for 30 min with 5% (v/v) goat serum diluted in 
PBS. Cells were then incubated with primary antibody (Table 2.11) overnight at 4 °C. The following 
day, primary antibody was removed and cells washed 3 times with PBS. Wells were then probed with 
an anti-mouse secondary antibody (Table 2.10) for 1 h in the dark. Wells were washed and nuclei 
stained by the addition of 200 µl DAPI (diluted 1:5000 in PBS) for 5 min in the dark. Finally, cells were 
washed as above, before the application of mountant and a cover slip. Cells were imaged 
immediately using a Leica DMI6000 microscope. 
 







Protein target Manufacturer Catalogue # Dilution  
Desmin Thermo Fisher MA5-13259 1: 200 
GLUT4 Abcam ab65267 1: 200 
Mouse IgG Thermo Fisher R37120 1:1000 
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2.20 MesoScale immunoassays 
Myotubes were cultured in 96-well plates and stimulated with 10 nM human insulin or 25-100 ng/ml 
of recombinant human vaspin. Cells were lysed in 90 µl MSD lysis buffer (MesoScale Discovery, 
Gaithersburg, Massachusetts) containing Phosphatase Inhibitor Cocktail 3 (1:100 dilution, Sigma-
Aldrich, Dorset, UK) and Protease Inhibitor Cocktail (1:100 dilution, Sigma-Aldrich, Dorset, UK). 
Insulin receptor, IGF1 receptor and AKT (Thr308) phosphorylation, as a percentage of total protein, 
was determined using Mesoscale Discovery phospho and total protein assays (MesoScale Discovery, 
MA, USA), performed according to the manufacturer’s instructions and detected on the SECTOR 
Imager 6000 (MesoScale Discovery, MA, USA). 
 
2.21 Measurement of primary human myotube glucose uptake  
Glucose uptake in primary human myotubes was quantified using either a radiometric or a 
fluorometric assay. For the radiometric assay, obese myotubes (differentiated for 8 days) were 
cultured in 6-well plates and either left unstimulated or were pre-incubated for 24 h with vaspin 
(100 ng/ml). The next day myotubes were washed twice in warm PBS and incubated in serum-free 
media (Ham’s F10) for 2 h. Myotubes were washed a further two times before incubation with 2 ml 
reaction buffer (138 mM NaCl, 1.85 mM CaCl2, 1.3 mM MgSO4, 4.8 mM KCl, 50 mM HEPES, pH 7.4, 
0.2% (W/V) BSA) for 45 min at 37 °C. Myotubes were then incubated with or without insulin (100 nM) 
for 30 min on a plate warmer at 37 °C before the addition of 250 µL of 27.8 kBq [3H]-2-DOG and 
10 µM 2-DOG at timed intervals to each well for 15 min. The buffer was aspirated with a vacuum 
pump and myotubes were washed three times with ice cold PBS containing 10 mM glucose. 
Myotubes were then lysed in 500 µL 0.5 M NaOH and 0.1% SDS then transferred to scintillation vials 
and 5 ml liquid scintillation fluid was added. Samples were vortexed and assayed for [3H]-2-DOG 
uptake expressed as disintegrations/min/well using a β-counter. 
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For the fluorometric assay, lean and obese myotubes cultured in 96-well plates were washed three 
times in PBS before incubation with glucose-free DMEM media (Gibco) for 3 h. Myotubes were 
washed a further three times before incubation with 100 µM 2-NBDG glucose (Sigma-Aldrich, Dorset, 
UK), diluted in glucose-free media with or without 100 nM insulin, for 30 min. Myotubes were 
subject to a further three washes with PBS before final addition of 100 µL PBS/well. Fluorescence was 
measured by excitation at 485 nm and emission at 528 nm using a Synergy 2 Multi-Detection 
Microplate Reader (BioTek, Swindon, UK). Untreated myotubes were included to correct for myotube 
auto-fluorescence. Five biological replicates were performed per condition for each primary human 
culture. 
 
2.22 Quantification of membrane-localised GLUT4 expression  
Primary human myoblasts (Passage 1-3, 105 cells/condition) from obese subjects were treated with 
either vaspin (100 ng/ml, 15 min) or insulin (100 nM, 15 min). Post-treatment, cells were washed 
with PBS (250 x g, 5 min, 4 °C) and stained for 20 minutes on ice with a mouse anti-human GLUT4 
monoclonal antibody (mAbcam65267, Abcam. 0.05 µg/105 cells, diluted in 2% BSA PBS). A second 
wash with PBS (250 x g, 5 min, 4 °C) was then performed, before cells were stained with 5 µg/ml 
Alexa Flour 488 goat anti-mouse IgG (Invitrogen, Thermofisher Scientific) for 20 min on ice. Following 
a single wash in PBS (250 x g, 5 min, 4 °C), cells were fixed for 20 minutes at RT with 50 µl of fixation 
medium (Medium A, Life Technologies). Following a single wash in PBS (250 x g, 5 mins, 4 °C), cells 
were re-suspended in 200 µl PBS and transferred to polypropylene FACS tubes in preparation for 
flow cytometric analysis. A minimum of 1,500 myoblasts were gated based on their forward/side 
scatter properties and analysed for GLUT4 expression, which was recorded as mean fluorescence 
intensity. Flow cytometry was performed on an AccuriC6TM bench top cytometer and analysis 
conducted using BD Accuri C6 software (BD Biosciences, Berkshire, UK). 
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2.23 Detection and quantification of adipose tissue derived extracellular 
vesicles  
Extracellular vesicles (EVs) were captured using a tetraspanin chip set with CD9, CD63, CD81 and 
Mouse IgG antibodies (Nanoview Biosciences, Boston, MA, USA). All assays were performed in 
accordance with the manufacturer’s protocol. Firstly, chip files on the USB drive provided were 
loaded onto the ExoView computer and chips pre-scanned using nScan2 V 2.76 acquisition software. 
Next, the void between wells of a 24-well tissue culture plate were filled with 0.22 µM filtered ddH20 
for humidification. Chips were then removed from storage (4 C) using tweezers and placed in the 
centre of a well with the chip ID facing up. Care was taken to avoid touching the face of the chip in 
order to prevent damage to antibody coated regions. Then, ACM samples, spun as described in 2.8 
were diluted 1:7 in incubation solution. 35 µL of diluted sample was then loaded onto the centre of 
the chip. The plate lid was then reapplied, before incubation for 16 h at RT in the dark. 
 
Following incubation, chips were washed by the addition of 1 ml of incubation solution, followed by 
shaking at 500 rpm for 3 min at RT. Afterwards, 750 l of the incubation solution was removed from 
the well and replaced with 750 µl of fresh incubation solution, followed by shaking at 500 rpm for 3 
min at RT. This process was repeated 3 times with 750 µl of incubation solution being removed after 
the final wash. Blocking solution was then prepared by diluting 2 ml of blocking solution (provided) 
1:1 with incubation solution. 5 l of CD9 Alexa-647, CD63 Alexa 488 and CD81 Alexa-555 fluorescent 
antibodies (provided) were then added to 3 ml of blocking solution. 250 µl of the antibody cocktail 
was then added to the well and incubated for 1 h at RT. 500 µl of incubation solution was then added 
to the well, followed by the immediate removal of 750 µl. 750 µl of fresh incubation buffer was then 
added to wells and plates washed at 500 rpm on a shaker for 3 min at RT. This process was repeated 
for a total of 3 washes. A final wash was then carried out by removing 750 l of incubation buffer 
followed by the addition of 750 l of rinse solution at 500 rpm on a shaker for 3 min at RT. 
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Finally, chips were removed using tweezers and placed into a 6 cm dish containing rinse solution. 
Chips were washed further with rinse solution by manually moving chips in a horizontal motion using 
tweezers. Chips were then slowly removed at a 45 angle, and placed on an absorbent paper towel 
to ensure chips were dry. Chips were then analysed using ExoView R100 (Nanoview Biosciences, 
Boston, MA, USA) with nScan2 V 2.76 acquisition software. Data was exported using nano-viewer 
V2.82 software, with particle size thresholds set to 50 to 200 nm. 
 
2.24 Treatment of primary human myotubes with adipose tissue derived 
extracellular vesicles 
EVs were isolated from ACM as described in section 2.9. Following ultracentrifugation, the EV pellet 
was re-suspended in an equal volume of myotube differentiation media. Primary human myotubes 
were then washed with PBS and incubated with EVs for 48 h followed by either functional 
experiments or extraction of RNA as described in section 2.15.  
 
2.25 Electrical pulse stimulation (EPS) of primary human myotubes 
Primary human myotubes derived from lean and obese individuals were cultured in a 6-well plate 
and subject to electrical pulse stimulation (EPS) at 11.5 V, 1 Hz and 2 ms for 24 h using a C-Pace EP 
(IonOptix, MA, USA). Differentiation media was replaced immediately prior to the start of EPS. 
Following EPS, protein or RNA was extracted as described in section 2.11 and 2.15 respectively. Three 
biological replicates for each condition were performed for primary human myotube culture. 
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2.26 Non-Radioactive Surface Sensing of Translation (SUnSET) Protein 
Synthesis  
Protein synthesis in response to EPS was measured via the SUnSET method, as described by 
Crossland et al. (390). Puromycin (Sigma-Aldrich, Dorset, UK) was added directly to myotubes 30 min 
prior to end of EPS to a concentration of 1 M. Protein was then extracted as described in section 
2.11 and immunoblotting for puromycin performed as described in section 2.13. 
 
2.27 Tissue Collection from Rodent models of Obesity and T2D 
Brown adipose tissue (BAT), subcutaneous white adipose tissue (SWAT) and epididymal white 
adipose tissue (EWAT) from various rat models of obesity and T2D (Table 2.11) were purchased from 
Charles River (Massachusetts, USA) and stored at -80°C until RNA was extracted as described in 
section 2.15. BAT, SWAT and EWAT from various mouse models of obesity and T2D (Table 2.12) were 
purchased from the Jackson Laboratory (Maine, USA) and stored at -80°C until RNA was extracted as 
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Strain Animal Characteristics 
 
Strain Code 
CD® Control Sprague Dawley rats, maintained on CRL 5L79 rodent chow. 1 
Zucker (Zuk) FA/FA Rat Obesity, Insulin Resistance, Hyperinsulinemia, Hypertriglyceridemia, 
Hypercholesterolemia, Metabolic Syndrome. Commonly used as an 
obese metabolic syndrome model. 
185 
ZDF FA/FA  ZDF (Zucker 
Diabetic Fatty) Rat 
Obesity, Insulin Resistance, Hyperinsulinemia, Type 2 Diabetes, 
Hyperglycemia, Hypertriglyceridemia, Hypercholesterolemia.  
370 
Obese Prone (OP)-CD 
Standard Diet (OP-CD)Rat 
Developed from a line of CD rats by selecting future breeders with 
accelerated weight gain. The OP-CD become obese when fed high-
fat diets. Polygenic obesity develops despite having a fully 
functioning leptin receptor. 
463 
Obese Resistant-CD Standard 
Diet (OR-CD) Rat 
Developed from a line of CD rats. This model does not become 
obese when fed high-fat diets. 
462 
OR-CD  (60% high fat diet) 10 
weeks- age matched to SD 
Fed D12492i rodent diet with 60 % Kcal fat, starting at 6 weeks of 
age and remained on HFD diet for 6 weeks (total 12 weeks of age). 
462 
OP-CD  (60% high fat diet) 10 
weeks- age matched to SD 
Fed D12492i rodent diet with 60 Kcal% fat starting at 6 weeks of age 
and remained on HFD diet for 6 weeks (total 12 weeks of age). 
463 
Table 2. 12 Details of mouse models from which adipose tissue samples were used. 
  
  
Strain Animal Characteristics 
 
Strain Code 
C57Bl6 J (SD) Control animals, fed LabDiet® 5K52 formulation (6% fat). 000664 
C57Bl6 J (HFD) C57BL/6J mice fed D12492 (60 kcal% fat) diet. Mice are obese and 
display mild hyperglycaemia, dyslipidaemia, and impaired glucose 
tolerance. 
380050 
B6.Cg-Lep ob/J (ob ob) Mice exhibit obesity, hyperphagia, transient hyperglycemia, glucose 
intolerance, and elevated plasma insulin. Mice were maintained on 
LabDiet® 5K20 formulation (10% fat). 
 
000632 
B6.BKS (D)-Lep db/J (db db) Mice exhibit obesity, polyphagia and hyperinsulinemia throughout 
an 18- to 20-month life span. Mice were maintained on LabDiet® 
5K52 formulation (6% fat) 
 
000697 
Table 2. 13 Details of rat models from which adipose tissue samples were used. 
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2.28 Data handling and statistical analysis 
Data analysis was carried out using GraphPad Prism v5 statistical package. Normality of data was 
established by performing Shapiro–Wilk analysis. For normally distributed data, statistical 
significance was determined by performing paired and unpaired t-tests as appropriate or ANOVA 
with Dunnett’s post-hoc tests for experiments with multiple groups, as detailed in the figure legends. 
Statistical significance of non-parametric data was assessed by performing a Wilcoxon-signed rank 
test for paired data or Man-Whitney U test for data with 2 independent groups. Correlations were 
assessed by determining the Pearson correlation coefficient for parametric data. Parametric data 
with more than 2 variables was assessed by performing 2-way ANOVA. Data is presented as 














    























    




Obesity is a significant risk factor for the development of skeletal muscle insulin resistance and is also 
associated with chronic inflammation and skeletal muscle atrophy (Sarcopenic obesity) (391). 
However, performing in vivo mechanistic studies to investigate the impact of increased adiposity on 
human skeletal muscle metabolic function is challenging, due to the presence of inter-organ crosstalk 
and limitations in both experimental conditions and subject numbers. As a result, immortalised 
murine (C2C12) and Rat (L6) myoblast cell lines have commonly been used in skeletal muscle 
research since the late 1960s (392, 393). These cell lines provide a valuable tool, as they can be 
rapidly expanded to facilitate numerous investigations, devoid of external stimuli. However, despite 
being of skeletal muscle origin, the translation of findings from such studies to human skeletal 
muscle has not been studied in depth and so should be interpreted with caution. 
It is also possible to culture primary human myotubes from satellite cells obtained via enzymatic 
digestion of human skeletal muscle tissue. Although obtaining human skeletal muscle tissue is an 
invasive procedure and culture growth rates are considerably slower than rodent cell lines, primary 
human myotubes are advantageous as they facilitate studies of skeletal muscle metabolic function 
that are physiologically relevant to humans. Indeed, a number of studies have reported that primary 
human myotubes from individuals with T2D retain the phenotype of their donor. Firstly, Nikoulina et 
al. demonstrated an impaired interaction of IRS1 with PI3K following insulin stimulation of primary 
human myotubes derived from individuals with T2D (394), a finding since corroborated by Bouzakri 
et al. (395). Further downstream in the insulin signalling cascade, Cozzone et al. reported blunted 
insulin induced phosphorylation of both AKTSer473 and AKTThr308 residues in primary human myotubes 
cultured from diabetic individuals (396). 
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Functionally, it appears that, as in vivo, such blunted activation of the insulin signalling pathway in 
T2D myotubes results in a reduction of both insulin stimulated glycogen synthesis and glucose uptake 
(397, 398). 
However, studies investigating the impact of obesity on primary human myotube function are 
limited, particularly in cells derived from elderly donors, the population most associated with skeletal 
muscle dysfunction. Therefore, in this chapter we aimed to investigate the impact of obesity on 
elderly primary human myotube function and determine if primary human myotubes provide a 
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3.1.1 Chapter aims 
 
This chapter aims to: 
 Measure the mRNA expression of genes associated with insulin signalling and glucose 
metabolism in human skeletal muscle tissue from lean and obese individuals to identify 
candidate genes that are differentially expressed with increased adiposity.  
 
 Determine if differential gene expression in human skeletal muscle tissue is retained in primary 
human myotubes cultured from lean and obese individuals. 
 
 Determine the impact of obesity on primary human myotube function, including myotube insulin 
sensitivity and inflammation. 
 
 Utilising an in vitro model of exercise, determine the impact of obesity on the hypertrophic 
response of primary human myotubes. 
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3.2 Results 
3.2.1 Insulin signalling associated gene expression in skeletal muscle tissue from 
individuals with differing adiposity 
We first investigated the expression of 48 genes related to the insulin signalling pathway in skeletal 
muscle tissue derived from lean, overweight and obese individuals, in order to identify candidate 
genes that are differentially expressed with increasing adiposity and may impact skeletal muscle 
insulin sensitivity. 
Overall, there was little difference in the gene expression profile between lean and obese individuals 
in all groups of genes (Figure 3.1 A-E). However, the expression of fructose bisphosphatase 1 (FBP1) 
was approximately 2-fold greater in skeletal muscle tissue obtained from obese individuals (2.8 ± 0.4) 
in comparison to both lean (1.4 ± 0.4) and overweight (1.5 ± 0.1) individuals (P = 0.011). Additionally, 
FBP1 expression displayed a significant positive correlation with BMI (P = 0.0058 r2 0.35), bodyweight 
(P = 0.028 r2 = 0.24) and % body fat (P = 0.0008, r2 = 0.48) (Figure 3.2 A-C). FBP1 expression also 
displayed a positive trend with waist to hip ratio; however this was not statistically significant (Figure 
3.2 D). Additionally, the mean expression of TBC1D4, (coding for AS160), was lower in skeletal muscle 
tissue derived from obese individuals (0.51 ± 0.05) in comparison to overweight individuals (0.9 ± 0.1, 
P = <0.05). Despite such differential expression, there was no correlation between TBC1D4 
expression and patient characteristics. 
Furthermore, mean PPARD expression was less on average in obese individuals in comparison to 
both lean and overweight individuals, although this difference did not reach statistical significance (P 
= 0.072) and again did not correlate with patient characteristics. Conversely both CEBPA and CEBPB 
expression was observed to be elevated in both overweight and obese skeletal muscle tissue in 
comparison to lean skeletal muscle tissue (Figure 3.1 D). Although such differences were not 
statistically significant, there was a significant positive correlation between CEBPA expression and % 
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body fat (P = 0.030, r2 = 0.20). Similarly a positive trend in CEBPB mRNA expression and % body fat (P 
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Figure 3. 1. mRNA expression of insulin signalling pathway associated genes in human skeletal 
muscle tissue of individuals with varying BMI. 
A. mRNA expression of early insulin signalling pathway genes, n = 8 Lean (L), n = 9 overweight (Ow) 
and n = 7 obese (Ob) for all genes, except IRS2 (n = 8 L, n = 9 Ow, n = 6 Ob) and IRS4 (n = 7 L, n = 6 Ow, 
n = 4 Ob). B. mRNA expression of PI3K-AKT signalling pathway genes, n = 8 L, n = 9 Ow and n = 7 Ob for 
all genes, except PI3K (n = 8 L, n = 9 Ow, n = 6 Ob). C. mRNA expression of insulin signalling 
downstream effector genes, n = 8 L, n = 9 Ow and n = 7 Ob for all genes. D. mRNA expression of genes 
associated with lipid metabolisms, n = 8 L, n = 9 Ow and n = 7 Ob for all genes, except CEBPB (n = 8 L, n 
= 9 Ow, n = 6 Ob) and IRS4 (n = 7 L, n = 6 Ow, n = 4 Ob). E. mRNA expression of genes associated with 
glucose metabolism. n = 8 L, n = 9 Ow and n = 7 Ob for all genes, except FEBP1 (n = 6 L, n = 8 Ow, n = 6 
Ob. Expression of mRNA was normalised to the mean of GAPDH and β actin housekeeping genes. Data 
are presented as mean ± S.E.M. *denotes a significant (P < 0.05) difference between groups as 
determined by post hoc t-tests with Bonferroni adjustment, following One-way ANOVA. 
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Figure 3. 2. Correlation of FBP1 mRNA expression in skeletal muscle tissue with subject 
characteristics. 
A. Correlation of FBP1 expression in skeletal muscle tissue with BMI. B. Correlation of FBP1 
expression in skeletal muscle tissue with bodyweight. C. Correlation of FBP1 expression in 
skeletal muscle tissue with % body fat as measured by bioimpedance. D. Correlation of 
FBP1 expression in skeletal muscle tissue with waist:hip. n = 20 for all correlations. 
Expression of mRNA was quantified by qRT-PCR, and normalised to the mean of GAPDH and 
β actin housekeeping genes. 
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PC                                                            D P = 0.0517 




A                                                              B 
Figure 3. 3. Correlation of CEBPA mRNA expression in skeletal muscle tissue with subject 
characteristics. 
A. Correlation of CEBPA expression in skeletal muscle tissue with BMI. B. Correlation of 
CEBPA expression in skeletal muscle tissue with bodyweight. C. Correlation of CEBPA 
expression in skeletal muscle tissue with % body fat as measured by bioimpedance. D. 
Correlation of CEBPA expression in skeletal muscle tissue with waist:hip. n = 24 for all 
correlations. Expression of mRNA was quantified by qRT-PCR, and and normalised to the 
mean of GAPDH and β actin housekeeping genes. 
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Figure 3. 4. Correlation of CEBPB mRNA expression in skeletal muscle tissue with subject 
characteristics. 
A. Correlation of CEBPB expression in skeletal muscle tissue with BMI. B. Correlation of 
CEBPB expression in skeletal muscle tissue with bodyweight. C. Correlation of CEBPB 
expression in skeletal muscle tissue with % body fat as measured by bioimpedance. D. 
Correlation of CEBPB expression in skeletal muscle tissue with waist: hip. n = 24 for all 
correlations. Expression of mRNA was quantified by qRT-PCR, and normalised to the mean 
of GAPDH and β actin housekeeping genes. 
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Figure 3. 5. Validation of differential gene expression in skeletal muscle tissue by qRT-PCR. 
A. FBP1 expression in skeletal muscle tissue from lean (n = 6) and obese (n = 6) subjects.  
B. TBC1D4 expression in skeletal muscle tissue from lean (n = 5) and obese (n = 5) subjects. Data 
presented as mean ± S.E.M. Expression of mRNA was quantified by qRT-PCR, and normalised using 















3.2.2 Validation of differential gene expression in skeletal muscle tissue by qRT-PCR 
Next, in order to validate the differential gene expression of FBP1 and TBC1D4 observed in the 
skeletal muscle tissue of obese individuals, we measured FBP1 and TBC1D4 mRNA expression in 
human skeletal muscle tissue samples derived from lean and obese individuals by performing 
individual qRT PCR. As in 3.2.1, mean FBP1 expression was greater in skeletal muscle tissue of obese 
individuals in comparison to lean individuals, but this was not statistically significant (Figure 3.5 A), 
while TBC1D4 expression was again significantly less in skeletal muscle tissue derived from obese 
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3.2.3 Validation of differential gene expression in primary human myotubes by qRT-PCR  
Having identified differentially expressed gene targets in the skeletal muscle tissue of obese 
individuals, we then aimed to identify if such differential expression is retained in primary human 
myotubes cultured from lean and obese individuals. All experiments were performed on myotubes 
differentiated for 8 days. 
Firstly, the successful culture of primary human myotubes from skeletal muscle tissue was confirmed 
via immunofluorescent staining of primary human myotubes for the muscle specific marker, desmin. 
Cells cultured from human skeletal muscle tissue consistently displayed multinucleated, desmin 
positive myotube structures (Figure 3.6 A). Similar to skeletal muscle tissue, the expression of FBP1 
was greater on average in primary human myotubes from obese individuals (0.002 ± 0.001) in 
comparison to lean individuals (0.0002 ± 0.0001), however this was not statistically significant (Figure 
3.6 C, P = 0.11). Additionally, TBC1D4 mRNA expression was ~50% less on average in obese primary 
human myotubes (0.04 ± 0.01) in comparison to lean myotubes (0.1 ± 0.06), however again this did 
not reach statistical significance (Figure 3.6 D). 
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Figure 3. 6. Differential gene expression in primary human myotubes from lean and obese 
donors. 
A. Brightfield imaging of primary human myotubes. B. Immunofluorescent staining of primary 
human myotubes for desmin (green) and DAPI (blue). C. FBP1 mRNA expression in primary 
human myotubes from lean (n = 5) and obese (n = 5). D. TBC1D4 mRNA expression in primary 
human myotubes from lean (n = 5) and obese (n = 5) donors. Expression of mRNA was 
quantified by qRT-PCR, and normalised using GAPDH, expressed as relative quantification (RQ). 
Data presented as mean ± S.E.M. Statistical significance was determined via unpaired T-tests. 
P = 0.11 
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3.2.4 Obesity impairs insulin sensitivity in primary human myotubes 
Following the observation that primary human myotubes may retain donor characteristics of mRNA 
expression, we next investigated if primary human myotubes derived from obese individuals 
(differentiated for 8-days) exhibit functional differences in insulin sensitivity. 
Primary human myotubes derived from lean individuals displayed relatively little basal 
phosphorylation of AKTSer473. Following acute insulin stimulation (100 nM, 0-30 mins) AKT 
phosphorylation increased rapidly in a time dependant manner, up to 3-fold (Figure 3.7 A). In 
contrast, myotubes derived from obese individuals appeared to exhibit increased phosphorylation of 
AKT at baseline and displayed a blunted response to insulin, increasing only 1.2-fold following 30 min 
of insulin stimulation (Figure 3.7 B). Additionally, insulin induced phosphorylation of AKTThr308 was 
also measured by mesoscale analysis (Figure 3.7 D). Phosphorylation of AKTThr308 increased 
approximately 1.5-fold in response to 3 - 30 nM insulin in lean myotubes. However, again, myotubes 
derived from obese individuals demonstrated a reduced response, increasing only approximately 1.2-
fold in response to 30 nM insulin. 
Following the observation of blunted insulin induced activation of the insulin signalling pathway in 
obese myotubes, we then investigated the potential downstream impact on glucose uptake. Primary 
human myotubes cultured from lean subjects increased glucose uptake approximately 2-fold in 
response to insulin (100 nM, 30 min) (Figure 3.8). In contrast, myotubes cultured from obese subjects 
displayed blunted glucose uptake to the same stimuli (Figure 3.8). 
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Figure 3. 7. The insulin signalling response is blunted in primary human myotubes derived from 
obese individuals. 
A. Phosphorylation of AKTSer473 in primary human myotubes derived from lean individuals following 
100 nM insulin stimulation (n = 3 primary donors, 15 g protein loaded per lane). B. 
Phosphorylation of AKTSer473 in primary human myotubes derived from lean individuals following 
100 nM insulin stimulation (n = 3 primary donors, 15 g protein loaded per lane). C. Densitometric 
analysis of Phospho AKTSer473 western blots normalised to total AKT. D. Phosphorylation of AKTThr308 
in lean (n = 2) and obese (n = 2) primary human myotubes in response to 30 min insulin, measured 
by mesoscale analysis. Data are represented as mean ± S.E.M. * signifies P < 0.05, ** signifies 
P < 0.01, indicating a significant increase in AKT phosphorylation following insulin stimulation, as 
determined by Bonferroni post- hoc tests following 2-Way ANOVA. 
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Figure 3. 8. Insulin stimulated glucose uptake is blunted in primary human myotubes cultured 
from obese individuals. 
Effect of insulin (100 nM, 30 min) on 2-NBDG glucose uptake in primary human myotubes derived 
from lean (n = 4 females) and obese (n = 3 females) subjects. Data presented as mean ± S.E.M. 
*P < 0.05, indicates a significant effect of insulin stimulation as determined by Bonferroni post- 
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3.2.5 Obesity increases proinflammatory cytokine release from primary human myotubes 
Obesity is often associated with a chronic increased inflammatory burden that may also contribute to 
the development of skeletal muscle insulin resistance. Therefore, we investigated whether primary 
human myotubes from obese individuals are inherently more inflammatory. Myotubes cultured from 
obese individuals secreted a significantly greater amount of IL-6 (144 ± 82 pg/ml) under basal 
conditions in comparison to lean individuals (Figure 3.9 A, P = 0.027), with IL-6 being undetectable in 
the supernatants from 3 of 4 lean individuals. Additionally, basal IL-6 secretion displayed a significant 
positive correlation with BMI (Figure 3.9 B, r2 = 0.89, P = 0.0072). Stimulation of primary human 
myotubes with IL-1 (1 ng/ml, 4 h) evoked a significant increase in IL-6 secretion of a similar amount in 
both lean and obese individuals (Figure 3.9 A). On average, basal secretion of IL-8 was also greater in 
obese myotubes compared to lean myotubes. However, the amount of secreted IL-8 detected was 
highly variable across patient samples and as such this observation did not reach statistical 
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Figure 3. 9. Pro-inflammatory cytokine secretion from primary human myotubes derived from 
lean and obese individuals. 
A. Concentration of IL-6 in the supernatant of primary human myotubes from lean (n = 4) and obese 
(n = 4) individuals under basal conditions (24 h) (clear bars) and following IL-1 stimulation (1 ng/ ml, 
4 h,) (filled bars). B. Correlation of basal IL-6 secretion (24 h) from primary human myotubes with 
BMI. C Concentration of IL-8 in the supernatant of primary human myotubes cultured from lean (n = 
4) and obese (n = 4) individuals under basal conditions (24 h). All myotubes were differentiated for 8 
days. Data are represented as mean ± S.E.M. *signifies a significant (P < 0.05) difference in IL-6 
secretion between unstimulated lean and obese myotubes as determined by Bonferroni post-hoc 
tests following 2-Way ANOVA. ** signifies a significant P < 0.01 effect of IL-1 stimulation on Il-6 
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Figure 3. 10. Oil Red O Staining of primary human myotubes cultured from lean and obese 
individuals. 
A. Size of Oil Red O positive lipid droplet particles in lean (n = 3) and obese (n = 3) primary human 
myotubes. B. Absorbance of liberated Oil Red O stain in lean (n = 3) and obese (n = 3) primary 
human myotubes, normalised to total protein content. Data are represented as mean ± S.E.M. 
 
3.2.6 Obesity does not affect intramyocellular lipid content in primary human myotubes 
 
In order to investigate the effect of obesity on intramyocellular lipid content, primary human 
myotubes were stained with Oil Red O. No significant difference in either the average particle size, or 
total intracellular lipid content (normalised to total protein content) was observed between primary 
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3.2.7 Atrophic gene expression is upregulated in the skeletal muscle of obese individuals 
In addition to insulin resistance, obesity is associated with the development of sarcopenic obesity, 
characterised a reduction of skeletal muscle mass and quality. Thus, we measured mRNA expression 
of atrophic genes in skeletal muscle tissue from lean and obese individuals. 
The expression of both the cysteine protease calpain 2 and myostatin was approximately 2-fold 
greater in the skeletal muscle tissue of obese individuals (P = 0.017 and P = 0.0026 respectively). 
Additionally, the expression of calpain 1 in obese individuals (1.6 ± 0.2) was greater on average than 
in lean individuals (1.1 ± 0.2) (P = 0.096). In contrast, no significant difference in MAFbx of MuRF1 
expression was observed between lean and obese individuals (Figure 3.11 A). 
Following the identification of differential expression of atrophic genes in human skeletal muscle 
tissue, we next measured such gene expression in primary human myotubes cultured from lean and 
obese individuals, in order to determine if differential expression of atrophic genes is maintained in 
primary human cultures. The expression of FOXO3, MAFbx and myostatin was significantly (P < 0.05) 
upregulated in the primary human myotubes cultured from obese individuals (Figure 3.11 B). 








    

































































































Figure 3. 11. Atrophic gene expression in human skeletal muscle tissue and primary human 
myotubes from lean and obese individuals. 
A. mRNA expression of MAFbx, MuRF1 (n = 8 lean, n = 10 obese) FOXO3, calpain 1, calpain 2 and 
myostatin (n = 5 lean, n = 6 obese) in skeletal muscle tissue. B Atrophic gene expression in primary 
human myotubes (n = 4 lean and n = 4 obese). Data are represented as mean ± S.E.M. Expression 
of mRNA was quantified by qRT-PCR, and normalised using GAPDH. Data are represented as 
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3.2.8 The Contraction induced hypertrophic response of myostatin suppression is 
intrinsically impaired in obese primary human myotubes 
Finally, we aimed to determine whether myotubes cultured from lean and obese individuals display a 
differential hypertrophic response to exercise. To achieve this, primary human myotubes were 
subject to electrical pulse stimulation (EPS) to replicate a hypertrophic exercise response in vitro. 
 First, to validate that EPS induced hypertrophy, protein synthesis was measured via the SUnSET 
method. Treatment of primary human myotubes with puromycin (30 min) increased puromycin 
positive protein expression indicating puromycin incorporation, as detected by immunoblotting 
(Figure 3.12). Additionally, puromycin positive protein was detected following EPS, even in the 
absence of puromycin. Following 24 h of EPS, more puromycin was detected in comparison to 
unstimulated myotubes via immunoblotting, indicating greater puromycin incorporation and 
therefore increased protein synthesis (Figure 3.12 A).  
EPS evoked a significant (2-fold) decrease in the expression of myostatin mRNA in primary human 
myotubes from lean individuals (Figure 3.12 B). In contrast, no decrease in myostatin mRNA was 
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Figure 3. 12. The hypertrophic response to EPS in primary human myotubes. 
A. Representative western blot of puromycin protein content in primary human myotubes with 
and with without EPS (24 h) and with and without puromycin (final 30 min of EPS stimulation) 
(15 µg protein loaded per lane). B. Myostatin mRNA expression in lean and obese primary 
human myotubes following 24 h EPS. Expression of mRNA was quantified by qRT-PCR, and 
normalised using GAPDH. Data are presented as mean ±S.E.M. * signifies a significant (P < 0.05) 
effect of EPS on myostatin expression as determined by post hoc T-tests with Bonferroni 
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3.3.1 The impact of obesity and primary human myotube insulin sensitivity and glucose 
uptake 
Profiling of genes associated with insulin signalling and glucose metabolism in human skeletal muscle 
tissue from lean, overweight and obese subjects identified a significant upregulation of FBP1 and a 
significant downregulation of TBC1D4 mRNA expression in obese individuals, in comparison to lean 
and overweight individuals. Additionally, differential expression of FPB1 and TBC1D4 was also 
observed between primary human myotubes cultured from lean and obese individuals, although 
such changes were not statistically significant. 
The gene FBP1 encodes for the protein fructose-1, 6-bisphosphatase (FBPase), a rate-limiting enzyme 
within the gluconeogenesis pathway, which acts to catalyse the irreversible hydrolysis of fructose 1, 
6-bisphosphate, in turn generating fructose-6-phosphate and inorganic phosphate. In line with the 
findings of this investigation, increased hepatic FBPase protein expression and activation has been 
reported in rodent models of obesity and insulin resistance (399, 400). Additionally, gluconeogenesis 
is upregulated in humans with T2D and contributes to the hyperglycaemia typically seen in this 
patient population (401). It is likely that such increased gluconeogenesis is due to increased FBPase 
protein expression and or activity (402, 403) although direct evidence of this in human tissue has not 
been reported to date.  
Experimentally, Zhang et al. demonstrated that FBP1 expression also increased in pancreatic β-cells 
following high glucose and lipid challenge and over-expression of FBP1 significantly impaired insulin 
secretion in these cells (404). In contrast, siRNA-mediated downregulation of FBP1 in pancreatic β-
cells induced insulin secretion, while pharmacological inhibition of FBPase in a ZDF rat model of T2D, 
significantly reduced gluconeogenesis and blood glucose concentrations within 2 weeks (404, 405). 
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Interestingly, glucose stimulated insulin secretion in this model was also increased following FBP1 
inhibition, indicating improved pancreatic function (405).  
In light of such data, FBP1 has gained interest as a therapeutic target for the treatment of T2D, with 
the aim of limiting hyperglycaemia by reducing glucose production at the source, as opposed to 
increasing insulin production and insulin sensitivity of target tissues. To this end, a number of FBP1 
inhibitors have progressed to clinical trials (406). Additionally, metformin, one of the most commonly 
used treatments for T2D, was recently demonstrated to achieve its anti-hyperglycaemic effect in part 
through FBP1 inhibition (407). It is important to note that the studies discussed above have almost 
exclusively been performed with a focus on liver metabolism and function, due to the liver being the 
primary site of gluconeogenesis in humans. As increased FBP1 expression was observed in skeletal 
muscle in this thesis, further investigation into the impact of increased FBP1 on skeletal muscle 
metabolism and its contribution to hyperglycaemia associated with obesity and T2D is needed. 
As discussed in depth in section 1.3.4, TBC1D4 codes for the protein AS160, a GEF that facilitates the 
conversion of a Rab protein associated with GLUT4 translocation from its GTP to GDP bound state. 
RabGDP is functionally inactive and as a result GLUT4 translocation to the cell membrane is inhibited, 
resulting in decreased glucose uptake. Therefore, a decrease in TBC1D4 expression would be 
expected to result in less conversion of RabGTP to RabGDP, facilitating greater GLUT4 translocation 
to the sarcolemma. This was unexpected, as obesity is associated with decreased glucose uptake and 
insulin resistance (408). A possible explanation for this observation is that a reduction in TBC1D4 
occurs as a compensatory mechanism to overcome reduced insulin stimulated AKT activation in the 
obese state. However, TBC1D4 knockdown models do in fact display impaired insulin resistance due 
to a dysregulation of GLUT4 trafficking, causing elevated membrane GLUT4 at baseline (409). 
Therefore such an effect may also be present in primary human myotubes. 
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Moreover, no significant differences in the mRNA expression of genes encoding for early insulin 
signalling pathway proteins, such as IR, IRS, PI3K, or AKT were observed between skeletal muscle 
tissue from lean, overweight and obese individuals. However, this was not surprising as a number of 
studies, including comparisons between diabetic and non-diabetic twins, have reported little change 
in the expression of such genes or their gene products (410, 411). Thus, skeletal muscle insulin 
resistance is more likely attributable to a disruption of protein kinase activation rather than a 
reduction in the insulin signalling capability of muscle.  
Therefore, we next investigated the functional impact of increased adiposity on primary human 
myotube insulin signalling and glucose uptake. As expected, acute insulin stimulation evoked an 
increase in both AKT activation and glucose uptake in lean myotubes. Critically, myotubes derived 
from obese individuals displayed a considerably blunted response to insulin stimulation, with no 
significant increase in either AKT phosphorylation or glucose uptake observed. A similar blunting of 
AKT phosphorylation has previously been reported in primary human myotubes derived from 
diabetic individuals, with AKT2 and AKT3 isoforms showing the greatest impairment (396). 
Additionally, a reduction in glucose uptake and glycogen synthesis has also been reported in primary 
human myotubes from diabetic individuals (397). In contrast, a similar investigation by Gaster et al. 
found no discernible difference in insulin stimulated glucose uptake in primary human myotubes 
derived from lean or obese individuals (412). However, this may have been due to the average age of 
subjects being considerably lower (49 years) in comparison to this thesis, suggesting metabolic 
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3.3.2 Obesity increases proinflammatory cytokine release from primary human myotubes 
Obesity is associated with a state of chronic low grade inflammation, attributable to an increased 
mass of inflamed adipose tissue, secreting a plethora of proinflammatory cytokines. In turn, such 
increased inflammation is associated with the development of skeletal muscle insulin resistance 
(413). However, few studies have investigated the direct impact of obesity on skeletal muscle 
inflammation. To this end, we measured proinflammatory cytokine release from primary human 
myotubes cultured from lean and obese donors.  
Under basal conditions, primary human myotubes cultured from obese individuals secreted a 
significantly greater amount of IL-6, in comparison to lean individuals. A similar increase in IL-6 
release from T2D myotubes has recently been observed by Ciaraldi et al. (414). In contrast, Jiang et 
al. reported that IL-6 secretion did not differ between primary human myotubes from T2D individuals 
in comparison to healthy individuals (415). However, this lack of differential IL-6 secretion may be 
attributable to both the control and T2D subjects being overweight, and of a similar BMI. Therefore, 
IL-6 secretion may still have been elevated in comparison to a lean control group. Transient IL-6 
secretion from skeletal muscle occurs in response to exercise, and in turn may improve skeletal 
muscle insulin sensitivity (416). Such a sensitising effect of IL-6 has since been demonstrated in 
primary human myotubes (415, 417-419). However, chronic elevation of IL-6 is associated with the 
development of skeletal muscle insulin resistance, potentially mediated by impairment of IRS1/2 
activation (420). Thus, increased skeletal muscle derived IL-6 in obese individuals, may act in an 
autocrine and paracrine fashion to drive the development of skeletal muscle insulin resistance. 
Furthermore, we also demonstrated, for the first time, the IL-1β-mediated secretion of IL-6 from 
primary human myotubes. Although there was no significant difference in the amount of IL-1β 
induced IL-6 secretion between donor groups, this finding may carry a greater impact in vivo. This is 
because muscle interstitial IL-1β concentrations are likely to be greater in the obese state and thus 
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more likely to evoke muscle IL-6 release, further contributing to a localised proinflammatory 
microenvironment conducive to the development of insulin resistance (421). 
Myotubes cultured from obese individuals also secreted a greater amount of IL-8 on average in 
comparison to lean myotubes, although this did not reach statistical significance. Similarly, Ciaraldi et 
al. also demonstrated that primary human myotubes cultured from individuals with T2D secreted a 
significantly greater amount IL-8, in addition to other myokines such as IL-15, MCP1 and TNFα in 
comparison to non-diabetic individuals (414). IL-8 is a potent neutrophil attractant; however the 
impact of obesity on neutrophil infiltration of skeletal muscle has not been reported. Indeed, studies 
investigating obesity induced immune cell infiltration of skeletal muscle and the consequent impact 
on its function are scarce, especially in comparison to similar studies in adipose tissue. However, 
there is evidence of M1 macrophage and T cell (CD4+ and CD8+) infiltration in both HFD fed mice and 
in obese insulin resistant humans (422-424). Additionally, such immune cell infiltration has been 
associated with muscle insulin resistance (422, 424). Thus, further studies investigating skeletal 
muscle and immune cell crosstalk in obesity and its impact on insulin sensitivity are warranted.  
The increase in proinflammatory cytokine secretion observed from obese myotubes in this thesis 
could be due, in part, to increased activation of NFKB signalling. NFKB is a well-known positive 
regulator of proinflammatory cytokine expression and has previously been shown to be activated to 
a greater extent in both obese muscle and myotubes cultured from obese individuals (425, 426). 
Additionally, CEBPA and CEBPB are members of the CCAAT/enhancer binding factor family of 
proteins and also function as positive regulators of proinflammatory cytokine transcription (427).  
Although not significantly different, a positive correlation of both CEBPA and CEBPB (P = 0.057) 
expression with percentage body fat was observed in skeletal muscle tissue in this thesis. Therefore, 
such an upregulation in CEBPA/B may also contribute to the increased proinflammatory cytokine 
secretion observed in obese myotubes. However currently, no studies have investigated CEBP family 
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mediated regulation of inflammation in skeletal muscle or primary human myotubes, thus further 
studies would be needed to confirm this. 
 
3.3.3 Obesity does not impact primary human myotube lipid content. 
Obese and T2D individuals classically present with ectopic accumulation of intramuscular adipose 
tissue and increased intramuscular lipid content (176, 396). Such increased intramyocellular lipid 
content has since been implicated in the development of skeletal muscle insulin resistance, as 
discussed in section 1.5 of this thesis. However, we observed no significant difference in lipid content 
or lipid droplet size between myotubes cultured from lean and obese individuals, as determined by 
oil red O staining. In line with this finding, Bajbeyi et al. also saw no significant difference in myotube 
lipid content in lean and obese individuals with T2D (184). This suggests such altered lipid 
accumulation observed in vivo is not retained in myotubes in culture, perhaps indicating that lipid 
accumulation is more dependent on available nutrient supply. However, it should be noted that 
although lipid staining in this thesis appeared to be located within myotubes, further 
immunohistochemical staining would have been useful to confirm that the cells used in this 
experiment were indeed multinucleated myotubes and that oil red O positive areas were not due to 
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3.3.4 Primary human myotubes from obese individuals maintain upregulated expression 
of atrophic genes 
Chronic low grade inflammation present in elderly obese individuals is also associated with increased 
skeletal muscle atrophy and such atrophy may also be associated with the development of T2D (428). 
Here we show for the first time that the mRNA expression of genes associated with atrophic 
signalling are upregulated in both the skeletal muscle tissue and myotubes from elderly obese 
individuals, in comparison to elderly lean individuals. 
Myostatin was upregulated in both the skeletal muscle and primary human myotubes of obese 
individuals in comparison to lean individuals. In support of this finding, increased myostatin protein 
secretion has previously been reported in myotubes cultured from obese middle aged women, while 
HFD feeding drives myostatin expression in mice (429, 430). Additionally, myostatin expression 
decreases in the skeletal muscle tissue of obese humans following weight loss and both aerobic and 
resistance exercise intervention (431-433). It is well defined that myostatin plays a central role in the 
TGF-β signalling pathway, functioning as a negative regulator of skeletal muscle mass, as 
demonstrated by the extreme increases in musculature in myostatin knockout animal models (434). 
Thus, the results of this thesis and the current literature suggest myostatin expression is closely 
linked to adiposity and may therefore play a critical role in the loss of muscle mass and quality in 
obese individuals.  
Interestingly, recent data has demonstrated that CEBPs are upregulated in mouse skeletal muscle 
during space flight (modelling disuse) and it appears that such increased expression of CEBPs drives 
activation of the myostatin promotor in C2C12 myotubes (435). Additionally, CEBPB expression has 
been demonstrated to be an important negative regulator of myogenesis, with CEBPB knockout mice 
having increased muscle mass (436). The fact that a positive correlation of CEBPA/B with adiposity 
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was observed in skeletal muscle in this thesis provides further support of these findings and may also 
explain the increased myostatin expression observed in obese individuals (436). 
Additionally, recently published data has also directly implicated myostatin in the development of 
insulin resistance. Firstly, Wilkes et al. provide evidence that short term administration of myostatin 
induces insulin resistance in mice, independent of changes in both adipose tissue and skeletal muscle 
mass (437). Further, administration of a myostatin neutralising peptibody upregulated GLUT4 
expression and augmented insulin signalling in the muscle of mice, whilst also protecting against HFD 
induced insulin resistance (438). Evidence in humans is less abundant, however exercise induced 
reductions in myostatin expression in muscle also correlate with improved insulin sensitivity, again 
independent of changes in adipose tissue or skeletal muscle mass (433). Thus, further research to 
elucidate the mechanism of both myostatin upregulation with obesity and consequently the 
induction of insulin resistance may identify novel therapeutic targets for the treatment of T2D in 
addition to atrophy. 
However, some discrepancies between tissue and myotube gene expression were observed in this 
thesis. Firstly, although both calpain 1 and 2 mRNA expression was upregulated in obese muscle, no 
significant difference in the mRNA expression of either gene was observed between lean and obese 
myotubes. In contrast, the expression of FOXO3 and its downstream target MAFbx were both 
significantly greater in obese myotubes in comparison to lean myotubes, but were not different in 
skeletal muscle tissue. Such inconsistencies between skeletal muscle tissue and isolated myotube 
gene expression likely reflects several factors. Firstly, unlike skeletal muscle tissue in vivo, primary 
human myotubes did not receive external stimuli such as contraction. Additionally, muscle tissue is 
made up of other cells types including those of the vasculature, connective tissue and neurons, not 
just myofibres, therefore potential influences of cellular crosstalk are lost in vitro. Finally, it is 
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possible that due to the absence of such external influences, de-differentiation of primary human 
myotubes may have occurred, impacting gene expression. 
 
3.3.5 The contraction induced hypertrophic response of myostatin suppression is 
intrinsically impaired in obese myotubes. 
Similarly to exercise in vivo, 24 h EPS decreased myostatin expression in primary human myotubes 
cultured from lean individuals. In agreement with this finding Tarum et al. reported a similar 
reduction of myostatin mRNA in primary human myotubes subject to 4 h of EPS (439). This EPS 
protocol was also associated with increased myotube thickness and activation of hypertrophic 
signalling pathways (439). Such an increase in hypertrophy following EPS is in line with the increased 
protein synthesis observed in this thesis and further supports EPS as a useful model of in vitro muscle 
contraction/exercise. In comparison, obese myotubes displayed a considerably blunted response to 
EPS, with no decrease in myostatin expression observed in response to the same EPS protocol. A 
similar blunted response to EPS-induced insulin sensitisation has also recently been demonstrated in 
obese myotubes by Park et al. while additionally, Feng et al. reported that EPS failed to increase lipid 
oxidation in obese myotubes (440, 441). Thus, collectively, these data and the results of this thesis 
provide further evidence to support the retention of donor characteristics in primary human 
myotubes. 
It should be noted that although EPS increased Puromycin expression in this thesis, indicating 
increased protein synthesis, puromycin positive protein was also detected in myotubes treated with 
EPS, in the absence of recombinant promyocin. A possible explanation for this may be that EPS 
increased protein synthesis to a level that resulted in non-specific binding of the puromycin antibody, 
giving the false indication of the presence of puromycin. This could perhaps indicate that EPS caused 
a supraphysiological increase in protein synthesis in primary human myotubes and therefore future 
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studies aiming to investigate how EPS protocols relate to in vivo exercise would be useful. 
Additionally, myotube thickness or size in response to EPS was not measured in this thesis, therefore 
future studies to confirm the effect of EPS on these parameters, in both lean and obese individuals, 
would also be valuable. 
 
3.3.6 Limitations 
The above studies have some limitations. The sample size used for the RT2 profiler gene card study 
was small and thus patient variability is likely to have masked potential gene expression changes 
between donor groups. Furthermore, although differential expression of target genes was identified, 
both protein expression and the functional impact of such differential expression were not 
determined in myotubes. Therefore, future studies investigating the function of these candidate 
genes would be beneficial. 
Additionally, although this thesis and other studies have demonstrated that primary human 
myotubes provide a valuable in vitro model of human skeletal muscle, it is not without limitation. For 
example, primary human myotubes are devoid of external stimuli unless stimulated by EPS. Although 
this is valuable for experimental studies, it means that the myotube model does not take into 
consideration the effects of cellular crosstalk and circulating factors. In particular, myotubes have no 
neural innervation and therefore lack both fluctuations in calcium currents and physical contraction 
which may limit myotube functionality. An example of this is GLUT4 translocation and glucose 
uptake. Myotubes display a reduced expression of GLUT4 and increased expression of GLUT1 
compared to tissue (442). Consequently, the approximate 2-fold increase in insulin induced glucose 
uptake in primary human myotubes observed in this thesis and similar studies is approximately 5-fold 
less than that of the in vivo response (397, 443, 444).  
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Furthermore, prolonged culture of primary human myotubes may also impact their function. For 
example, although useful for increasing the growth rate of myogenic cultures, supraphysiological 
glucose concentrations, often found in cell culture media, can induce myotube insulin resistance 
(445). Therefore, although low glucose media was utilised for this thesis (1.1 g/L) and cultures were 
limited to passage 4, a direct impact of culture conditions may have contributed to the differential 
insulin responses observed between subjects. Additionally, although primary human myotubes are 
multinucleated structures that express contraction machinery, the inherent nature of cell culture 
leads to a random organisation of myotubes on a 2-dimensional plane, rather than the organised 
3-dimensional parallel structures observed in striated muscle. In an attempt to overcome this, 
recent investigations have explored the use of 3-D culture systems to help guide myotube 
alignment (446). The ultimate goal for future studies of in vitro skeletal muscle would be to use 
such techniques in combination with either co-culture systems or electrical stimulation. In relation 
to studies utilising EPS, a recent publication by Evers-van Gogh et al. demonstrated that 
physiological changes in myotube function induced by EPS could also be induced via the 
application of EPS stimulated culture media to myotubes (447). Therefore, studies into the effect 
of EPS on primary human myotubes should currently be interpreted with caution.  
Additionally, although our group has previously demonstrated that the myoblast culture method 
used in this thesis generates multinucleated structures that express muscle specific genes (448), 
this thesis did not measure markers of myotube differentiation or nuclear fusion index for each 
experiment. Therefore, although all myoblasts were differentiated for 8 days, myoblasts were 
limited to passage 4 and all experiments were repeated with patient replicates, it is possible that 
some of the results presented in this thesis may be attributable to differing levels of myotube 
differentiation, rather than adiposity.  
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3.3.7 Conclusions 
Ageing and obesity are associated with increased inflammation, a blunted anabolic hypertrophic 
response and skeletal muscle insulin insensitivity. Myotubes from elderly obese individuals appear to 
maintain these facets, displaying increased insulin resistance, expression of atrophic markers and 
proinflammatory cytokine secretion. Therefore, the next chapters of this thesis will investigate the 
role of adipose tissue and skeletal muscle crosstalk in mediating these changes in elderly skeletal 















    






CHAPTER 4: The novel adipokine vaspin is upregulated in 
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4.1 Introduction 
Adipokines have emerged as central mediators of tissue cross talk, playing important roles in the 
regulation of metabolism, energy homeostasis and inflammatory responses. Critically, in obese 
individuals, adipose tissue is known to become more “inflammatory”, leading to an increased 
production of proinflammatory adipokines and a reduction in beneficial, anti-inflammatory 
adipokines (449). At present, the effect of adipokines on human skeletal muscle insulin sensitivity 
and glucose handling is poorly understood (413). This is largely due to the fact that the majority of 
studies in this field have been performed using non-human skeletal muscle cell lines or animal 
models. Understanding the functional and mechanistic role of adipokines on skeletal muscle insulin 
signalling may provide new insights into how obesity affects insulin resistance and could identify 
novel targets for therapeutic intervention. 
A novel adipokine that may play an important role in regulating skeletal muscle insulin sensitivity 
with obesity is vaspin. First reported as a 47 KDa protein in the visceral adipose tissue of genetically 
obese OLETF rats, administration of vaspin to obese mice has been shown to increase insulin 
sensitivity and glucose tolerance (450). Additionally, in SAT; leptin, resistin and TNFα mRNA was 
suppressed, while the expression of GLUT4 and adiponectin gene transcripts increased following 
vaspin administration (450). Similar increases in insulin sensitivity have since been reported in db/db 
and C57BL6 mice following vaspin delivery (451). Central administration of vaspin to obese mice 
resulted in a sustained suppression of appetite that consequently resulted in a reduction in both 
bodyweight and plasma glucose concentrations (274). Furthermore, transgenic mice overexpressing 
vaspin displayed improved glucose tolerance and were protected from obesity when challenged with 
a high fat diet (275). The results of this study also suggest vaspin may have an anti-inflammatory role, 
as a reduction in serum IL-6 was observed following vaspin treatment (275). 
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Currently, vaspin has been poorly characterised in human tissue and its potential crosstalk with 
human skeletal muscle has not been explored. This chapter aimed to investigate the impact of 
obesity on vaspin expression in human adipose tissue and skeletal muscle and in turn the impact of 
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4.1.1 Chapter aims 
 
This chapter aims to: 
 Determine the expression of vaspin in human subcutaneous adipose tissue, skeletal muscle 
and primary human myotubes. 
 
 Confirm vaspin secretion from human adipose tissue in order to validate vaspin as a novel 
adipokine capable of performing tissue crosstalk. 
 
 Determine the role of vaspin in mediating insulin sensitivity in primary human myotubes by 
performing functional studies utilising recombinant vaspin protein. 
 
 Validate GRP78 as a potential receptor for vaspin in human skeletal muscle tissue and 
primary human myotubes. 
 
 
Some of the results within this chapter have been published by Nicholson et al. in the Journal of 
Endocrinology. 
Nicholson T, Church C, Tsintzas K, Jones R, Breen L, Davis ET, et al. Vaspin promotes insulin sensitivity 
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4.2 Results 
4.2.1 Vaspin is differentially expressed in rodent models of obesity and insulin resistance  
To validate vaspin as a candidate adipokine central to metabolic homeostasis, we first investigated its 
mRNA expression, and that of its putative receptor GRP78, in epididymal white adipose tissue 
(EWAT), SWAT and BAT depots in Zucker (Zuc FA/FA) and Zucker diabetic (ZDF FA/FA) fatty rat 
models. We also examined the mRNA expression of leptin in order to confirm the effect of the obese 
phenotype on the adipose tissue expression of adipokines.   
Leptin mRNA expression was significantly greater in both the SWAT and EWAT of Zuc FA/FA and Zuc 
ZDF FA/FA rats, in comparison to control animals (Fig. 4.1). Similarly, SWAT and EWAT vaspin mRNA 
expression was also significantly greater in Zuc FA/FA rats compared to control animals (Fig. 4.1). 
SWAT and EWAT vaspin expression was also greater on average in Zuc ZDF FA/FA rats, however this 
did not reach statistical significance. Conversely, no difference in GRP78 expression was observed in 
the SWAT or EWAT of Zuc FA/FA or Zuc ZDF FA/FA animals in comparison to control animals (Figure 
4.1). Additionally, no difference in BAT leptin, vaspin or GRP78 expression was observed between 
groups (Figure 4.1). 
Furthermore, we also investigated leptin, vaspin and GRP78 expression in the SWAT and EWAT of 
obese resistant (OR) and obese prone (OP) rats fed either a control diet (CD) or a high fat diet (60% of 
total kcal) for a period of 6 weeks. HFD increased leptin expression in the EWAT and SWAT of both 
OP and OR rats (Fig. 4.2 A and D). Of note, there was no significant difference between the effect of 
the HFD on leptin expression between OP and OR rats (Fig. 4.2 A and D). Following HFD, EWAT vaspin 
expression decreased (P = 0.057) in OP rats, but remained unchanged in OR rats (Fig. 4.2 B). EWAT 
vaspin expression following HFD was also significantly greater in OR rats compared to OP rats (Fig. 
4.2 B). In SWAT, no significant difference in vaspin mRNA expression was observed in either OP or OR 
fed a control diet (Fig. 4.2 D). Additionally, HFD did not affect the expression of vaspin in either OR or 
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OP rats (Fig. 4.2 E). Furthermore, GRP78 mRNA expression in both EWAT and SWAT was significantly 
greater following HFD in both OP and OR rats (Fig. 4.2 C and F) However, there was no significant 
difference in the expression of GRP78 between OP and OR rats (Fig. 4.2 C and F).  
Moreover, we also investigated the effect of HFD, obesity and the diabetic phenotype on the 
expression of vaspin and GRP78 mRNA expression in the SWAT, EWAT and BAT of mice. In EWAT, 
db/db mice displayed significantly greater vaspin mRNA (59 ± 19) expression in comparison to 
control mice (2 ± 0.5) (Fig. 4.3 A). Vaspin mRNA expression was also ~ 5-fold and 50-fold greater on 
average in HFD fed and ob/ob mice respectively, however these observations did not reach statistical 
significance (Fig. 4.3 A). Additionally, vaspin mRNA expression was also significantly upregulated in 
the BAT of ob/ob mice, (Fig. 4.3 E). BAT vaspin mRNA expression was also greater on average in HFD 
fed and db/db mice, in comparison to control mice, but again such differential expression did not 
reach statistical significance. No significant difference in SWAT vaspin mRNA expression was 
observed in murine models of obesity and diabetes (Fig. 4.3 C). SWAT and EWAT GRP78 expression 
was not different between groups (Fig. 4.3 B, D). However, BAT GRP78 expression was upregulated in 
all groups in comparison to control animals (Fig. 4.3 F). 
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Figure 4. 1. Vaspin mRNA is upregulated in rat models of obesity and insulin resistance. 
A-C. Leptin, vaspin and GRP78 mRNA expression in EWAT of control diet (CD), Zuc FA/FA and Zuc ZDF 
FA/FA rats. D-F. Leptin, vaspin and GRP78 mRNA expression in SWAT of control diet, Zuc FA/FA and Zuc 
ZDF FA/FA rats. G-I. Leptin, vaspin and GRP78 mRNA expression in BAT of control diet, Zuc FA/FA and 
Zuc ZDF   FA/FA rats. n = 5 animals per group, except ZDF FA FA EWAT where n = 4. Data are 
represented as mean ± S.E.M. * signifies P < 0.05, ** signifies P <0.01, ***signifies P ≤ 0.001, significant 
difference from control animals as determined by one-way ANOVA followed by Dunnett’s post hoc 
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Figure 4. 2. Vaspin is differentially expressed in obese prone and obese resistant rat models. 
A-C. Leptin, vaspin and GRP78 mRNA expression in the EWAT of obese prone (OP) and obese 
resistant (OR) rats with and without HFD. D-F. Leptin, vaspin and GRP78 mRNA expression in SWAT 
of obese prone (OP) and obese resistant (OR) rats with and without HFD. n = 4 animals per group, 
except OP HFD where n = 5. Data are represented as mean ± S.E.M. *signifies P < 0.05, **signifies P 
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Figure 4. 3. Vaspin is differentially expressed in mouse models of obesity and insulin resistance. 
A-B. Vaspin and GRP78 mRNA expression in EWAT of SD, HFD, ob ob and db db mice. C-D. vaspin 
and GRP78 expression in SWAT of SD, HFD, ob ob and db db mice. E-F. vaspin and GRP78 mRNA 
expression in BAT of SD, HFD, ob ob and db db mice.  n = 5 animals per group. Data are 
represented as mean ± S.E.M. * P < 0.05, ** P <0.01 significantly different from SD mice as 
determined by ANOVA followed by Dunnett’s post hoc tests. 
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4.2.2 The expression of vaspin and its putative receptor GRP78 are increased in the 
skeletal muscle and SAT of obese humans 
Following the observation that vaspin mRNA expression was increased in rodent models of obesity 
and diabetes, we next examined the expression of vaspin and its putative plasma membrane 
receptor GRP78 (HSPA5) in both SAT and skeletal muscle tissue of humans with varying BMI. 
Characteristics of subjects included in this thesis are presented in Table 4.1 and Figure 4.4. Vaspin 
mRNA expression was significantly greater in both SAT (2.5-fold, P < 0.01) and skeletal muscle (1.5-
fold, P < 0.05) of obese subjects in comparison to lean subjects (Fig. 4.5 A-B) and demonstrated a 
significant positive correlation with BMI (Fig. 4.5 E-F). Similarly, expression of GRP78 was significantly 
greater in both SAT (1.5-fold, P < 0.05) and skeletal muscle (1.8-fold, P < 0.05) of obese subjects in 
comparison to lean subjects (Fig. 4.5 C-D) and was positively correlated with BMI in both tissue types 
(Fig. 4.5 G and 4.5 H). 
We next investigated whether such increased vaspin and GRP78 expression was maintained in 
primary human myotube cultures from lean and obese individuals (Figure 4.6). The mean expression 
of both vaspin and GRP78 mRNA was again greater in primary human myotubes from obese 
individuals in comparison to lean individuals, although such differences did not reach statistical 
significance. 
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  Table 4. 1 Human subject characteristics 
  
 Lean Obese P value 
n 21 17 N/A 
Male/female (n) 9/12 10/7 N/A 
Age 70.6 ± 1.6 65.8 ± 2.1 0.0718 
BMI 22.8 ± 0.3 34.5 ± 0.9 <0.0001 
Body fat % 23.6 ± 3.0 38.6 ± 2.1 0.0006 
Weight (kg) 61.5 ± 2.7 99.2 ± 3.3 <0.0001 
Waist circumference (cm) 81.6 ± 2.9 111.0 ± 2.2 <0.0001 
Hip circumference (cm) 95.9 ± 1.9 115.0 ± 2.2 <0.0001 
Waist: hip 0.85 ± 0.02 0.95 ± 0.02 0.004 
% HbA1c 5.4 ± 0.1 5.7 ± 0.07 0.11 
    






































































     A                                                      B                                       
C                                                                                           Figure 4. 4. Serum HBA1C concentrations in lean 
and obese individuals. 
(A) Serum HBA1C was measured via ELISA. n = 27. 
(B) Correlation of serum HBA1C with % body fat. 
(C) Correlation of HBA1C with waist: Hip. 
 
r2 = 0.29 
P = 0.087 
r2 = 0.46 
P = 0.0056 
    



























































































































Figure 4. 5. Vaspin and GRP78 mRNA expression are upregulated in subcutaneous adipose tissue 
and skeletal muscle in obese elderly individuals. 
A. The mRNA expression of vaspin in SAT of lean (n = 21) and obese (n = 17) elderly individuals. B. 
The mRNA expression of vaspin in skeletal muscle tissue of lean (n = 4) and obese (n = 4) elderly 
individuals. C. The mRNA expression of GRP78 in SAT of lean (n = 8) and obese (n = 9) elderly 
individuals. D. The mRNA expression of GRP78 in skeletal muscle of lean (n = 7) and obese (n = 9) 
elderly individuals. E. Correlation of vaspin mRNA expression in SAT with BMI. F. Correlation of 
vaspin mRNA expression in skeletal muscle tissue with BMI. G. Correlation of GRP78 mRNA 
expression in SAT with BMI. H. Correlation of GRP78 mRNA expression in skeletal muscle tissue with 
BMI. Expression of mRNA was quantified by qRT-PCR, and normalised using GAPDH. Data are 
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Figure 4. 6. Vaspin and GRP78 in primary human myotubes from lean and obese individuals. 
 
A. Vaspin mRNA expression in lean (n = 5) and obese (n = 5) primary human myotubes. B. 
correlation of myotube vaspin mRNA expression with BMI. C. correlation of myotube vaspin mRNA 
expression with bodyweight. D. GRP78 mRNA expression in lean (n = 5) and obese (n = 7) primary 
human myotubes. E. correlation of myotube vaspin mRNA expression with BMI. F. correlation of 
myotube vaspin mRNA expression with bodyweight. (n/s signifies no significance). 
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Figure 4. 7. Lean myotube Vaspin mRNA expression in response to an obese microenvironment. 
Lean primary human myotubes (n = 4 biological replicates) were stimulated with palmitate (0.3 M), 
glucose (10 mM), insulin alone (100 nM), or in various combinations for 24 h. Vaspin mRNA 
expression was determined by qRT-PCR and normalised to GAPDH. Data are reported as mean ± 
S.E.M. Data was analysed fow statistical significance via one way ANOVA. 
 
In order to identify possible drivers of the increased vaspin mRNA expression observed in skeletal 
muscle tissue with obesity, lean primary human myotubes were cultured for 24 h in conditions 
aiming to replicate an obese microenvironment. Vaspin mRNA expression was increased on average 
following stimulation with all treatment conditions, with the largest increase in vaspin mRNA 
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4.2.3 Vaspin is rapidly secreted from human adipose tissue and muscle tissue and is detectable 
systemically in both lean and obese individuals 
To investigate the potential for vaspin to signal between human SAT and skeletal muscle we first 
examined, by immunoblotting, the ex vivo secretion of vaspin from SAT and skeletal muscle into 
serum free Ham’s F10 media over a 24 h time course as described in section 2.7. Vaspin was detected 
in serum-free culture media that had been conditioned with either SAT or skeletal muscle for 1 h, 
indicating that vaspin is rapidly secreted from both tissue types. The amount of vaspin detected in 
both SAT and skeletal muscle-conditioned media increased up to 6 h and was maintained for the 
duration of 24 h (Fig. 4.8 A and B). Further, a significantly greater level of vaspin was detected in SAT 
conditioned media of obese individuals (n = 16) in comparison to lean (n = 17) at 24 h (Fig. 4.9 A).  
 
We then examined by ELISA whether vaspin could be detected systemically in human sera, and 
whether there was a difference in the systemic concentration of vaspin between lean (n = 16) and 
obese (n = 15) individuals. Vaspin was detected in the serum of both lean and obese individuals, but 
there was no significant difference between levels found in obese individuals in comparison to lean 
individuals in either males or females (Fig. 2.9 B). However, serum vaspin was on average higher in 
obese females compared to lean females. Furthermore, although there was no significant correlation 
between serum vaspin and BMI in males (Fig. 2.9 C), in females we found a significant positive 
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Figure 4. 8. Vaspin is rapidly secreted from human subcutaneous adipose tissue. 
Detection of vaspin protein in A. SAT conditioned media and B. skeletal muscle-conditioned media 
in lean (n = 3 patient replicates) and obese (n = 3 patient replicates) subjects over a 24 h time 
course, as measured by immunoblotting. 10 µL adipose or skeletal muscle-conditioned media was 
loaded per sample lane. Bars represent mean densitometric units ± S.E.M. of immunoblots 
from lean (n = 3) and obese (n=3) subjects. *P < 0.05, **P < 0.01, ***P < 0.001, significantly 
different from time = 0 media control sample as determined by one-way ANOVA with Dunnett’s 
post-hoc tests.  
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Figure 4. 9. Vaspin is systemically elevated in obese individuals. 
A. Densitometric analysis of vaspin protein expression in adipose conditioned media at 24 h 
from lean (n = 17) and obese (n = 16) subjects as measured by immunoblotting. 10 µL of adipose 
conditioned media was loaded per sample lane. P < 0.05 as determined by unpaired t-test. B. 
Detection of vaspin protein in the serum of male (n = 8 lean; n = 8 obese) and female (n = 8 
lean; n = 7 obese) subjects by ELISA, data was analysed for statistical significance by performing 
2-way ANOVA. C. Pearson correlation of serum vaspin with BMI in males. D. Pearson correlation 
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4.2.4 The effect of vaspin on insulin signalling pathways in primary human myotubes 
We next examined the effect of stimulating primary human myotubes with recombinant human 
vaspin on insulin signalling pathways. First, lean primary myotubes were acutely stimulated with 
recombinant vaspin (100 ng/mL) for 5, 10 or 15 min and AKT activity (phosphorylation) quantified 
using MesoScale immunoassays (MesoScale Discovery). Myotubes stimulated with vaspin for either 
10 or 15 min showed a significant 3-fold increase in phospho AKT(Thr308)/total AKT expression (which 
along with activation of the other AKT phosphorylation site (serine473) was validated by 
immunoblotting (n = 4 patient replicates) (Fig. 4.10).  
 
To investigate the mechanism of the vaspin-mediated induction in basal AKT activity we examined 
whether acute or chronic stimulation of human myotubes with vaspin led to activation of either the 
IR or the IGF receptor. As expected, 15 min of insulin stimulation alone induced a significant increase 
in the phosphorylation of both the IR and the IGF receptor (Fig. 4.11 A and B). However, stimulation 
of myotubes with vaspin for either 15 min or chronic stimulation for 24 h induced no phosphorylation 
of either the IR or the IGF receptor (Fig. 4.11 A and B) indicating that vaspin did not directly affect 
activation of upstream insulin signalling. Given these findings, we then examined whether vaspin 
affected the activity of downstream insulin signalling by determining the activity status of PI3K by 
immunoblotting. Acute stimulation of primary human myotubes (n = 4 patients) with vaspin 
(100 ng/mL) induced a transient increase in phosphorylation of PI3K between 10 and 15 min as 
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Figure 4. 10. Vaspin activates AKT in primary human myotubes. 
  
A. The effect of acute stimulation (0, 5, 10, 15 min) of primary human myotubes with recombinant 
human vaspin (100 ng/mL) on AKTThr308 phosphorylation measured by mesoscale analysis (n = 4 
biological replicates, 2 male and 2 female). B. Representative immunoblots of AKTSer473 and AKTThr308 
phosphorylation in untreated and vaspin (100 ng/mL)-stimulated myotubes after 0, 5, 10 and 15 min 
stimulation (n = 4 primary donors: 2 male, 2 female, 15 µg of total protein was loaded per sample). 
C. Densitometric analysis of AKTThr308 western blots normalised to Total AKT protein (n = 4). D. 
Densitometric analysis of AKTSer473 western blots relative to Total AKT protein (n = 4). Data are 
represented as mean ± S.E.M. * P < 0.05, ***  P < 0.001 significantly different from untreated control 
as determined by Dunnett’s post-hoc tests following 1 way ANOVA). 
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Figure 4. 11. Vaspin activates PI3K in primary human myotubes. 
A. Effect of insulin (0–30 nM, 30 min) and acute (15 min) or chronic (24 h) vaspin stimulation 
(100 ng/mL) on the phosphorylation of insulin receptor and B. IGF receptor as measured by mesoscale 
analysis (n = 16 biological replicates from 8 primary donors: 4 male, 4 female). C. Time course of acute 
vaspin stimulation (100 ng/mL) on the activation of PI3K assessed by immunoblotting (n = 4 primary 
donors: 1 male, 3 female, 15 µg total protein was loaded per sample). D. Densitometric analysis of 
Phospho-PI3K P85 western blots normalised to total PI3K. Data are represented as mean ± S.E.M. * 
signifies P < 0.05, ** signifies P < 0.01, *** signifies P < 0.001 significantly different to control as 
determined by Dunnett’s post-hoc tests, following 1-way ANOVA. 
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4.2.5 Vaspin induces the expression and translocation of GLUT4 protein and promotes glucose 
uptake in obese elderly primary human myotubes  
Following these data, and with the observation that vaspin induced activation of downstream insulin 
signalling components, we then investigated the functional metabolic role of vaspin by examining 
whether vaspin affected GLUT4 expression and glucose uptake in primary human myoblasts and 
myotubes from obese subjects. 
First, we examined whether there was a difference in skeletal muscle GLUT4 mRNA expression 
between old obese (n = 8), old lean (n = 8) and young (n = 7) subjects. Compared to young 
subjects, GLUT4 expression was 69% lower in the skeletal muscles from old obese subjects 
(P < 0.05; Fig. 4.12 A). In line with the relatively low expression of GLUT4 in old obese muscle, 
myotubes derived from old obese subjects also displayed a blunted glucose uptake response to 
insulin (100 nM, 30 min), in comparison to myotubes cultured from old lean subjects, as reported 
above (Figure 3.8). Stimulation of old obese myotubes with vaspin (100 ng/mL) for 24 h induced a 
significant (P < 0.05) ~5-fold increase in the expression of GLUT4 mRNA (Fig. 4.12 B), which translated 
into a significant (P < 0.05) increase in GLUT4 protein (Fig. 4.12 C). Furthermore, stimulation of 
primary human myoblasts with either insulin (100 nM) or vaspin (100 ng/mL) for 15 min caused a 
significant (P < 0.05) increase in GLUT4 protein surface expression, compared to non-stimulated 
myoblasts, indicative of an increase in GLUT4 protein translocation (Figure 4.12 D). Such increased 
vaspin mediated GLUT4 translocation appeared to be confirmed in primary human myotubes via 
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We then investigated whether these vaspin-mediated effects on both the expression and 
translocation of GLUT4 were sufficient to impact on glucose uptake in previously insulin-insensitive 
old obese myotubes. Primary human myotubes from old obese subjects that had not been pre-
treated with vaspin showed no increase in glucose uptake in response to 30 min of insulin 
stimulation (100 nM), compared to unstimulated controls (Fig. 4.12 E). However, 30 min insulin 
stimulation significantly increased glucose uptake in vaspin pre-treated myotubes, compared to 
control myotubes (Fig. 4.12 E). Finally, since p38 and AMPK activation have been implicated in 
promoting GLUT4 expression we examined the effect of vaspin stimulation on their activation status. 
Acute stimulation of primary human myotubes (0 – 15 min) with 100 ng/mL vaspin induced a 
significant activation of both p38 (n = 4 biological replicates) and AMPK (n = 4 biological replicates), as 
measured by immunoblotting (Fig. 4.14 A and B). 
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Figure 4. 12. Vaspin induces GLUT4 expression and sensitises insulin-mediated glucose uptake in 
primary human myotubes. 
A. GLUT4 mRNA expression relative to GAPDH in skeletal muscle tissue derived from lean young 
(n = 7), lean old (n = 8) and obese old (n = 8) subjects. *P < 0.05, significantly different between young 
and old obese as determined by one-way ANOVA with Dunnett’s post-hoc tests. B. GLUT4 mRNA 
expression in primary human myotubes from obese subjects stimulated for 24 h with recombinant 
vaspin (100 ng/mL) or left untreated (n = 5 primary donors: 2 male, 3 female). Expression was 
determined by qRT-PCR and normalised to GAPDH. *P < 0.05, significantly different from unstimulated 
control, as determined by t-test. C. GLUT4 protein expression as measured by immunoblotting in 
primary human myotubes from obese subjects stimulated for 24 h with vaspin (100 ng/mL) or left 
untreated (n = 6 primary donors: 2 male, 4 female). * signifies P < 0.05, significantly different from 
unstimulated control, as determined by t-test. D. Primary human myoblast membrane localised 
GLUT4 expression in response to insulin (100 nM 15 min), or vaspin (100 ng/mL 15 min), (n = 5 obese 
primary donors: 2 male, 3 female). Relative surface expression of GLUT4 was quantified by measuring 
the mean fluorescence intensity (MFI) of GLUT4 staining in a minimum of 1500 cells/condition by flow 
cytometry. *P < 0.05, significantly different from unstimulated control as determined by one-way 
ANOVA with Dunnett’s post-hoc tests. E. Effect of 24 h exposure of primary obese myotubes (n = 3, 
female donor) to recombinant vaspin (100 ng/mL) on basal and insulin-stimulated radiolabelled 
glucose uptake ([3H]-2-DOG). *P < 0.05, significantly different from unstimulated control as 
determined by one-way ANOVA with Dunnett’s post-hoc tests. Data are represented as mean ± S.E.M. 
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Figure 4. 13. Vaspin increases GLUT4 translocation in primary human myotubes. 
 A- C. Bright field imaging of control, insulin stimulated (100 nM, 15 min) and Vaspin stimulated 
(100 ng/ ml, 15 min) primary human myotubes. D – F. DAPI Stained nuclei of control, insulin 
stimulated (100 nM, 15 min) and Vaspin stimulated (100 ng/ ml, 15 min) primary human 
myotubes. G- I. GLUT4 expression in control, insulin stimulated (100 nM, 15 min) and Vaspin 
stimulated (100 ng/ ml, 15 min) primary human myotubes. Arrows indicate examples of 
increased fluorescence at the myotube sarcolemma (n = 3 patient replicates). 
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Figure 4. 14. Acute vaspin stimulation increases activation of P38 and AMPK. 
A. Representative immunoblots for phospho and total p38 (n = 4 primary donors) and phospho 
AMPK and total AMPK (n = 4 primary donors: 1 male, 3 female) in untreated and vaspin 
(100 ng/ml) stimulated myotubes after 0, 5, 10 and 15 min stimulation. 10 µg of total protein was 
loaded per sample. B. Densitometrtic quantification of phospho-p38 immunoblots relative to total 
p38 protein. Bars represent mean densitometric units ± S.E.M. (n = 4). *P < 0.05, significantly 
different from unstimulated control as determined by one-way ANOVA. C. Densitometric 
quantification of phospho-AMPK immunoblots relative to total AMPK. Bars represent mean 
densitometric units ± S.E.M. (n = 3). **P < 0.01, significantly different from unstimulated control as 
determined by Dunnett’s post hoc tests following one-way ANOVA. 
 
    
















































































Figure 4. 15. siRNA mediated knockdown of GRP78 in primary human myoblasts and 
myotubes. 
A. GRP78 mRNA expression in primary human myoblasts 24 h post treatment with either 
TransIT-X2 lipid only (control), non-targeting control siRNAs #1/#2 or siRNA #1/#2 targeting 
GRP78 (n = 3 biological replicates). B. GRP78 mRNA expression in primary human myotubes 24 h 
post treatment with either TransIT-X2 lipid only (control) non-targeting siRNA #1/#2 or siRNAs 
targeting GRP78 (#1 and #2). (n = 3 biological replicates). GRP78 mRNA expression was 
determined by qRT-PCR and normalised to GAPDH. Data are presented as mean ± S.E.M. 
*P < 0.05, ***P < 0.001 significantly different from control as determined by one-way ANOVA 
with Dunnett’s post-hoc tests.  
 
4.2.6 Validation of GRP78 as a vaspin receptor in primary human myotubes 
Finally, we aimed to validate GRP78 as a potential vaspin receptor in skeletal muscle by performing 
siRNA mediated loss of function studies in primary human myotubes. Delivery of siRNA targeting 
GRP78 to both primary human myoblasts and primary human myotubes using TranIT-X2 resulted in 
significant knockdown of GRP78 mRNA expression of approximately 85% and 50% respectively in 
comparison to control cells, as determined via qRT-PCR (Figure 4.15 A and B). 







     A                                                                 
B                                           
C                             
D         
      Myoblasts                                                                         Myotubes 
      B                                          
C                             
D         
    
   
143 
Next, as we reported that vaspin increases GLUT4 mRNA expression in section 4.2.5 of this thesis, we 
investigated the effect of 24 h vaspin stimulation on myoblast GLUT4 mRNA expression, following 
GRP78 knockdown. Post transfection with GRP78 siRNAs for 24 h, myoblasts were treated with 
vaspin (100ng/ml) for a further 24h. At 48 h post transfection, GRP78 mRNA expression was not 
significantly different in comparison to control cells (Figure 4.16 A). Additionally, no significant 
increase in GLUT4 mRNA expression was observed following vaspin stimulation in control cells 
(Figure 4.16 B). The expression of GLUT4 mRNA was similar across all other conditions (Figure 4.16 
B). 
We also investigated whether GRP78 knockdown could prevent vaspin stimulated activation of AKT 
in primary human myotubes. 24 h post GRP78 knockdown, primary human myotubes were treated 
with vaspin (100 ng/ml, 15 min). In control cells, vaspin evoked a significant increase in the activation 
of AKT(Ser473). Such an increase in AKT phosphorylation did not occur in myotubes with GRP78 
knockdown (Figure 4.16 C-D). However, significant activation of AKT was observed at baseline in 
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Figure 4. 16. The effect of GRP78 knockdown on the functional effects of vaspin  
A. GRP78 mRNA expression in lean primary human myoblasts 48h h post treatment with either 
TransIT-X2 lipid only (control),  siRNA #1/#2 or NTC1 in the absence or presence (+) of recombinant 
human vaspin (100 ng/ml, final 24 h of transfection) (n = 3 biological replicates). B. GLUT4 mRNA 
expression in primary human myoblasts 48h post treatment with either TransIT-X2 lipid only 
(control), siRNA #1/#2 or NTC1 in the absence or presence (+) of recombinant human vaspin (100 
ng/ml, final 24 h of transfection) (n = 3 biological replicates). C. Phospho and total AKT expression in 
lean primary human myotubes in the absence or presence of recombinant human vaspin (100 ng/ml, 
15 min) following 24 h treatment with either TransIT-X2 lipid only (control) or siRNA #1/#2, 
measured by immunoblotting (n = 2 biological replicates). D. Densitometric quantification of 
phospho-AKT immunoblots relative to total AKT protein. Bars represent mean Densitometric 
units ± S.E.M. *P < 0.05, significantly different from control as determined by Dunnett’s post hoc 
tests following 2-way ANOVA. 
GRP78                                                                       GLUT4 
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4.3 Discussion 
With the current dearth of human data on the adipokine vaspin, this thesis is the first to characterise 
the expression of vaspin in both skeletal muscle and adipose tissue in elderly individuals of varying 
BMI and to report the functional effect of vaspin on human skeletal muscle insulin signalling 
pathways and glucose uptake. 
4.3.1 Adipose tissue vaspin mRNA expression is increased in obese and diabetic rodent 
models 
Firstly, before progressing to work in human tissue and primary cells, we investigated the effect of 
obese and diabetic phenotypes on the expression of vaspin in adipose tissue depots of rodent 
models, to confirm vaspin as a candidate adipokine associated with obesity. To validate the use of 
such models, we first examined the expression of leptin, an adipokine known to increase with 
adiposity. As expected, SWAT and EWAT leptin mRNA expression was upregulated in Zucker FA/FA, 
ZDF FA/FA, HFD obese prone and HFD obese resistant rats, compared to control animals, indicating 
these animal models displayed a characteristic response associated with obesity. 
In support of previously published data reporting increased vaspin mRNA expression in obese rats 
(450), both SWAT and EWAT Vaspin mRNA expression was significantly upregulated in Zucker FA/FA 
animals in comparison to control animals (450), (452). Interestingly, vaspin expression was also 
higher at baseline in obese resistant animals compared to obese prone animals (P = 0.14) and was 
significantly greater in the EWAT of obese resistant animals fed a HFD, in comparison to obese prone 
animals fed a HFD. Indeed, vaspin mRNA expression in obese prone animals was observed to 
decrease with HFD (P = 0.057). Furthermore, we also demonstrate, for the first time, that vaspin 
mRNA expression was significantly greater in the EWAT and BAT of db/db and ob/ob mice 
respectively. Additionally, a number of considerable increases (up to 50-fold) were also observed in 
ob/ob, db/db and control mice fed a HFD, although such differential expression did not reach 
    
   
146 
statistical significance, likely due to the small sample size in this investigation. Collectively, these data 
suggest that increased vaspin mRNA expression in both EWAT and SWAT is positively associated with 
increased adiposity. Additionally, unlike most adipokines, it appears such increased vaspin expression 
may be beneficial, protecting against obesity. However, in contrast to EWAT and SWAT, the 
expression of leptin and vaspin were not differentially expressed in the BAT of obese or diabetic rat 
models. This may reflect BATs more prominent role in regulating energy expenditure rather than 
regulating adipokine production and secretion (as discussed in section 1.6 of this thesis). 
 
4.3.2 Characterisation of vaspin expression and secretion in humans  
In humans, vaspin mRNA has previously been reported to be detectable in only around 15% of SAT 
samples, with no expression reported in SAT of lean subjects (453). In the present study, we detected 
vaspin mRNA in both SAT and skeletal muscle from both lean and obese individuals. However, vaspin 
was more highly expressed in the SAT and skeletal muscles from obese individuals and in both tissue 
types its expression positively correlated with BMI. We also found that vaspin expression was 
maintained in primary human myotubes and vaspin protein was rapidly secreted from both human 
SAT and skeletal muscle tissue, with the quantity secreted from obese tissues being greater than 
from lean tissues. Together these data support the findings in rodents from this thesis and previous 
studies that describe an increase in vaspin tissue expression with obesity (450). It is important to 
note that our finding that vaspin expression in adipose and muscle tissue was increased with obesity 
was in patients without T2D.  
 
Gene array data in the GEO database does not reveal any significant difference in vaspin adipose 
tissue expression between patients with or without insulin resistance or in those with T2D compared 
to individuals with normal glucose tolerance (454). Furthermore, a recent report found that 
circulatory levels of vaspin in morbidly obese individuals declined following weight loss induced by 
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laparoscopic sleeve gastrectomy (455). In addition, newly published data has also demonstrated a 
strong positive correlation of serum vaspin with other markers of obesity, including serum TAG and 
cholesterol (456). These findings, together with our data here, support the notion that vaspin 
expression in humans is dependent on BMI irrespective of diabetic status.  
 
Contrary to previous reports (281), we found no significant difference in serum levels of vaspin in 
obese individuals compared to lean. This was despite the greater expression and secretion of vaspin 
from obese SAT of these individuals. This might suggest that elevated secretion of vaspin from SAT in 
obese individuals is more likely to have localised effects, rather than systemic effects on distal 
tissues. However, it should be noted that serum concentrations of vaspin were variable and so a 
significant difference in circulating vaspin concentrations in lean and obese individuals may have 
been identified with larger cohorts. A number of previous publications have examined systemic levels 
of vaspin in males and females of varying BMI, with contrasting results. In individuals aged 17–79 it 
was found that serum vaspin was significantly higher in obese male subjects compared to lean male 
subjects, but was not significantly different between obese and lean females (281). However, the 
study by Esteghamati et al. found that serum vaspin levels positively correlated with BMI in both 
males and females (457). In addition, higher levels of serum vaspin were reported in females 
compared to males in individuals with normal glucose tolerance, but no gender difference was seen 
in individuals with T2D (281). However, Seeger et al. examined serum vaspin levels in diabetic and 
non-diabetic patients in both controls and in patients on chronic haemodialysis with BMI between 26 
and 30 and found that vaspin was higher in females and furthermore that gender was an 
independent predictor of circulating vaspin concentrations (458). Together these observations could 
reflect sex dimorphism in SAT distribution and quantity (459, 460). It is known for example that 
females predominantly accumulate more SAT than males (461), and thus vaspin may play a greater 
role in mediating glucose homeostasis in females than in males. Indeed, some studies have 
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previously reported that the prevalence of metabolic syndrome is higher in females than in males 
(462), with central adiposity being a greater risk factor for metabolic diseases in females (463, 464). 
 
Contrary to the above studies, we found no significant difference between serum vaspin 
concentration between males and females in either lean or obese individuals. Furthermore, unlike 
the findings of Esteghamati et al. we did not find a significant correlation between BMI and vaspin 
levels in males (457). However, we did observe that serum vaspin in females significantly correlated 
with BMI. These disparities may be a reflection of the relatively smaller sample size used in our study, 
but also likely reflects differences between subject cohorts. For example, the male subjects studied 
by Youn et al. had a mean age of 39 years, whilst both the male and female subjects studied 
by Esteghamati et al. had a mean age of 49 years, considerably lower than the mean age of subjects 
in this thesis (male 71 years, 66 years female) (281, 457). 
 
What drives such increased vaspin expression with increasing adiposity is currently unknown. To 
address this, we attempted to replicate an obese microenvironment by culturing primary human 
myotubes with high glucose, insulin and palmitate, either individually or in combination. Vaspin 
mRNA expression increased on average with all treatment conditions; however such effects did not 
reach statistical significance. The greatest increase in vaspin mRNA (2-fold) occurred in response to 
simultaneous glucose, insulin and palmitate, which may suggests that a combination of factors drives 
increased vaspin mRNA expression in obese individuals, however further study with larger sample 
sizes are needed to confirm such an effect. Recent data by Aibara et al. has demonstrated a similar 
increase in murine hepatic vaspin mRNA in response to refeeding with a high fructose diet. 
Conversely, fasting and specific destruction of pancreatic β-cells reduced hepatic vaspin mRNA in 
mice (465). The authors suggest that vaspin mRNA may be positively regulated by CEBPA/B, which is 
interesting, as in chapter 1 of this thesis we report increased CEBPA/B expression in human skeletal 
muscle with increasing adiposity (466). Further studies would be beneficial to determine the 
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mechanism in which such circulating factors may drive vaspin mRNA expression in humans and 
whether CEBPA/B is involved in this process. Furthermore, we only investigated the effect of glucose, 
insulin and palmitate on myotube expression for 24 h, therefore it would also be interesting to 
explore the role of other obesity associated factors such as adipokines and more chronic stimulations 
in the regulation of primary human myotube vaspin mRNA expression. Further studies are also 
necessary to identify the stimuli and mechanisms responsible for increasing vaspin expression and 
secretion from SAT, either ex vivo, or by utilising primary adipocyte cultures. 
 
4.3.3 Vaspin increases insulin sensitivity in obese primary human myotubes 
Functionally, vaspin-mediated activation of PI3K/AKT has been reported previously in several other 
cell types, including pancreatic cells (467), 3T3-L1 preadipocytes (468) and endothelial progenitor 
cells (469). Furthermore, it was recently reported that vaspin promotes the PI3K/AKT signalling 
pathway leading to increased GLUT4 protein expression in rats fed a high-fat diet (470) and can 
improve glucose tolerance in mice (471). Therefore, our demonstration that vaspin induces 
activation of PI3K-AKT signalling and increases insulin sensitivity in obese human myotubes is 
significant. These vaspin-induced effects appear to occur independently of upstream insulin 
signalling, since vaspin had no direct effect on either the insulin receptor or IGF-1 receptor 
phosphorylation status. Activation of PI3K/AKT signalling is known to promote GLUT4 translocation 
and glucose uptake in skeletal muscle cells (472), and here we report that vaspin promotes GLUT4 
expression and translocation and facilitates glucose uptake in human obese myotubes. Notably, 
15 min stimulation of primary human myoblasts derived from obese subjects with vaspin was able to 
significantly increase GLUT4 surface translocation to a similar magnitude to that observed with 
insulin stimulation. This finding may be of clinical significance given that GLUT4 translocation is 
impaired in T2D patients with insulin insensitivity (473). Indeed, since our data shows that vaspin 
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induces insulin signalling independent of activating the insulin receptor, this could provide a novel 
route to therapeutically improve glucose maintenance in insulin-resistant individuals. 
 
Despite being able to promote GLUT4 translocation we found that insulin stimulation of obese 
myotubes did not result in glucose uptake. Previous studies in rats have demonstrated that GLUT4 
expression declines with age (474) and obesity (475). Here we report for the first time in humans that 
muscle tissue derived from elderly obese individuals displayed a significantly lower expression 
of GLUT4 mRNA in comparison to young lean individuals. The retention of this phenotype in primary 
human myotubes from elderly obese subjects may therefore explain the blunted insulin response 
observed at baseline. 
 
Importantly, prolonged (24 h) pre-treatment of obese myotubes with vaspin sensitised them to 
insulin-mediated glucose uptake. This sensitisation is likely due to vaspin increasing the bioavailable 
intracellular pool of GLUT4. Previous studies in 3T3-L1 adipocytes and mice have reported that vaspin 
induces GLUT4 mRNA expression (450, 468). Here, we report for the first time that vaspin 
significantly induces GLUT4 mRNA and GLUT4 protein expression in human skeletal muscle. 
Importantly, we also demonstrate that vaspin is able to activate both AMPK and p38 signalling in 
primary human myotubes. AMPK activation has previously been reported to upregulate GLUT4 
expression in primary human myotubes (476), while p38 is known to regulate transcription factors 
that control the expression of GLUT4 (477, 478). Activation of these signalling pathways may 
therefore be a potential mechanism to explain the vaspin-induced upregulation in GLUT4 mRNA and 
protein expression observed. 
 
However, it should be noted that primary human myotubes in culture elicit relatively low insulin-
stimulated glucose uptake, compared to skeletal muscle tissue (479-481). This could be due to low 
basal expression of GLUT4, which has been attributed to denervation (482-484) and the subsequent 
absence of contraction. Therefore, in our model system, treatment of myotubes with vaspin may 
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only be increasing the pool of bioavailable GLUT4 towards physiological levels. Whether vaspin 
administration in obese elderly humans in vivo would have the same effect remains to be seen. 
 
4.3.4 Validation of GRP78 as a possible vaspin receptor in primary human myotubes. 
A cell surface receptor for vaspin has yet to be fully elucidated. One possible mechanism is that 
vaspin signals through GRP78, a protein that has an important intracellular regulatory role during 
cellular ER stress (484, 485). However, recent evidence shows GRP78 also functions as a cell surface 
receptor, with membrane localised GRP78 binding vaspin and in turn promoting AKT and AMPK 
signalling in H-4-II-E-C3 cells (471).  
 
Here, we show GRP78 expression is present in SWAT, EWAT and BAT depots of both mouse and rat 
animal models. Additionally a significant increase in GRP78 expression was observed in HFD fed 
obese prone and obese resistant models. A similar increase in GRP78 protein has previously been 
reported in the abdominal adipose tissue of rats fed a HFD (486). Furthermore we also demonstrate 
that GRP78 is expressed in both human SAT and skeletal muscle in older individuals. Expression 
of GRP78 was found to be significantly greater in both SAT and skeletal muscle of obese subjects and 
displayed a positive correlation with BMI in each case. This is concurrent with the results of Khadir et 
al. who also found increased GRP78 expression in SAT of obese humans (487). Chronic ER stress can 
be induced by obesity (488) and is associated with inflammatory adipose tissue (489), this may 
explain the increased GRP78 expression in muscle and adipose tissue of obese individuals in our 
present study. Additionally, ER stress has been shown to promote re-localisation of GRP78 to the cell 
membrane, thus increasing ligand-binding capacity (490).  
 
In an attempt to determine if the effects of vaspin on primary human myotube function reported in 
this thesis were mediated by GRP78 signalling, we performed siRNA mediated loss of function studies 
utilising primary human myoblasts and myotubes. Successful knockdown of GRP78 was achieved in 
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both primary human myoblasts and myotubes 24 h post transfection. Next, following knockdown, 
primary human myoblasts were treated with recombinant human vaspin for a further 24 h in order 
to investigate whether GRP78 knockdown would prevent vaspin mediated increases in GLUT4 mRNA. 
In control cells, GLUT4 expression following vaspin stimulation was variable, with no significant 
increase in GLUT4 mRNA observed. This was unexpected, as in section 4.2.6 of this thesis we 
observed a strong induction of vaspin mRNA expression in primary human myotubes. This suggests 
the TransIT-X2 reagent may have interfered with this vaspin mediated effect, preventing GLUT4 
mRNA upregulation. Additionally, it appeared GRP78 knockdown was either unsuccessful in this 
attempt or was transient, returning towards basal levels by the 48 h time point. Consequently, we 
are unable to conclude the role of GRP78 on vaspin mediated GLUT4 expression. We also 
investigated whether GRP78 knockdown could blunt vaspin induced activation of AKT, as described in 
section 4.2.4 of this thesis. As expected, acute vaspin stimulation significantly increased the 
activation of AKT(ser473) in primary human myotubes, as measured by immunoblotting. In contrast, no 
such vaspin mediated effect was observed in primary human myotubes treated with either siRNA #1 
or siRNA #2. However, basal AKT activation was also greater in myotubes treated with both siRNA 
#1/#2. Therefore an off-target effect of siRNA treatment may have caused an induction of AKT that 
meant further activation by vaspin was not possible. Thus we cannot conclude whether the blunted 
AKT activation was indeed due to GRP78 knockdown. As a result, future studies are still required to 
elucidate the potential role of GRP78 in vaspin signalling. Utilising lentiviral knockout or CRISPRi gene 
editing would be useful to remove the potential effect of lipid interaction and off target effects of 
siRNAs. Lentiviral knockout or CRISPRi gene editing could also produce more sustained knockdown to 
overcome the issue of transient GRP78 knockdown encountered in this thesis.  
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4. 3.5 Limitations 
In addition to the limitations of the myotube model and cohort numbers as previously discussed, it is 
also important to note that these studies were conducted using ex vivo adipose tissue rather than 
isolated adipocyte cells. Although the use of whole adipose tissue is physiologically more relevant, 
we are unable to determine the cellular source of the adipose-secreted vaspin. Therefore, future 
studies should aim to identify the predominant source of vaspin from adipose tissue, by performing 
studies utilising primary human adipocytes and immune cells. Additionally, due to issues with 
antibody specificity, we only report vaspin expression at the mRNA level in human skeletal muscle 
tissue, adipose tissue and primary human myotubes. Use of different antibodies would be beneficial 
to confirm differential vaspin protein expression within such tissues and primary human cultures.  
 
4.3.6 Conclusions 
In summary, this thesis chapter shows that vaspin is directly secreted from both human SAT and 
skeletal muscle and its expression is increased with increasing adiposity in older individuals. 
Functionally, vaspin induces PI3K/AKT activation, increases both GLUT4 expression and translocation 
and promotes insulin-stimulated glucose uptake in primary obese older human myotubes. These 
data support a role for vaspin as a protective adipokine in the development of insulin resistance in 
elderly obese individuals. Further studies are needed to identify the mechanism of action of vaspin as 





    










CHAPTER 5: Adipose tissue derived extracellular 
vesicles: a novel mechanism of adipose tissue and 
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5.1 Introduction 
It has become increasingly recognised that extracellular vesicles (EVs) are an important mechanism 
of tissue crosstalk throughout the body. EVs can be further sub-classified as exosomes (50-150 nm in 
diameter), created intracellularly via the endosomal system, or microvesicles (approximately 100 -
1000 nm in diameter), derived by budding from the plasma membrane (Figure 5.1) (491). EVs carry a 
variety of internal cargo including mRNAs, non-coding RNAs and proteins (492). Recent evidence has 
even shown the presence of functionally active enzymes and phosphorylated proteins within EVs 
(493). Systemic transportation of such cargo between cells appears to be vital for health, while it is 
also becoming apparent that dysregulated vesicle release is an important driver of many pathological 




















Figure 5. 1. The biogenesis and secretion of exosomes and microvesicles. 
Exosomes are formed within the cytosol of the secreting cell, with cargo packaged before their 
release via exocytosis. In contrast, microvesicles are shed from the plasma membrane through 
membrane budding and cleavage and thus often express cell surface markers. 
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As discussed in the earlier chapters of this thesis, adipose tissue is known to secrete a plethora of 
adipokines, which in turn impact the function of other tissues such as skeletal muscle (496). 
Furthermore, it is now well established that the production of adipokines becomes dysregulated with 
obesity, likely contributing to the development of many obesity associated pathologies, including 
skeletal muscle insulin resistance (413). Similarly, recent work by Kranendonk described both the 
secretion of EVs from human adipose tissue and the presence of adiponectin positive EVs in human 
plasma (497). Additionally, elegant experiments by Thomou et al. demonstrated that microRNAs 
carried in adipose tissue derived EVs regulate liver gene expression in mice, providing the first 
evidence that adipose tissue derived EVs are capable of mediating tissue crosstalk (498).  
In light of such data we hypothesise that, as seen with adipokines, obesity drives increased vesicle 
release from human adipose tissue. Additionally, we propose that such vesicles may mediate obesity 
associated changes in skeletal muscle function in humans; such as increased inflammation and 
skeletal muscle insulin resistance. 
 
5.1.1 Chapter aims 
 
This chapter aims to: 
 Characterise EVs derived from both lean and obese human adipose tissue. 
 
 Determine the functional role of EVs derived from both lean and obese human adipose tissue 
in mediating the obese phenotype of human skeletal muscle by performing crosstalk studies 
with isolated EVs and primary human myotubes.  
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5.2 Results  
5.2.1 Detection of differential populations of EVs derived from lean and obese human 
adipose tissue 
Firstly, Exoview chips specific for the tetraspanins CD9, CD81 and CD63 (markers of EVs), were used 
to detect the presence of EVs in serum free ACM derived from both lean (n = 5) and obese (n = 5) 
individuals. EVs were successfully captured on all human tetraspanin antibody spots, for all 
individuals, while there was very little interaction with the mouse IgG negative control (Figure 5.2). 
The average total number of EVs captured with each antibody was approximately 2-fold lower in 
obese individuals (Figure 5.3), however this was only significant (P = 0.031) for vesicles captured on 
CD81 antibody spots (Figure 5.3). Additionally, in both lean and obese populations, approximately 2-
fold less EVs were captured on the CD63 spots compared to CD9 and CD81 spots (Figure 5.3). The 
sizes of vesicles were similar on all capture antibody spots, for both lean and obese individuals, with 
the majority of vesicles having a diameter of 50-100 nm, typical of exosomes (Figure 5.4). 
Next, EVs captured on CD63 antibody spots were probed with fluorescent antibodies against CD9, 
CD63 and CD81 to identify if captured vesicles also expressed other tetraspanin markers. In lean 
individuals, 52 ± 8% of captured vesicles displayed CD63 fluorescence. This was significantly greater 
than the number of particles positive for CD81 (18 ± 3%), but not particles positive for CD9 (31 ± 8%). 
In contrast, 71 ± 8% of particles displayed expression of CD63 in obese individuals. Although this was 
not significantly different to lean individuals, such CD63 expression was significantly greater than 
both the number of vesicles expressing CD9 (16 ± 5%) and CD81 (13 ± 4%). This difference in vesicle 
populations between lean and obese subjects is visually represented in Figure 5.5, with Figure 5.5 B 
demonstrating greater fluorescence heterogeneity in EVs derived from lean individuals in 
comparison to the more dominant red staining attributable to CD63 apparent in EVs derived from 
obese individuals (Figure 5.5 C). No significant difference between lean and obese induvial was 
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Figure 5. 2. Fluorescently labelled adipose tissue derived EVs in serum free media for EV 
markers. 
Representative images of serum free ACM derived EVs from an obese individual captured on a 
CD63 capture antibody spot of an exoview tetraspanin chip followed by staining  with secondary 
antibodies against A. CD9 (green) B. CD63 (red) and C. CD81 (blue). D. serum free ACM derived 
EVs captured with a mouse IgG antibody spot of the same tetraspanin chip and probed with 
CD63 (Red) secondary antibody. 
 
    





































Figure 5. 3. Quantification of EVs in serum free ACM derived from lean and obese 
individuals. 
Total number of EVs captured on the CD81, CD63 and CD9 capture antibody spots in 
serum free ACM derived from lean and obese individuals, determined by light scatter 
using Exoview. n = 5 lean and n = 5 obese. Data are expressed as mean ± S.E.M. * (P < 
0.05), ** (P <0.01) denotes a significantly different number of vesicles as determined 
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Figure 5. 4. Diameter of EVs in serum free ACM derived from lean and obese individuals. 
Average diameter of EVs captured on the CD81 A. CD63 B. and CD9 C. antibody spots of 
exoview tetraspanin chips in serum free ACM derived from lean and obese individuals. n = 5 
lean and n = 5 obese. Data are expressed as mean ± S.E.M. 
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Figure 5. 5. Differential populations of EVs derived from lean and obese individuals. 
A. Detection of CD81, CD9 and CD63 expressing vesicles derived from lean (n = 5) and 
obese (n = 5) adipose tissue captured on a CD63 capture antibody spot. Data are 
expressed as mean ± S.E.M. *** indicates P < 0.001, ** indicates P < 0.01, * Indicates P < 
0.05 as determined by  Bonferroni post-hoc tests following 2-way ANOVA. B 
Representative image of EVs derived from a lean individual captured on the CD63 capture 
antibody. Red fluorescence indicates CD63. Green fluorescence indicates CD81, Blue 
indicates CD9. C. Representative image of EVs derived from an obese individual captured 
on a CD63 capture antibody spot. Red fluorescence indicates CD63. Green indicates 
CD81, Blue indicates CD9. EVs were captured on 3 spots for each antibody, for each 
sample.  
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Figure 5. 6. Fluorescent staining of EVs detected on CD9 and CD81 capture antibody 
spots. 
A. Detection of CD81, CD9 and CD63 expressing vesicles derived from lean (n = 5) and 
obese (n = 5) EVs captured on CD9 capture antibody spots. *** indicates a significant 
difference from CD9-CD63 as determined by Tukey post-hoc tests following 2 way ANOVA 
2 way ANOVA. B. Detection of CD81, CD9 and CD63 expressing vesicles derived from lean 
(n = 5) and obese (n = 5) EVs captured on the CD81 capture antibody spots. EVs were 
captured on 3 spots for each antibody, for each sample. *** indicates a significant 
difference from CD81-CD63 vesicles (P < 0.001) as determined by Tukey post-hoc tests 
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5.2.2 Adipose tissue derived EVs increase proinflammatory cytokine release from lean 
primary human myotubes 
We next investigated whether EVs isolated from either lean or obese individuals impact on primary 
human myotube function. Previous studies and data presented in chapter 3 of this thesis indicated 
that obese skeletal muscle is more inflammatory, secreting increased amounts of proinflammatory 
cytokines such as IL-6. We therefore hypothesised that adipose tissue derived EVs may be implicated 
in mediating this effect. To investigate this, primary human myotubes from a lean individual were 
treated with EVs derived from the adipose tissue of both lean and obese individuals for 24-48 h and 
the impact on proinflammatory cytokine secretion measured by ELISA.  
Primary human myotubes treated for 24 h with EVs derived from lean adipose tissue secreted a 
significantly greater amount of IL-6 (1328 + 17 pg/ml) in comparison to untreated controls (415 ± 67 
pg/ml) (Figure 5.7 A). Similarly, myotubes treated with EVs derived from obese adipose tissue also 
secreted approximately 2-fold more IL-6 on average (1565 + 645 pg/ml). However, vesicles derived 
from 1 of the 3 obese individuals did not elicit an IL-6 response (334 pg/ml) and so this effect did not 
reach statistical significance. Similar to IL-6, myotubes treated with both lean and obese EVs for 24 h 
also secreted approximately 2-fold more IL-8 on average, although this did not reach statistical 
significance (Figure 5.7 B). 
We next investigated whether pre-treatment with EVs would prime myotubes to become more 
inflammatory and thus secrete greater amounts of IL-6 in response to challenge with an 
inflammatory stimulus. To this end, lean primary human myotubes were treated with either lean or 
obese EVs for 48h. Media containing EVs was then removed and myotubes were then treated with IL-
1β (1 ng/ml IL-1β, 3 h). Il-1β stimulation evoked a significant increase in IL-6 secretion from untreated 
lean primary human myotubes, as reported in chapter 3 of this thesis. Similarly, IL-1β also evoked a 
significant increase in IL-6 secretion from myotubes pre-treated with both lean and obese EVs. 
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Although such a response was approximately 1.5-fold greater in myotubes pre-treated with obese 
EVs (1283 ± 102 pg/ml) this was not statistically significant from untreated myotubes (863 ± 162 
pg/ml). Similarly, no significant difference in IL-1β mediated IL-6 secretion was observed in myotubes 
pre-treated with lean EVs. Finally, ELISA was also performed in order to determine if such EV-
mediated increased IL-6 and IL-8 secretion in myotubes was due to the presence of these cytokines 
in isolated vesicles. Significantly greater concentrations of IL-6 and IL-8 were detected in media 
containing obese vesicles. However, the concentration of both IL-6 and IL-8 in EVs was negligible (5-
20 pg/ml), in comparison to the concentrations detected in EV-stimulated primary human myotubes. 
To identify a possible mechanism for such EV induced secretion of proinflammatory cytokines, we 
next investigated the impact of adipose tissue derived EVs on the activation of NF-κB signalling, a 
known regulatory pathway of inflammatory cytokine secretion (425, 499). Firstly, it was necessary to 
determine whether the complete secretome of adipose tissue caused activation of NF-κB in primary 
human myotubes. To this end, lean primary human myotubes were treated with obese ACM for 48 h 
in the presence or absence of the IKKβ inhibitor 5-(p-Fluorophenyl)-2-ureidothiophene-3-
carboxamide (TPCA-1). ACM caused a significant (P < 0.05) increase in NF-κB activation, as evidenced 
by increased phosphorylation of P65Ser536, which was prevented by the co-stimulation with TCPA1 
(Figure 5.8 A-B). Similarly, treatment of myotubes with EVs isolated from both lean (n = 3) and obese 
(n = 3) ACM also induced activation of P65Ser536 (Figure 5.8 C), although densitometric analysis did not 
reach statistical significance (P = 0.104) (Figure 5.8 D). 
 
    



















































































































































 C                                                                    D 
Figure 5. 7. Adipose tissue derived EVs drive pro-inflammatory cytokine release from lean 
primary human myotubes 
 A. IL-6 Secretion from lean primary human myotubes in response to 24 h stimulation with lean (n 
= 3) and obese (n = 3) EVs. *** Indicates a significant (p<0.01) difference from control as 
determined by Dunnet’s post-hoc tests following 1-way ANOVA. B. IL-6 Secretion from lean 
primary human myotubes in response to 24 h stimulation with lean (n = 3) and obese (n = 3) EVs. 
C. IL-6 secretion in response to 3 h IL-1 stimulation (1 ng/ ml), in lean primary human myotubes 
pre-treated with either lean (n = 3) or obese (n = 3) EVs for 48 h, * indicates a significant (P < 0.05) 
increase in IL-6 secretion in response to IL-1 treatment, as determined by Bonferroni post-hoc 
tests following 2-way ANOVA. D. IL-6 and IL-8 concentration in culture media treated with either 
lean or obese vesicles only for 24 h. * indicates a significant (P < 0.05) difference in cytokine 
concentration as determined by unpaired T-tests. Data are presented as mean ± S.E.M. 
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Figure 5. 8. Adipose tissue derived EVs activate NF-ƘB signalling in lean primary human myotubes 
A. Activation of NF-ƘB P65 (Ser536) in primary human myotubes following 48 h stimulation with adipose 
conditioned media (n = 3) in the absence or presence of TCPA1 (40 nM), as determined by western 
blotting (10 µg protein loaded per sample). B Densitometric analysis of NF-ƘB P65 blots normalised to 
β-actin. C. Activation of NF-ƘB P65 in lean primary human myotubes following 48h stimulation with EVs 
derived from either lean (L) (n = 3) or obese (Ob) (n = 3) individuals as determined by western blotting 
(10 µg protein loaded per sample). D Densitometric analysis of EV stimulated phosphorylation of NF-ƘB 
P65 blots normalised to normalised to β-actin. Data are presented as mean ± S.E.M.* Signifies 







    



















































Figure 5. 9. EVs derived from lean and obese adipose tissue upregulate candidate gene 
expression in primary human myotubes 
Gene expression was determined via qRT-PCR and normalised to GAPDH (n = 3 lean, n = 4 obese 
EVs). Data are represented as mean ± S.E.M. * indicates significantly different expression from 
untreated myotubes as determined via 1-way ANOVA, followed by Dunnett’s post-hoc tests. 
 
5.2.3 EVs derived from lean and obese adipose tissue affect the expression of candidate 
genes in primary human myotubes 
We next investigated whether EVs drive changes in lean primary human myotube gene expression 
associated with increased adiposity, as identified in chapters 3 and 4 of this thesis by stimulating lean 
primary human myotubes with EVs from lean and obese adipose tissue for 24h.  Treatment of lean 
primary human myotubes with EVs from both lean and obese individuals evoked an approximate 2-
fold increase in vaspin mRNA expression (P = 0.079) as determined by qRT-PCR. Additionally EVs 
derived from obese individuals elicited a 3-fold increase in the expression calpain 1 (P < 0.05). 
Interestingly, no such effect on calpain 1 expression was observed in myotubes treated with lean 
EVs. No significant difference was observed in the expression of FBP-1, IL-6 or other genes associated 
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5.2.4 Effect of EVs derived from lean and obese adipose tissue on primary human 
myotube insulin signalling 
Finally, ACM from obese individuals and adipokines upregulated with obesity have been reported to 
drive primary human myotube insulin resistance associated with obesity and T2D. Therefore we also 
investigated whether adipose tissue derived EVs could induce a similar blunting of insulin signalling in 
lean primary human myotubes. Insulin increased phosphorylation of AKT approximately 1.2-fold in 
untreated myotubes (Fig. 5.10 A). Insulin induced activation of AKT was reduced on average in 
primary human myotubes pre-treated with both lean and obese EVs, however none of these insulin 
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Figure 5. 10. Effect of pre-treating lean primary human myotubes with adipose tissue 
derived EVs on the insulin induced activation of AKT 
Lean primary human myotubes were pre-treated with EVs derived from the adipose tissue of 
lean (n = 3) or obese (n = 3) individuals for 48 h. Primary human myotubes were then 
stimulated with insulin (100 nM, 30 min) or left untreated. A. Activation of AKTser473 in primary 
human myotubes as determined by western blotting (10 µg protein loaded per sample). B. 
Densitometric analysis of western blots. Data are represented as mean ± S.E.M. 
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5.3 Discussion   
Extracellular vesicles are becoming increasingly regarded as an important mechanism of intercellular 
communication and are implicated in the development of many pathologies. This is the first study to 
identify and characterise human adipose tissue derived EVs from both lean and obese individuals and 
report the novel EV mediated crosstalk between human adipose tissue and primary human 
myotubes. 
 
5.3.1 Human adipose tissue derived EVs are differentially secreted between lean and 
obese individuals 
Adipose tissue derived EVs from both lean and obese individuals were detected on CD9, CD63 and 
CD81 capture antibodies using Exoview in combination with tetraspanin chips. Interestingly, there 
was approximately 2-fold less EVs in the ACM derived from obese individuals in comparisons to lean 
individuals, on all capture antibody spots. This was surprising, as previous studies have reported an 
increased concentration of EVs in both the plasma and serum of obese individuals (500-503). 
Additionally, circulating EVs have also been demonstrated to display a positive correlation with 
insulin resistance (497, 503), while plasma vesicles positive for the adipocyte marker perilipin 
decreased following diet induced weight loss in humans (500).  
Such a discrepancy between the findings of this thesis and the current literature may be due to the 
method of vesicle detection. Previous studies described above used either nanoparticle tracking 
analysis (NTA) or flow cytometry to quantify vesicles, with each method having considerable 
limitations in this respect. Firstly, NTA utilises laser light scatter microscopy and Brownian motion in 
order to detect particles (504). Although this has the advantage of facilitating the detection of all 
vesicle populations present in a sample, this non-specific nature also results in detection of non-
vesicular particles, such as protein aggregates. Therefore, studies utilising NTA may have 
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overestimated the vesicle populations in both lean and obese individuals, with potential differences 
between sample populations being attributable to non-vesicular particles. Additionally, NTA also only 
reliably detects particles with a diameter of 70 nm and above (505). Therefore, as the majority of 
vesicles detected in this thesis were approximately 50-100 nm, a considerable amount of particles 
are likely not represented in studies utilising NTA. Similarly, vesicles are often below the lower size 
limit for detection and characterisation by flow cytometry (506). Subsequently, utilisation of flow 
cytometry to measure EVs may also give an untrue reflection of the vesicle populations present. 
However, it should be noted that this thesis did only capture vesicles expressing the tetraspanins 
CD9, CD63 and CD81, markers typically associated with exosomes (507). Thus, although such 
exosome populations may indeed decrease in the obese state, other populations of exosomes and 
microvesicles, not detected in this thesis, could increase with obesity leading to a net increase in 
total vesicle number as previously reported. For clarification, it would be useful to analyse the same 
samples using both nanoview and NTA/flow cytometry. 
Additionally, this thesis has only investigated SWAT derived EVs. VAT is widely accepted to be more 
inflammatory in terms of cytokine and adipokine release. Therefore increased vesicle release from 
VAT depots, in addition to other tissues, may also explain the previously reported elevated 
circulating vesicles in obesity. Furthermore, SAT is often more inflammatory in obese individuals, 
displaying a significantly increased population of immune cells (508). Importantly, recent data has 
reported that adipose tissue derived EVs are taken up by monocytes, in turn driving their 
differentiation to macrophages (497). Therefore, it may be hypothesised that there was also 
increased clearance of adipocyte derived vesicles in obese adipose tissue, due to increased monocyte 
content. Subsequently, it may be useful to measure vesicle release at earlier time points, in order to 
limit this effect. Critically, in addition to differences in vesicle number, it appears there may also be 
different vesicle populations released from lean and obese SAT. Vesicles from obese SAT captured on 
the CD63 capture antibody spot displayed a significantly greater expression of CD63 in comparison to 
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both CD9 and CD81. This was not observed in vesicles from lean SAT and thus suggests a loss of CD9 
and CD81 expression may occur with obesity. Although the functional impact of this population shift 
was beyond the scope of this thesis, it is becoming increasingly recognised that, in addition to simply 
being markers associated with exosome biogenesis, the expression of tetraspanins may mediate the 
functional effects of EVs. Firstly, tetraspanins have been shown to play an important role in the 
uptake of vesicles, often through their interaction with other proteins such as integrins at the 
membrane of target cells (509). Indeed, overexpression of Tspan8, on vesicles derived from the 
BSp73ASML cell line, directs vesicles to the pancreas and lungs of rats in vivo (510). Therefore, 
differential expression of tetraspanins on EVs derived from obese SAT may direct vesicles to different 
target cells. Additionally, tetraspanin expression may also affect vesicle production or release. For 
example, CD9 knockout mice demonstrate significantly reduced vesicle release from dendritic cells 
(511). As EVs derived from obese SAT also appeared to have reduced CD9 expression, this may offer 
another explanation for the reduced total vesicle number in the ACM of obese individuals. 
Importantly, tetraspanin expression may also impact vesicle function. Brzozowski et al. recently 
reported that CD9 knockdown in the RWPE1 human prostate cell line significantly affected the 
proteome of EVs released from these cells (512). Thus vesicles derived from obese adipose tissue 
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5.3.2 Adipose tissue derived EVS mediate crosstalk with primary human myotubes 
We next sought to determine if human SAT derived EVs, from either lean or obese individuals affect 
skeletal muscle function. Following the identification of increased proinflammatory cytokine release 
from obese primary human myotubes in chapter 3 of this thesis, we first investigated whether SAT 
derived EVs are involved in mediating this effect. 
24 h incubation of EVs derived from lean SAT evoked a significant increase in IL-6 secretion from lean 
primary human myotubes. Similarly, vesicles from 2 of 3 obese individuals also evoked an increase in 
IL-6 secretion from primary human myotubes and to a greater extent than observed with lean EVs. 
However, a limited response with EVs derived from a third obese individual meant that this effect did 
not reach statistical significance. Similarly, the secretion of IL-8 from lean primary human myotubes 
also increased, on average, in response to both lean and obese EVs, although this also did not reach 
statistical significance, again likely due to the small sample size. Critically, increases in IL-6 and IL-8 
secretion were not simply derived from EVs, as IL-6 and IL-8 measured in media containing vesicles 
alone was negligible. In support of these findings, pioneering work by Deng et al. demonstrated that 
injecting EVs derived from the VAT of donor mice, into recipient mice, caused a similar increase in 
the release of the proinflammatory cytokines; IL-6 and TNF from bone marrow derived macrophages 
(513). These findings and the results of the present investigation suggest that chronic exposure of 
skeletal muscle to SAT derived EVs may contribute to the development of the inflammatory skeletal 
muscle phenotype described in chapter 3 of this thesis.  
To identify a mechanism for such increased cytokine release, we investigated whether EVs activate 
the NF-κB signalling pathway, a major regulator of proinflammatory cytokine transcription (499). 
Whole ACM evoked a robust activation of NF-κB signalling after 48 h. NF-κB activation was also 
observed following 48 h stimulation with EVs, although this did not reach statistical significance. This 
suggests that EVs are responsible, at least in part, for mediating the proinflammatory effect of 
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adipose tissue on primary human myotubes. It should be noted that the measurement of NF-κB 
activation was performed after 48 h treatment with EVs rather than 24 h, to coincide with the 
investigation of 48 h pre-treatment of myotubes with EVs before IL-1β stimulation. Therefore it is 
possible that NF-κB activation had already peaked and began to decline by 48 h. Additional time 
course experiments would be valuable to confirm this. 
Despite increased NF-κB activation and IL-6 secretion, no effect of EVs on IL-6 mRNA expression was 
observed in this thesis. Nevertheless, this investigation only measured IL-6 mRNA expression 
following 24 h stimulation with EVs. Previous studies have observed transient increases in IL-6 mRNA 
that peak at around 4-6 h in response to proinflammatory stimuli; therefore again it is possible that 
IL-6 mRNA expression peaked within this 4-6 h window and then returned to baseline by 24 h (514, 
515). Alternatively, EVs may promote the translation and/or secretion of IL-6 without affecting mRNA 
expression. Further time course experiments would also be needed to clarify the effect of EVs on 
primary human myotube gene expression.  
This thesis also investigated the impact of EVs on the expression of other genes found to be 
differentially expressed with increased adiposity in chapters 3 and 4 of this thesis, in order to 
determine if EVs may also play a role in mediating such effects. Interestingly, vaspin mRNA was found 
to be increased in primary human myotubes cultured from lean individuals in response to 24 h 
treatment with EVs (P = 0.079). Thus EVs from SAT may be partly responsible for driving the 
increased expression of vaspin in the obese state as reported in chapter 4 of this thesis. Obese EVs 
also increased calpain 1 expression in lean primary human myotubes. Consequently SAT EVs may also 
play a role in driving increased muscle catabolism with obesity (391). In contrast, other genes 
associated with skeletal muscle atrophy such as MAFbx, MuRF1 and myostatin (also identified to be 
upregulated with obesity; chapter 3) were unaffected by either lean or obese SAT EV stimulation. 
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However, again, this was only at a 24 h time point and thus changes in mRNA expression could have 
occurred with different stimulation duration.  
Finally, as ACM and individual adipokines have previously been reported to drive insulin resistance in 
primary human myotubes (413, 516), we also investigated whether SAT EVs derived from lean and 
obese individuals blunt insulin signalling in lean primary human myotubes. No significant difference 
in insulin induced activation of AKTSer473 was observed in primary human myotubes pre-treated with 
either lean or obese EVs for 48 h. However, this was based on the response of primary human 
myotubes cultured from one individual. Additionally, this particular individual did not display a strong 
insulin response in untreated conditions and so replication of this experiment is necessary. A similar 
study by Kranendonk et al. also found no effect of human adipose derived EVs on AKT 
phosphorylation in C2C12 myotubes; however insulin induced activation of AKT was blunted in liver 
cells following 24 h pre-treatment with EVs (517). Interestingly, considerable inter-donor variation 
was also observed in this study, with vesicles from some individuals even causing increased insulin 
sensitivity. In contrast, Deng et al. report that 24 h pre-treatment of EVs derived from murine visceral 
adipose tissue did in fact impair glucose uptake in C2C12 myotubes, however no mechanistic studies 
were performed in this investigation (513). Further studies are needed to conclusively determine the 
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5.3.3 Limitations and future directions 
Initial experiments in this thesis chapter were performed using EVs isolated from SAT cultured in 
myotube differentiation medium, with the aim of performing future crosstalk studies between SAT 
derived EVs and primary human myotubes. However, due to a significant interaction between horse 
serum derived EVs and the human CD9 antibody spots on exoview chips, SAT was cultured in serum 
free media for 24 h. This is likely to have caused stress to adipocytes and immune cells present within 
adipose tissue and so may have stimulated aberrant vesicle release. Therefore, although 
comparisons between lean and obese samples in this thesis remain valid, due to exposure to the 
same conditions, future studies utilising culture media with EV depleted serum to better maintain 
cellular viability would provide more representative data of in vivo EV secretion from SAT. 
Another limitation of this study was that for the functional studies it was not possible to quantify and 
normalise the number of vesicles before their application to primary human myotubes. Subsequently 
myotubes will likely have been treated with a different total numbers of EVs from each donor. This 
could partly explain the varied responses of primary human myotubes observed when performing 
functional studies. Furthermore, although EVs were released under basal condition in this study, 
further investigation is needed to identify stimuli that evoke adipose tissue EV release. In turn, this 
might identify novel therapeutic targets with the aim of modulating EV release to improve skeletal 
muscle function in obesity.  
Moreover, further functional studies, such as primary human myotube glucose uptake and glucose 
metabolism are required to further establish the functional impact of adipose tissue derived EVs on 
primary human myotubes. Furthermore, the biggest un-answered question in this thesis chapter 
remains to be, what is the cargo of adipose tissue derived EVs and is such cargo affected by 
increasing adiposity? To address this at a protein level, we are currently performing proteomic 
analysis on the contents of SAT EVs derived from both lean and obese individuals. Such proteomic 
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screening may help identify differential protein cargo associated with increased adiposity an in turn 
enable more targeted functional studies to be performed in recipient cells such as primary human 
myotubes. 
Additionally, EVs have also been frequently reported to be associated with carrying micoRNAs (518). 
Such micro RNAs and potentially other non-coding RNAs, including lncRNAs and circRNAs could be 
another potential mechanism of adipose tissue derived EV crosstalk, by regulating mRNA and protein 
content in target cells. Hence performing RNA sequencing of such vesicle content would be valuable.  
 
5.3.4 Conclusions 
This chapter reports the first data demonstrating differential populations of EVs derived from lean 
and obese SAT. We also provide evidence that SAT derived EVs are novel mediators of adipose tissue 
and skeletal muscle crosstalk, capable of driving inflammation and regulating mRNA expression in 
primary human myotubes. In conclusion, EVs likely have a significant impact on skeletal muscle 
function in obese individuals. Developing a further understanding of EV functions and mechanism of 
action could identify new therapeutic targets for the treatment of obesity associated skeletal muscle 
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6.1 Discussion of main findings and future directions 
One of the major risk factors for the development of insulin resistance and T2D is obesity. Current 
evidence indicates that the increased secretion of proinflammatory adipokines from adipose tissue 
leads to the development of a chronic proinflammatory state (519). In turn, chronic exposure to such 
inflammation over months and years is linked to the development of skeletal muscle dysfunction, 
including insulin resistance (413) (Figure 6.1). However, there is a dearth of knowledge surrounding 
the mechanism of action of many candidate adipokines in human tissues, including skeletal muscle, 
with much of the current knowledge in this field derived from studies utilising non-human cell lines 
and rodent models (399). Additionally, EVs are also capable of mediating tissue crosstalk in humans 
(493). However again, adipose tissue derived EVs have not been characterised from lean and obese 
individuals and their functional impact on human skeletal muscle is unknown. To address these gaps 
in current knowledge, this thesis utilised ex vivo human adipose tissue and primary human myotubes 
derived from elderly human muscle as an in vitro model in order to perform novel crosstalk studies 
examining the impact of adiposity on human skeletal muscle inflammation and insulin sensitivity 
associated with the ageing obese phenotype. 
The first chapter of this thesis established that primary human myotubes provide a viable in vitro 
model of elderly skeletal muscle, with characteristics associated with the obese phenotype, such as 
the increased expression of atrophic markers, insulin resistance and inflammation retained in 
myotubes from obese donors. There is currently limited evidence to explain such retention of donor 
muscle phenotype in vitro. It could be hypothesised that chronic exposure of myocytes to either 
chronic low grade inflammation, or other circulating factors associated with the obese state such as 
lipids, causes epigenetic changes in skeletal muscle. Such epigenetic changes may in turn regulate 
gene expression in skeletal muscle satellite cells. Critically, as such satellite cells are isolated and 
differentiated to myotubes, an inherently altered genome may explain their altered functionality. 
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Indeed, HFD, ageing and resistance exercise have been implicated in potentiating epigenetic changes 
in human muscle tissue (520-522). Additionally, a recent investigation by Davegårdh et al. reported 
the first evidence that obesity impacts the epigenome of primary human myotubes. They observed a 
300% increase in the DNA methylation response to myoblast differentiation, in myotubes cultured 
from obese individuals in comparison to lean individuals (523). Since, Davegårdh et al. have also 
reported a difference in methylation status of myotubes cultured from men and women, further 
supporting a role for differential epigenetic modifications in determining primary human myotube 
phenotype (524). Future studies could investigate the impact of obesity and candidate adipokines on 
the primary human myotubes epigenome, with the aim of identifying causes for differential gene 
expression in response to such conditions. This may identify novel therapeutic targets to improve 
skeletal muscle insulin sensitivity.  
Collectively, the findings from chapter 3 of this thesis highlight the need to consider donor 
characteristics in the design of future studies of musculoskeletal research, in order to ensure that 
data is representative of the desired cohort. For example, the findings of a study investigating the 
mechanisms related to sarcopenia utilising primary human myotubes derived from donors in their 
twenties, may not be replicated in myotubes derived from elderly sarcopenic individuals. 
The main limitation with the work presented in this chapter was that the analysis of differential gene 
expression between lean, overweight and obese skeletal muscle was limited to 48 genes. Therefore, 
many genetic changes associated with obesity were likely over looked. Future studies would benefit 
from the utilisation of RNA sequencing to perform a thorough comparison of genetic changes that 
occur in skeletal muscle tissue with increasing adiposity. Generated data could in turn be analysed 
with algorithmic software such as Ingenuity Pathway Analysis, in order to identify specific 
intracellular signalling pathways affected by obesity, thus purposefully directing future research. 
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Next, this thesis focused on the novel adipokine vaspin. Vaspin was chosen as a candidate adipokine 
as it had previously been demonstrated to have a number of beneficial effects on rodent insulin 
sensitivity, but had been unstudied in a human setting. We describe increased expression and 
secretion of vaspin from the adipose tissue and skeletal muscle of obese humans. We also provide 
evidence that vaspin is able to activate the PI3K/AKT signalling pathway in primary human myotubes, 
increase the expression of GLUT4 and in turn sensitise previously insulin resistant obese primary 
human myotubes to insulin (Figure 6.1). Significantly, these effects appeared to occur independently 
of insulin receptor activation. Currently, the receptor and mechanism of such vaspin mediated 
effects in skeletal muscle has not been defined. It appears that vaspin can physically bind to the cell 
membrane receptor GRP78 (471). We report the expression of GRP78 in human adipose tissue and 
skeletal muscle and the upregulation of GRP78 in these tissues with obesity. We also provide 
evidence of GRP78 expression in primary human myotubes. Although we were able to achieve 
successful knockdown of GRP78 in primary human myotubes, we were not able to conclude whether 
GRP78 is a functional receptor for vaspin in human muscle. Therefore future studies aiming to 
continue such work would be valuable in attempting to identify a vaspin receptor which could in turn 
be targeted, with the aim of improving skeletal muscle insulin sensitivity, independently of the insulin 
receptor. 
Moreover, this chapter mainly focused on the impact of obesity on insulin sensitivity, yet obesity is 
also associated with a reduction in skeletal muscle mass and quality. Indeed, many adipokines 
associated with the obese state, such as resistin, have been implicated in driving such skeletal muscle 
atrophy (448). In contrast, adipokines such as IL-15 may promote increases in skeletal muscle mass 
(389). As reported in chapter 4, vaspin was able to acutely activate AKT signalling. Importantly, one of 
the downstream targets of AKT is mTOR, a major regulator of the signalling pathway associated with 
increasing skeletal muscle hypertrophy (102). Additionally, we have also observed increased 
proliferation of primary human myoblasts in the presence of vaspin (appendix 3). Therefore, studies 
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investigating the role of vaspin in mediating changes in skeletal muscle mass would be interesting. It 
would also be interesting to consider the effect of skeletal muscle contraction on vaspin release and 
in turn investigate not just potential autocrine effects of vaspin on muscle, but also its effect on other 
tissues such as adipose and the liver. Elucidating such functional effects will be crucial for the 
potential development of vaspin based therapeutics. For example, although targeting a vaspin 
receptor may improve insulin sensitisation, systemic modulation of the vaspin receptor may be 
harmful. 
Ultimately, the findings of this chapter highlight that previously understudied adipokines can have 
important paracrine physiological effects. Critically, as discussed in the introduction of this thesis 
(Table 1.2), the impact of many adipokines on human skeletal muscle insulin sensitivity and indeed 
skeletal muscle function as a whole is very limited. Therefore, it is imperative that there is a 
continued effort to identify the function and mechanism of action of candidate adipokines in both 
health and disease. In turn, this may lead to the identification of novel therapeutic targets, either 
through the development of adipokine mimetics or small molecules to modulate receptor activation, 
not just in skeletal muscle, but throughout the human body. 
Finally, as extracellular vesicles are now acknowledged as an important mechanism of cellular 
crosstalk in humans, we undertook studies to investigate the possibility that, like adipokines, 
extracellular vesicles derived from human adipose tissue influence the function of human skeletal 
muscle. We report, for the first time, the differential secretion of adipose tissue derived EVs positive 
for the classical exosome markers CD9, CD63 and CD81, between lean and obese individuals. 
Functionally, we demonstrate the novel EV induced release of inflammatory cytokines and regulation 
of gene expression in lean primary human myotubes. We therefore propose that adipose tissue 
derived EVs are novel facilitators of adipose tissue and skeletal muscle crosstalk. 
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To continue this work, efforts need to be made to further characterise the phenotypic markers of 
vesicles secreted from adipose tissue and more importantly, their cargo. Highlighting particular cargo 
of interest such as microRNAs, long non coding RNAs or even functionally active proteins will be 
important in understanding the crosstalk between skeletal muscle and adipose tissue. Ultimately 
studies able to sort vesicles into different population prior to characterisation of cargo, or the 
performance of functional studies would be powerful. However, such studies are currently limited to 
a certain extent by current technologies, as the small size of EVs still presents a considerable hurdle.  
Adipose tissue derived EVs may also impact other functions of skeletal muscle. For example, we 
identified activation of NFκB as a possible mechanism for increased EV mediated secretion of 
proinflammatory cytokines from primary human myotubes. There is also increasing evidence to 
suggest that activation of NFκB is also associated with inhibiting myogenesis (448). Therefore, 
coupled with the fact that EVs increased the expression of calpain 1 (a skeletal muscle protease), 
adipose tissue derived EVs could contribute to the development of sarcopenia. Additionally, adipose 
tissue derived EVs have also been demonstrated to affect the function of both the liver and immune 
cells (497, 517). Thus, similar to adipokines, adipose tissue derived EVs likely have a number of 
important effects throughout the body. Subsequently, dysregulation of such EV secretion with 
obesity may be associated with the development of many obesity associated diseases.  
Moreover, as EVs can be detected in fluids such as urine, blood and saliva, in depth profiling of 
obesity-associated EVs may identify novel biomarkers capable of predicting obesity associated 
disease. The unique potential for EVs in this regard has recently been demonstrated in cancer 
biology. For example Melo et al. showed that the presence of EVs expressing markers associated with 
pancreatic cancer can be detected before any evidence of tumour development (525). Similarly, 
many cancer specific micro-RNAs have also been detected within serum EVs (526). Efforts to 
characterise obesity-associated EVs has the potential for the rapid identification of “at risk” 
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individuals who could then be subject to further diagnostic tests, or stratified to interventions 
designed to prevent disease development. Such opportunities further highlight the translational 
potential in profiling adipose tissue derived EV cargo. Conversely, the collection of EVs from adipose 
tissue may offer a unique vehicle for the delivery of novel therapeutic agents, such as RNAs and small 
molecules. To this end, adipose tissue derived EVs could be isolated from the patient and ‘loaded’ 
with such cargo before being re-administered to the patient. Doing so offers the potential to utilise 
specific surface markers on adipose tissue derived EVs to perform targeted delivery of therapeutics 
to tissues as required, which currently presents a significant challenge. 
 
6.2 Lifestyle interventions for the treatment and prevention of T2D 
It is evident that there is still a demand for the development of novel therapeutics to treat the 
increasing number of individuals presenting with T2D. However, it is equally important that 
significant efforts are made to raise public awareness of the association between weight gain and the 
development of T2D, as well as the self-measures individuals can take to prevent and manage this 
disease. 
There is increasing evidence that dietary interventions are able to reverse and prevent the 
development of hyperglycaemia that is typical of T2D pathology, with low carbohydrate diets 
seeming to yield the best results (527-529). Indeed, some reports even suggest it is possible to stop 
pharmacological intervention entirely in patients with T2D by using this approach (530-533). 
Although a simple solution in theory, achieving such results at a population level is difficult, primarily 
due to relying on patient adherence to often dramatic lifestyle changes. In general, low carbohydrate 
diets appear to show better adherence than low calorie diets, likely due to the intake of fat and 
protein facilitating relatively greater total calorie consumption. However studies with long term 
follow up (> 1 year) are scarce (527). Additionally, the effectiveness of such dietary interventions 
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appear to be negatively associated with a number of variables, including; the length of time an 
individual has been diabetic, the number or dosage of medication an individual is taking and 
increased HbA1c level at the start of intervention (534). Therefore early intervention is also likely 
needed in order to obtain the best results. 
Furthermore, as discussed in chapter 1 of this thesis, both aerobic and resistance exercise are also 
effective in improving insulin sensitivity in obese and diabetic individuals. Hence, such interventions 
should also be incorporated into the lifestyle of individuals with, or at risk of the development of 
T2D. However, this is also easier said than done, since many individuals with T2D are either elderly or 
present with significant co-morbidities. Therefore, the introduction of regular physical activity in 
these cohorts is often not feasible. Additionally, adherence also offers a significant challenge for 
those capable of following exercise intervention. Finally, such lifestyle interventions also come with 
socio-economic challenges such as the cost of fresh, nutrient dense food and the accessibility and 
availability of exercise facilities. Therefore, in addition to raising public awareness, ultimately a 
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6.3 Final comments  
The data presented in this thesis has been generated using biological replicates, performed across 
multiple patient/subject samples to ensure its validity. Throughout, myotube data has been 
generated using primary cultures from human muscle biopsy samples, unlike previously published 
studies that have predominately utilised rodent cell lines. In comparison to the majority of murine 
studies conducted, human subject replicates are more limited for most functional studies. Due to 
time restraints involved in recruiting subjects and culturing primary human cells, this was the 
compromise accepted in order to perform work more physiologically relevant to humans. 
Consequently, the potential for variability amongst the responses of cultured cells means further 
research would be needed to corroborate some of the major findings of this work. 
Since adipose tissue secretes a number of adipokines that can have both positive and negative 
effects on insulin sensitivity and metabolism, targeting adipokine signalling has emerged as a 
potential area to identify and develop novel therapeutics for obesity associated diseases such as T2D. 
This thesis has demonstrated that vaspin is a novel adipokine associated with obesity, which has 
insulin sensitising effects on human skeletal muscle (Figure 6.1). Looking to the future it appears that, 
like adipokines, adipose tissue derived EVs may also impact skeletal muscle function with obesity. 
Collectively, further understanding how the complete adipose tissue secretory milieu affects skeletal 
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Figure 6. 1. Summary of findings. 
Following chronic energy excess, adipose tissue undergoes hypertrophy and becomes inflamed, 
resulting in increased infiltration of immune cells including T-cells, M2 macrophages and possibly 
neutrophils. Consequently, obese adipose tissue secretes more proinflammatory cytokines and 
proportionally less anti-inflammatory adipokines. Additionally, obese adipose tissue secretes a 
different population of extracellular vesicles exhibiting high CD63 and low CD9 and CD81 surface 
expression. Together these adipokines and EVs contribute to driving increased skeletal muscle 
inflammation, atrophy and insulin resistance. Ultimately, this likely contributes to the development of 
obesity associated diseases such as type II diabetes and sarcopenia. In an attempt to reduce the 
development of such skeletal muscle insulin resistance, we suggest obese adipose tissue and skeletal 
muscle secrete vaspin to increase skeletal muscle insulin sensitivity. 
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Manufacturer Species Primer/ probe sequence 
Calpain 1 Applied Biosystems UK Human Forward: 5’- CATGGAGACTATTGGCTTCGC -3’ 
Reverse: 5’- GAGACGCATTGGCCAGGA -3’  
Calpain 2 Applied Biosystems UK Human Forward: 5’- GCACACCATCGGCTTTGG -3’ 
Reverse: 5’- CCCGGAGGTTGATGAAGGT -3’  
FBP1 Applied Biosystems UK Human Forward: 5’GGCCGCACGTGGAATG-3’ 
Reverse: 5’- TTGAACGGCAAGAACTTGATGT-3’ 
FOXO3 Applied Biosystems UK Human Forward: 5’- CGGCTCACTCTGTCCCAGAT -3’  
Reverse: 5’- TGTCGCCCTTATCCTTGAAGTAG -3’  
GAPDH Primer Design Human Proprietary  
GRP78 
 
Applied Biosystems Human Forward: 5’GGCCGCACGTGGAATG-3’ 
Reverse: 5’- TTGAACGGCAAGAACTTGATGT-3’ 
GSK3B Applied Biosystems UK Human Forward: 5’GGCCGCACGTGGAATG-3’ 
Reverse: 5’- TTGAACGGCAAGAACTTGATGT-3’ 
LDLR Applied Biosystems UK Human Forward: 5’GGCCGCACGTGGAATG-3’ 
Reverse: 5’- TTGAACGGCAAGAACTTGATGT-3’ 
MAFbx Primer Design Human Forward: 5’AACTCAAATACAAAATAGGACGCTTT -3’ 
Reverse: 5’- CCTTCGCTTCTCAAAACAAAC -3’ 
mTOR Applied Biosystems UK Human Forward: 5’- AGGCCGCATTGTCTCTATCAA -3’ 
Reverse: 5’- GCAGTAAATGCAGGTAGTCATCCA -3’  
MuRF-1 Primer Design Human Forward: 5’- GACGCCCTGAGCCATT -3’ 
Reverse: 5’- CCTCTTCCTGATCTTCTTCTTCAAT -3’ 
MyoD Primer Design Human Forward: 5’- CGCCTGAGCAAAGTAAATGAG -3’ 
Reverse: 5’- GCCCTCGATATAGCGGATG -3’  
SLC2A4 
(GLUT4)  
Primerdesign Human Forward: 5’-ATGGCTGTGGCTGGTTTCT- 
Reverse: 5’-AGCAGGAGGACCGCAAATA-3’ 
TBC1D4 Applied Biosystems UK Human Forward: 5’GGCCGCACGTGGAATG-3’ 
Reverse: 5’- TTGAACGGCAAGAACTTGATGT-3’ 
Vaspin 
 
Applied Biosystems Human Forward: 5’-GGG AGC CTT GGC ATG ATG 
Reverse: 5’-AGC AAA GGC AAG GGC AGA T-3’ 
Vaspin Thermo fisher Mouse Probe: Proprietary 
GRP78 Thermofisher Mouse Probe Proprietary 
Vaspin Thermo fisher Rat Probe: Proprietary 
GRP78 Thermofisher Rat Probe Proprietary 
Appendix 1. Primer sequences used for qRT-PCR. 
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Housekeeping Insulin & Receptors PI3Kinase Signalling PI3 Kinase  Target Genes Insulin Signalling Target Genes Metabolism Other 
18S Insulin receptor AKT1 GLUT4 CEBPA ACACA ENPP1 
GAPDH IRS1 AKT2 UCP1 CEBPB ACOX1 PTPN1 
B Actin IRS2 AKT3 G6PC FOS FASN PREX1 
 IRS4 MTOR BCL2L1 JUN FBP1 lin28a 
 SORBS1 EIF2B1 PCK2  PPARdelta  
 PPP1CA GSK3A HK2  PPARgamma  
  GSK3B SREBF1  EIF4EBP1  
  PDPK1   LDLR  
  PIK3CA     
  PRKCG     
  PRKCZ     
  FOXO1     
  AS160     
  Rac1     
  PGC1 alpha     
  Lactate dehydrogenase     
Appendix 2. Genes on microfluidics cards.  
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Appendix 3. Effect of Vaspin stimulation on primary human 
myoblast proliferation as determined by MTS assay. N=5 
biological replicates from one patient. Data are presented as 
mean ± SEM. * (p<0.05) ** (p<0.01) denotes a significant 
increase in absorbance from control as determined by 
Dunnetts’s post-hoc tests following 1 way ANOVA. 
